Update of the Scientific Opinion on opium alkaloids in poppy seeds by Knutsen, Helle Katrine et al.
SCIENTIFIC OPINION
ADOPTED: 22 March 2018
doi: 10.2903/j.efsa.2018.5243
Update of the Scientiﬁc Opinion on opium alkaloids in
poppy seeds
EFSA Panel on Contaminants in the Food Chain (CONTAM),
Helle Katrine Knutsen, Jan Alexander, Lars Barregard, Margherita Bignami, Beat Br€uschweiler,
Sandra Ceccatelli, Bruce Cottrill, Michael Dinovi, Lutz Edler, Bettina Grasl-Kraupp,
Christer Hogstrand, Laurentius (Ron) Hoogenboom, Carlo Stefano Nebbia, Isabelle P Oswald,
Annette Petersen, Martin Rose, Alain-Claude Roudot, Tanja Schwerdtle, G€unter Vollmer,
Heather Wallace, Diane Benford, Girolamo Calo, Albert Dahan, Birgit Dusemund,
Patrick Mulder, Eva Nemeth-Zamborine, Davide Arcella, Katleen Baert, Claudia Cascio,
Sara Levorato, Marijke Schutte and Christiane Vleminckx
Abstract
Poppy seeds are obtained from the opium poppy (Papaver somniferum L.). They are used as food and to
produce edible oil. The opium poppy plant contains narcotic alkaloids such as morphine and codeine.
Poppy seeds do not contain the opium alkaloids, but can become contaminated with alkaloids as a result
of pest damage and during harvesting. The European Commission asked EFSA to provide an update of
the Scientiﬁc Opinion on opium alkaloids in poppy seeds. The assessment is based on data on morphine,
codeine, thebaine, oripavine, noscapine and papaverine in poppy seed samples. The CONTAM
Panel conﬁrms the acute reference dose (ARfD) of 10 lg morphine/kg body weight (bw) and concluded
that the concentration of codeine in the poppy seed samples should be taken into account by converting
codeine to morphine equivalents, using a factor of 0.2. The ARfD is therefore a group ARfD for morphine
and codeine, expressed in morphine equivalents. Mean and high levels of dietary exposure to morphine
equivalents from poppy seeds considered to have high levels of opium alkaloids (i.e. poppy seeds from
varieties primarily grown for pharmaceutical use) exceed the ARfD in most age groups. For poppy seeds
considered to have relatively low concentrations of opium alkaloids (i.e. primarily varieties for food use),
some exceedance of the ARfD is also seen at high levels of dietary exposure in most surveys. For
noscapine and papaverine, the available data do not allow making a hazard characterisation. However,
comparison of the dietary exposure to the recommended therapeutical doses does not suggest a health
concern for these alkaloids. For thebaine and oripavine, no risk characterisation was done due to
insufﬁcient data. However, for thebaine, limited evidence indicates a higher acute lethality than for
morphine and the estimated exposure could present a health risk.
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Summary
In October 2011, the EFSA Panel on Contaminants in the Food Chain (CONTAM) adopted the Scientiﬁc
Opinion on the risks for public health related to the presence of opium alkaloids in poppy seeds. For that
opinion, the European Food Safety Authority (EFSA) received the results from analyses of opium alkaloids,
primarily morphine, codeine, thebaine, papaverine and noscapine, in samples of poppy seeds, bakery
products and baking ingredients. Based on the relative prevalence of the alkaloids present in poppy seed
and food samples analysed, and on their pharmacological potency, the CONTAM Panel concluded that the
risk assessment could be based on dietary exposure to morphine alone. The CONTAM Panel established an
acute reference dose (ARfD) of 10 lg morphine/kg body weight (bw) based on the lowest known single
oral therapeutic dose of 30 lg morphine/kg bw and applying an uncertainty factor of 3 for extrapolation
from the lowest-observed-effect-level (LOEL) to a no-observed-effect level (NOEL) considering that the
LOEL was derived from patients and not from the general population.
The European Commission asked EFSA for an update of the Scientiﬁc Opinion on the human health
risks related to the presence of opium alkaloids in poppy seeds taking into account the alkaloid proﬁle
of the poppy seed samples submitted to EFSA since 2011. Recent occurrence data on the presence of
opium alkaloids in poppy seeds available on the European market indicate that the alkaloids proﬁle of
the poppy seed samples submitted to EFSA after the 2011 opinion may be different compared to the
data used in the EFSA opinion, and this issue is particularly important for thebaine.
The CONTAM Panel concluded that the update of this opinion should comprise: (i) a re-evaluation
of the toxicity of opium alkaloids present in poppy seed samples, for humans considering all relevant
toxicological endpoints; (ii) an evaluation of the alkaloid proﬁle (i.e. composition of the alkaloids and
their concentration) of the poppy seed samples submitted to EFSA since 2011 and whether the proﬁle
is similar to that of the poppy seed samples used in the 2011 opinion; (iii) an estimation of the dietary
exposure of the EU population to opium alkaloids from poppy seeds, including the consumption
patterns of speciﬁc groups of the population if appropriate; (iv) an assessment of the human health
risks for the EU population, including speciﬁc groups of the population if appropriate, as the
consequence of the estimated dietary exposure.
Poppy seeds are obtained from the opium poppy (Papaver somniferum L.). The latex (milky sap) of
the opium poppy contains up to 80 different alkaloids, including morphine and codeine, which have
been used by man for the treatment of severe pain for generations but are also subject to misuse. The
seeds are used as food and to produce edible oil. Alkaloid accumulation in the poppy plant depends on
both genetic factors and environmental/cultivation conditions. Breeding is focusing on the development
of either cultivars with a high and speciﬁc alkaloid content to fulﬁl the requirements of the
pharmaceutical industry or cultivars with a low alkaloid content for seed/oil production. However,
poppy seeds from P. somniferum varieties with high alkaloid content especially bred for pharmaceutical
purposes are used as a by-product for food purposes. Mature poppy seeds do not contain the latex,
but can become contaminated with opium alkaloids as a result of pest damage and during harvest.
Opium alkaloids detected in samples of poppy seeds and poppy seed-containing foods include the
phenanthrenes: principally morphine, codeine, thebaine and oripavine, and the benzylisoquinolines:
principally papaverine and noscapine. In this Scientiﬁc Opinion, the term ‘opium alkaloids’ refers to
these compounds.
Morphine is extensively absorbed from the gastrointestinal (GI) tract and is distributed throughout
the body. The oral bioavailability of morphine is reduced by both Phase I and II presystemic
metabolism in the GI tract and liver. Though the brain is its primary site of action, morphine does not
cross the blood-brain barrier easily. Morphine diffuses across the placenta, and transfers into milk.
Morphine is metabolised via N-demethylation and O-glucuronidation in the gut and the liver.
Metabolites are normorphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G
has similar or higher activity than morphine. The rate and pathways of opioid metabolism may be
inﬂuenced by genetic factors and medical conditions.
Codeine is readily and extensively absorbed from the GI tract following oral administration. Codeine
is distributed throughout the body, penetrates the placental barrier and enters fetal circulation.
Codeine and its metabolites are almost fully excreted via the kidneys mainly as glucuronides. The
principal pathways for metabolism of codeine occur in the liver, although some metabolism occurs in
the intestine and brain. Codeine is converted to codeine-6-glucuronide (C6G), norcodeine and
morphine. The formed morphine is further metabolised into normorphine, M3G and M6G. Codeine
metabolism to morphine is dependent of the CYP2D6 activity. Individuals can be classiﬁed into poor
metaboliser, intermediate metaboliser, extensive metaboliser or ultra-rapid metaboliser. The distribution
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of poor, extensive and ultra-rapid metabolisers differs signiﬁcantly between ethnic groups; the
extensive metabolisers represent the majority of the Caucasian population. Signiﬁcant differences were
detected between the groups in areas under the plasma concentration vs time curves (AUCs) and the
maximum plasma concentrations (Cmax) of morphine. No new data were identiﬁed that provide a basis
to change the previous conclusion from 2011 that the maximal metabolic conversion of codeine into
morphine does not exceed 20%.
Based on limited information, oral bioavailability of thebaine, oripavine, noscapine and papaverine
appears to be reduced due to presystemic metabolism in the GI tract and liver, primarily involving
demethylation reactions but also glucuronidation. There are indications that thebaine is metabolised
into several metabolites including oripavine and morphine.
In experimental animals, morphine acts on the nervous system and its development. Chronic
toxicity, including carcinogenicity, of morphine has not been systematically evaluated. However, based
on the lack of carcinogenicity of codeine which is metabolised to morphine, it is unlikely that morphine
is carcinogenic. Morphine is genotoxic only in vivo but most likely by a non-DNA reactive mode of
action. Recent studies in rats and mice add to the weight of evidence that morphine has reproductive
and developmental effects. Depressed sexual activity, reduced testicular function and spermatogenesis,
disruption of ovarian cyclicity and decreased pregnancy rate have been observed in rats exposed to
morphine. Oral morphine exposure of pregnant rats or mice affects the normal development of the
placenta and the brain which could lead to postnatal neurological and behavioural deﬁcits in the
animals including memory loss. It has also been shown that morphine causes immunosuppressive
actions. These data do not allow assessment of dose-response relationships in support of the risk
assessment for opioids in food.
Long-term feeding studies in rats and mice showed no evidence of carcinogenic activity of codeine.
Codeine is not genotoxic. Based on limited data, it is concluded that oral administration of codeine did
not result in teratogenicity. There are no data to make conclusions on the neurotoxic effects of
codeine.
Based on acute toxicity data, thebaine and oripavine are more toxic than morphine. Lower LD50
values have been reported for thebaine compared to morphine, both by oral and parenteral routes.
However no other data on the oral toxicity of thebaine were identiﬁed and therefore its critical effects
are unknown. No oral LD50 values have been reported for oripavine, but lower intraperitoneal (i.p.)
and subcutaneous (s.c.) LD50 values have been reported for oripavine than for morphine. Apart from
one study showing convulsions following i.p. and s.c. administration, no other data on the toxicity of
oripavine were identiﬁed. Therefore the toxicological proﬁle of oripavine is unclear.
High LD50 values for noscapine, following both oral and parenteral administration, indicate a lower
acute toxicity compared to the other opioid alkaloids. Repeated exposure of rats and dogs to
noscapine did not result in adverse effects. Noscapine is an aneugen in vitro most likely by a non-DNA
reactive mechanism. A risk of genotoxic damage caused by noscapine in humans at therapeutic
dosages is very unlikely. LD50 values of papaverine by oral and parenteral administration are similar to
morphine. However, no evidence of toxicity was seen following oral administration of papaverine to
rats and dogs. Therefore the critical effects of papaverine are unclear.
Based on human data, the CONTAM Panel conﬁrms its previous conclusion that the critical effects
of morphine are on the central nervous system (CNS) mediated by its high afﬁnity to the l-opioid
receptor as an agonistic ligand. These adverse effects include nausea, vomiting, sedation, drowsiness,
euphoria, miosis, respiratory depression and obstipation. Therapeutic doses of morphine may reduce
attentiveness and reactive skills, with potential impact on driving and operating machinery. From data
on humans and experimental animals, it is clear that morphine can interfere with brain development of
the fetus resulting in behavioural effects at later life-stages; however, data are too limited to derive a
dose–response relationship. The lowest known single oral therapeutic dose reported is 1.9 mg
morphine, corresponding to 27 lg/kg bw for an adult weighing 70 kg.
The pharmacology of codeine is strongly related to that of morphine, as it is a precursor of
morphine itself. Codeine has some direct activity at the l-opioid receptor, but with a much lower
potency than morphine, and therefore, a direct effect of codeine is negligible compared to the effect
of its metabolite morphine. More recent literature focused on cases of life-threatening toxicity in
paediatric patients given therapeutic doses of codeine. This has been associated with the genotype
predisposing to ultra-rapid metabolism of codeine into morphine by the isoenzyme CYP2D6. The
adverse reactions to codeine are similar to those of morphine but seen to a lesser extent at clinical
doses. The most frequent side effects of codeine are constipation and nausea. Morphine and codeine
have dependency potential. Longer term use can result in tolerance.
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For oripavine and thebaine, no data after oral or parenteral exposure of humans are available.
Noscapine is used as a centrally acting antitussive compound and has neither an analgesic,
respiratory depressive nor obstipating effect. Although its toxicological properties have not been
characterised, less severe adverse effects (e.g. headache, dizziness) are known from the therapeutic
uses in humans.
Papaverine does not show opiate-like pharmacology. It acts as a smooth muscle relaxant that is
most pronounced on blood vessels. The side effects of papaverine, that have been reported after oral
administration, are dizziness, drowsiness, headache, tiredness, GI disturbance, tachycardia, skin rash,
sweating and hypotonia. After long-term administration eosinophilia, icterus and liver enzyme changes
(reversible) have been reported. Overdosage may lead to seizures.
The pharmacological effects of opioid drugs derive from their ability to interact with the l-, d- and
j-opioid receptors. The l-opioid receptor plays a crucial role not only in opioid-induced analgesia but
also in the unwanted actions of opioids. Morphine behaves as a potent full agonist at the l-receptor
and it has 200-fold greater afﬁnity to the l-opioid receptor than codeine. M6G has a similar or higher
afﬁnity as morphine. Oripavine displays moderate potency (30- to 70-fold less than morphine) at the
l-receptor. Thebaine is able to stimulate opioid receptors only at very high concentrations (micromolar
range). No indication has been found that the effects of noscapine and papaverine are mediated via
opioid receptors.
For morphine, the CONTAM Panel again concluded that the dose–response analysis should be
based on the lowest oral therapeutic dose of morphine (1.9 mg morphine/person). Applying the
default body weight of 70 kg, this dose corresponds to 27 lg/kg bw per day or 30 lg/kg bw per day
when rounded to one signiﬁcant ﬁgure.
The CONTAM Panel previously concluded that the establishment of an ARfD was required for
morphine because of the short-term nature of its effects, and that ensuring exposure is below the ARfD
would also protect against possible effects of repeated exposure. An ARfD of 10 lg/kg bw was derived
from the lowest known single oral therapeutic dose of morphine, which was regarded as a LOEL, with
application of an uncertainty factor of 3. The more recently available data do not provide a basis for
revising the 2011 conclusions and therefore the CONTAM Panel conﬁrms the ARfD of 10 lg/kg bw.
The CONTAM Panel considered whether combined exposure to morphine and codeine from poppy
seed containing-foods, expressed as morphine-equivalents, should be estimated. The currently
available occurrence data demonstrate that the concentration of codeine can be much higher than that
of morphine in some poppy seed samples on the European market. The CONTAM Panel therefore now
concludes that the concentration of codeine in the poppy seed samples should be taken into account
in the exposure assessment and risk characterisation, by converting it to morphine equivalents, using a
factor of 0.2, based on the maximal metabolic conversion of codeine into morphine. The ARfD is
therefore a group ARfD for morphine and codeine, expressed in morphine equivalents.
Oripavine also acts as an agonist to the l-opioid receptor, with a lower activity than morphine and
a higher activity than codeine. Non-oral LD50 values in rodents indicate that oripavine is more acutely
toxic than morphine. However, the available data are insufﬁcient to characterise the hazard or to
identify a factor for conversion to morphine equivalents.
The toxicological properties of thebaine have not been well characterised. A contribution to
morphine-like toxicity due to its possible metabolism into morphine and oripavine may occur, but is
expected to be small. Oral LD50 values in rodents indicate that thebaine is more acutely toxic than
morphine. The available data are insufﬁcient to identify a factor for conversion to morphine
equivalents, to propose a health-based guidance value (HBGV) or to identify a reference point for
calculating margins of exposure.
Noscapine and papaverine do not exhibit morphine-like properties, and therefore, they are not
included in the group ARfD. Their toxicological properties have not been well characterised and it is
not possible to establish HBGVs. Based on the limited data available, it appears that noscapine and
papaverine are less toxic than the other alkaloids discussed in this opinion.
The CONTAM Panel considered that only acute dietary exposure to opium alkaloids had to be
assessed as for the previous opinion. Two batches of analytical results on the occurrence of opium
alkaloids in food and poppy seeds were available. A ﬁrst batch of 2,678 analytical results were
collected by EFSA until 2011 and presented in the previous CONTAM opinion on opium alkaloids. This
data set contained analytical results from 55 Australian poppy seed samples that were not used for
dietary exposure assessment since their opium alkaloid proﬁle was considered different from poppy
seed samples available on the EU market at that time. A second batch of data contained
4,991 analytical results and was collected by EFSA between 2012 and 2017.
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Considering the limited amount of data on food categories other than poppy seeds, the CONTAM
Panel decided to base the assessment on poppy seed samples only. The occurrence data on opium
alkaloids show the presence of poppy seed samples with high concentrations of morphine, codeine
and/or thebaine. The opium alkaloid proﬁle seems to be related to the country of origin of the poppy
seed samples and ultimately to the poppy variety. Based on the available data per country of origin
and batch, the CONTAM Panel concluded that the proﬁles in the two batches are comparable. In
addition, the proﬁle in the Australian poppy seeds is compatible with the proﬁle in the European poppy
seeds. Therefore, the Australian data were included in the data set and the two batches of data
submitted to EFSA were merged.
Based on evidence from the currently available data set and background information, the CONTAM
Panel divided the poppy seed samples with known country of origin into two groups. The ‘high-morphine’
group, which is assumed to represent primarily varieties grown for the pharmaceutical sector and the
‘low-morphine’ group, which is assumed to represent primarily varieties grown for the food sector. It
emerged that both types are available, although in unknown proportion, on the European market,
therefore, the CONTAM Panel has elaborated two separate acute exposure scenarios.
In poppy seed samples, highest mean middle bound (MB) concentrations were reported for
morphine (147 mg/kg in the ‘high-morphine’ group and 16.4 mg/kg in the ‘low-morphine’ group) and
thebaine (92.5 and 3.92 mg/kg, respectively) compared to codeine (22.7 and 2.88 mg/kg,
respectively) and oripavine (20.0 and 2.14 mg/kg, respectively). For noscapine and papaverine, the
mean MB concentrations were smaller and not exceeding 2 mg/kg. In the ‘high-morphine’ group,
thebaine was present at a concentration higher than morphine in more than 25% of the samples and
codeine was higher than morphine in about 5% of the samples. In the ‘low-morphine’ group,
morphine was the opium alkaloid present at the highest concentration in almost all samples.
Among consumers of poppy seeds, the average estimated poppy seed consumption from the
Comprehensive Food Consumption Database ranged from 0.5 (Other children, Sweden) to 25 g poppy
seeds/day (Adults, Hungary) in 44 population groups (age class within a country). Only in 7 population
groups, it was possible to calculate the 95th percentile (P95) ranging from 1 (Other children, Sweden)
to 55 g poppy seeds/day (Adults, Germany).
The CONTAM Panel calculated the acute dietary exposure for morphine, codeine, thebaine,
morphine equivalents, papaverine and noscapine for consumers of poppy seeds only. However, for
oripavine, the exposure was not assessed due to the low amount of occurrence data. Considering the
low percentage of left-censored data, and consequently the small difference between lower bound
(LB), MB and upper bound (UB) concentrations for morphine, codeine and thebaine, only the MB acute
dietary exposure is presented. Due to the higher percentage of left-censored data for noscapine and
papaverine, the LB and UB acute dietary exposure is presented.
For morphine, the mean MB acute dietary exposure for consumers only (based on the mean
occurrence and the mean consumption) ranged from 2.1 to 100 lg/kg bw per day across dietary
surveys and age groups when considering the poppy seed samples from the ‘high-morphine’ group.
The P95 acute dietary exposure (based on the P95 occurrence and the P95 consumption) ranged from
21 up to 330 lg/kg bw day. For the ‘low-morphine’ group, the acute mean MB acute dietary exposure
ranged from 0.2 to 11 lg/kg bw per day across dietary surveys and age groups and the P95 from 2.8
to 46 lg/kg bw per day. The mean acute dietary exposure was the highest for other children.
Maximum exposure at the P95 was similar for all age groups for which data were available.
For codeine, acute dietary exposure was lower compared to morphine, with the P95 dietary
exposure similar to the mean dietary exposure to morphine. Acute dietary exposure estimates for
morphine and codeine, expressed as morphine equivalents are quite similar compared to morphine
alone and codeine makes a minor contribution to the morphine equivalents.
For thebaine, the mean MB acute dietary exposure for consumers only, ranged from 1.3 to 63 lg/kg
bw per day across dietary surveys and age groups when considering the poppy seed samples from the
‘high-morphine’ group. For the ‘low-morphine’ group, the mean MB acute dietary exposure ranged from
0.06 to 2.7 lg/kg bw per day across dietary surveys and age groups. The P95 acute dietary exposure
ranged from 18 to 288 lg/kg bw per day for the ‘high-morphine’ group and from 0.7 to 11 lg/kg bw per
day for the ‘low-morphine’ group. The mean acute dietary exposure was the highest for other children.
Maximum exposure at the P95 was similar for all age groups for which data were available.
For noscapine, the mean dietary exposure for consumers only, ranged from 0.02 to 1.5 lg/kg bw
per day (min LB–max UB) across dietary surveys and age groups and was the highest for other
children. The P95 acute dietary exposure ranged from 0.3 to 4.4 lg/kg bw per day (min LB–max UB)
across dietary surveys and age groups. Among the opium alkaloids considered in this Scientiﬁc
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Opinion, acute dietary exposure for consumers only, was the lowest for papaverine, not exceeding
1 lg/kg bw per day.
It should be noted that exposure estimates are based on reported concentrations of alkaloids in
poppy seed samples due to the low amount of occurrence data on food products containing poppy
seeds. However, food processing steps (i.e. washing, soaking, heat treatment, grinding) may reduce
the alkaloid content in raw poppy seeds by 25–100% in the ﬁnal product. Therefore, the group ARfD is
most likely to be exceeded when large portions are consumed, or if foods containing unprocessed
poppy seeds are consumed.
Considering data related to poppy seeds containing relatively high levels of opium alkaloids, such as
those from varieties primarily grown for pharmaceutical use (‘high-morphine’ group), mean and high
levels of dietary exposure to morphine from poppy seeds result in the group ARfD of 10 lg morphine
equivalents/kg bw being exceeded in most age groups by up to 33-fold. For poppy seeds considered
to have relatively lower concentrations of opium alkaloids (primarily varieties for food use; ‘low-
morphine’ group), exceedance of the group ARfD is also seen at high levels of dietary exposure in
most surveys, but to a lesser extent at up to 4- to 5-fold. Based on the mean morphine occurrence,
34 out of 44 population groups are estimated to be exposed for at least 50% of the consumption days
to a level of morphine higher than the group ARfD of 10 lg/kg bw for the ‘high-morphine’ scenario
and only one population group for the ‘low-morphine’ scenario.
Codeine makes a minor contribution to exceedance of the group ARfD. However when considering
individual poppy seed samples containing high concentrations of codeine, their consumption might
result in a codeine exposure exceeding the group ARfD.
There are few reports of adverse reactions arising from traditional consumption of poppy seeds in
foods, but in the absence of formal reporting systems, it cannot be assumed that such reactions do
not occur from time to time, particularly in sensitive individuals. Pregnant women, infants, people
above 75 years of age and those suffering from health conditions with impaired respiratory function
are subgroups that are more sensitive to adverse effects of morphine.
In principle, oripavine could contribute to morphine-like effects, but the available toxicological and
occurrence data were insufﬁcient for risk characterisation. For thebaine, no quantitative risk
characterisation could be carried out. The estimated dietary exposures are slightly lower than those for
morphine. On the other hand, although the lack of data did not allow the establishment of a HBGV, the
CONTAM Panel noted that LD50 values for thebaine are 3- to 10-fold lower than for morphine,
suggesting that the estimated exposure levels might pose a health risk. For noscapine, the dietary
exposure is at least 80-fold lower than the recommended therapeutical dose, which does not suggest
a health concern. For papaverine, the dietary exposure is about 2,000-fold lower than the
recommended therapeutical dose and it is highly unlikely that this would be a health concern.
The CONTAM Panel concluded that there is a need for toxicological data on thebaine and oripavine,
including toxicokinetic data particularly on the formation of active metabolites. More occurrence data
for foods containing poppy seeds are required for the opium alkaloids considered in this opinion. There
is also a need for clariﬁcation of the occurrence of oripavine in poppy seed samples available on the
EU market. Certiﬁed reference materials of food products that contain opium alkaloids at relevant
concentrations should become available, as well as international proﬁciency tests. Finally, more
information on consumption of poppy seeds and poppy seed-based food in the EU is needed.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
On 5 October 2011, the EFSA Panel on Contaminants in the Food Chain (CONTAM) adopted the
Scientiﬁc Opinion on the risks for public health related to the presence of opium alkaloids in poppy
seeds (EFSA CONTAM Panel, 2011).
For that opinion, EFSA received the results from analyses of opium alkaloids, primarily morphine,
codeine, thebaine, papaverine and noscapine, in samples of poppy seeds, bakery products and baking
ingredients. Based on the relative prevalence of the alkaloids present in poppy seed and food samples
analysed, and on their pharmacological potency, the CONTAM Panel concluded that the risk
assessment could be based on dietary exposure to morphine alone. The CONTAM Panel established an
acute reference dose (ARfD) of 10 lg morphine/kg body weight (bw). Estimates of dietary exposure to
morphine from foods containing poppy seed demonstrate that the ARfD can be exceeded during a
single serving by some consumers, particularly children, across the EU. Furthermore, the CONTAM
Panel stressed that this risk assessment relates to poppy seed samples with an alkaloid proﬁle
comparable to that of the submitted data and should not be extrapolated to poppy seed samples with
a qualitatively different alkaloid proﬁle.
In the opinion it is concluded that morphine has a high afﬁnity for the l-opioid receptor as an
agonistic ligand. The pharmacology of codeine is strongly related to that of morphine, as it is a
precursor of morphine itself. Up to 20% of codeine can be converted to morphine. Oripavine and
thebaine show only partial agonistic activity at the l-receptor and thebaine has been shown to act as
an antagonist at higher dosages based on the limited data available. Papaverine and noscapine do not
show opiate-like pharmacology since papaverine acts as a smooth muscle relaxant that is most
pronounced on blood vessels, and noscapine is an antitussive agent.
Recent occurrence data on the presence of opium alkaloids in poppy seeds of European origin
indicate that the alkaloids proﬁle of the poppy seed samples submitted to EFSA after the 2011 opinion
may be different compared to the data used in the EFSA opinion, and this issue is particularly
important for thebaine.
Therefore, it seems appropriate to consider an update of the Scientiﬁc Opinion taking into account
the alkaloid proﬁle of the poppy seed samples submitted to EFSA since 2011.
1.1.2. Terms of Reference
In accordance with Art. 29 (1) of Regulation (EC) No 178/2002, the European Commission asks the
European Food Safety Authority for an update of the Scientiﬁc Opinion on the human health risks
related to the presence of opium alkaloids in poppy seeds taking into account the alkaloid proﬁle of
the poppy seeds samples submitted to EFSA since 2011.
1.2. Interpretation of the Terms of Reference
The CONTAM Panel concluded this opinion should comprise the:
a) re-evaluation of the toxicity of opium alkaloids present in poppy seed samples, for humans
considering all relevant toxicological endpoints;
b) evaluation of the alkaloid proﬁle (i.e. composition of the alkaloids and their concentrations) of
the poppy seed samples submitted to EFSA since 2011 and whether the proﬁle is similar to
that of the poppy seed samples used in the 2011 opinion;
c) estimation of the dietary exposure of the EU population to opium alkaloids from poppy seeds,
including the consumption patterns of speciﬁc groups of the population if appropriate;
d) assessment of the human health risks for the EU population, including speciﬁc groups of the
population if appropriate, as the consequence of the estimated dietary exposure.
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1.3. Supporting information for the assessment
1.3.1. Chemical and physical properties
The chemical properties of opium alkaloids have been reviewed in the previous EFSA opinion on
opium alkaloids (EFSA CONTAM Panel, 2011). The following chapter is an adapted version of this
review.
Opium alkaloids can be divided into two distinct chemical classes, phenanthrenes and
benzylisoquinolines. Among the more than 80 alkaloids of poppy, the principal phenanthrenes are
morphine, codeine and thebaine whereas the principal benzylisoquinolines are noscapine and
papaverine. In this Scientiﬁc Opinion, the term ‘opium alkaloids’ refers to these compounds. Figure 1
shows the chemical structures of the predominant alkaloids reported to occur in poppy seed samples.
The opium alkaloids with a phenanthrene structure are also called morphinans, which are typiﬁed by
an aromatic A ring and (partly) saturated B and C ring and with an additional nitrogen-containing D
ring, spanning carbons 9 and 13 of the phenanthrene structure. In the biosynthetic pathway, thebaine
is the precursor of oripavine and of codeine, which are both precursors of morphine (Appendix A). The
benzylisoquinolines noscapine and papaverine are not closely related in the biosynthetic pathway.
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Substance
Name/CAS/chemical formula/MW/pKa/logP/salts
Structure
Morphine CAS: 57-27-2
IUPAC name: (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-
hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-
diol
CA Index name: 7,8-didehydro-4,5 -epoxy-17-
methylmorphinan-3,6 -diol
C17H19NO3; MW: 285.34 
pKa: 8.21; LogP: 0.89
Salts: hydrochloride (MW: 321.80); hydrochloride trihydrate 
(MW: 375.85); sulphate (MW: 668.75); sulphate pentahydrate 
(MW:758.83)
Codeine    CAS: 76-57-3
IUPAC name: (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-
2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-
e]isoquinoline-7-ol
CA Index name: 7,8-didehydro-4,5 -epoxy-3-methoxy-17-
methylmorphinan-6 -ol
C18H21NO3; MW: 299.36
pKa: 8.21; LogP: 1.19
Salts: hydrochloride (MW: 335.83); sulphate (MW: 696.81); 
sulphate trihydrate (MW: 750.86); phosphate (MW: 397.36), 
phosphate hemihydrate (MW: 406.37); phosphate sesquihydrate 
(MW: 848.77)
O
OH
OH
N
CH3
H
1
10
9
12
8
5
11
3
4
2
7
13
14
15 16
6
17
O
O
OH
N
H
CH3
CH3
Thebaine    CAS: 115-37-7
IUPAC name: (4R,7aR,12bS)-7,9-dimethoxy-3-methyl-2,4,7a,13-
tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline
CA Index name: 6,7,8,14-tetradehydro-4,5 -epoxy-3,6-
dimethoxy-17-methylmorphinan
C19H21NO3; MW: 311.37
pKa: 8.38; logP: 1.53 
Salts: hydrochloride (MW: 347.84)
O
O
CH3
O
CH3
N
CH3
MW: molecular weight; CAS: chemical abstracts service number; pKa: log of acid dissociation constant; logP: log of
octanol: water partition coefﬁcient. Different sources were used for retrieving the chemical structures above.1
Figure 1: Structures of opium alkaloids considered in this Scientiﬁc Opinion
1 Sources: http://www.commonchemistry.org; https://www.drugbank.ca; https://pubchem.ncbi.nlm.nih.gov; http://www.che
mspider.com; https://www.rsc.org/Merck-Index/monograph
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1.3.2. Analytical methods
The analytical methods for the detection of opium alkaloids in poppy seeds and food have been
reviewed in the previous EFSA opinion on opium alkaloids (EFSA CONTAM Panel, 2011). Only a short
update is presented here.
Extraction of opium alkaloids from the biological matrix is often performed with the use of (mixtures)
of aqueous or organic solvents under acidic conditions. Depending on the matrix or the limit of detection
(LOD) that is required, additional clean-up by solid-phase extraction (SPE) or liquid/liquid extraction (LLE)
may be necessary. Detection methods most often used are high-performance liquid chromatography-
ultraviolet (HPLC-UV), Gas chromatography–mass spectrometry (GC–MS) and liquid chromatography
coupled to tandem mass spectrometry (LC–MS/MS). GC–MS and LC–MS/MS have the advantage of
higher selectivity and sensitivity than HPLC–UV. GC–MS has as drawback that derivatisation may be
required to obtain sufﬁcient sensitivity. Nowadays, LC–MS/MS, equipped with an electrospray ionisation
source, has become the most popular technique for targeted analysis of opium alkaloids. Due to the high
sensitivity of LC–MS/MS, sample preparation can often be minimal (dilute-and-shoot) resulting in a higher
sample through-put (Lopez et al., 2018). For analysis of opium alkaloids in more complex matrices, or at
low levels, additional clean-up steps may still be required in order to reduce matrix interferences and
suppression/enhancement effects that may otherwise hamper quantiﬁcation. GC–MS, LC–MS/MS or liquid
chromatography coupled to high-resolution mass spectrometry (LC–HRMS) techniques are also
increasingly used for comprehensive metabolite proﬁling of poppy cultivars or opium latex (Choe et al.,
2011; Desgagne-Penix et al., 2012; Liu et al., 2016a).
Oripavine    CAS: 467-04-9
IUPAC name: (4R,7aR,12bS)-7-methoxy-3-methyl-2,4,7a,13-
tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-9-ol
CA Index name: 6,7,8,14-tetradehydro-4,5 -epoxy-6-methoxy-
17-methylmorphinan-3-ol
C18H19NO3; MW: 297.34
pKa: 8.38; logP: 1.46 
Noscapine    CAS:128-62-1
IUPAC and CA Index name: (3S)-6,7-dimethoxy-3-[(5R)-4-
methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-
5-yl]-3H-2-benzofuran-1-one
C22H23NO7; MW: 413.42
pKa: 7.80; logP: 2.88
Salts: hydrochloride (MW: 449.88); hydrochloride hydrate (MW: 
467.89)
Papaverine    CAS 58-74-2
IUPAC and CA Index name: 1-[(3,4-dimethoxyphenyl)methyl]-
6,7-dimethoxyisoquinoline
C20H21NO4; MW 339.39
pKa: 8.07; logP: 3.08
Salts: hydrochloride (MW: 375.85)
O
OH
O
CH3
N
CH3
O
O
N
CH3
O
CH3
O
CH3
O
O O
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Isotope-labelled standards are commercially available for the major opium alkaloids and for many
of their synthetic derivatives. In most cases, these are D3 or D6 analogues of the unlabelled congener.
13C-isotope-labelled standards are much less common, but a 13C4 analogue of morphine and codeine is
commercially available. The isotopically labelled standards can be used as internal standards in
LC–MS/MS and GC–MS methods to improve the accuracy of the determination of the corresponding
unlabelled congeners as the internal standard will correct for matrix effects and recovery.
No progress has been made with respect to the availability of certiﬁed reference materials of food
products that contain opium alkaloids at relevant concentrations. No international proﬁciency tests for
their determination were identiﬁed.
LC–MS- and GC–MS-based analytical methodologies are also widely applied for the determination of
opium alkaloids and their metabolites in human biological samples such as urine, plasma, serum, hair,
saliva, cerebrospinal ﬂuids, often in relation to forensic cases, drug abuse or palliative care (see for
reviews: Bosch et al., 2007; Barroso et al., 2011). As these methods are not directly used for food,
they are beyond the scope of this opinion and thus not further described.
1.3.3. Previous assessments
In 2011, the EFSA CONTAM Panel issued an opinion on the risks for public health related to the
presence of opium alkaloids in poppy seeds intended for human consumption (EFSA CONTAM Panel,
2011). EFSA received results from analyses of opium alkaloids, primarily morphine, codeine, thebaine,
papaverine and noscapine in samples of poppy seeds, bakery products and baking ingredients. Based
on the relative prevalence of the alkaloids present in poppy seed and food samples analysed, and on
their pharmacological potency, the Panel concluded that the risk assessment could be based on dietary
exposure to morphine alone. This assessment included the estimation of morphine-equivalents based
on morphine and codeine concentrations, but the CONTAM Panel concluded that codeine has a minor
impact.
The CONTAM Panel established an ARfD of 10 lg morphine/kg bw based on the lowest known
single oral therapeutic dose of 30 lg morphine/kg bw and applying an uncertainty factor of 3 for
extrapolation from the lowest-observed-effect-level (LOEL) to a no-observed-effect level (NOEL)
considering that the LOEL was derived from patients and not from the general population.
The CONTAM Panel concluded that a considerable proportion of consumers of foods that contain
large amounts of poppy seeds, such as are common in central-eastern European countries, are likely
to exceed the ARfD for morphine on at least some eating occasions. Taking the possible reduction
during food processing into account, the ARfD was most likely to be exceeded when single large
portions were consumed or if foods containing raw, unground poppy seeds were consumed. The
CONTAM Panel stressed that this risk assessment related to poppy seed samples with an alkaloid
proﬁle comparable to that of the submitted data and should not be extrapolated to poppy seed
samples with a qualitatively different alkaloid proﬁle.
Several institutions, including the European Medicines Agency (EMA), recently re-evaluated the
pharmaceutical use of codeine and developed recommendations restricting the use in infants, children,
breast-feeding mothers and ultra-rapid metabolisers (see Section 3.1.3.2 Codeine).
1.3.4. Legislation
1.3.4.1. Food
In order to protect public health, Article 2 of the Council Regulation (EEC) No 315/932 stipulates
that, where necessary, maximum tolerances for speciﬁc contaminants shall be established. Thus, a
number of maximum tolerances for contaminants as well as natural plant toxicants are currently laid
down in Commission Regulation (EC) No 1881/20063. However, no maximum levels for opium alkaloids
in poppy seeds have been established neither under this nor under another Regulation.
In 2014, the European Commission published a recommendation on good practices to prevent and
to reduce the presence of opium alkaloids in poppy seeds and poppy seed products.4 These include
2 Council Regulation (EEC) No 315/93 of 8 February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–3.
3 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
4 Commission Recommendation of 10 September 2014 on good practices to prevent and to reduce the presence of opium
alkaloids in poppy seeds and poppy seed products (2014/662/EU). OJ L 271, 12.9.2014, p. 96–100.
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good agricultural practices to prevent the presence of opium alkaloids during growing, harvesting and
storage, and good practices to prevent the presence of opium alkaloids during processing. These
recommendations include:
• adequate control of pests and diseases,
• prevention of bad harvesting conditions caused by lodging of plants,
• application of appropriate harvesting conditions (i.e. moisture content and appropriate
harvesters),
• post-harvest cleaning including the removal of dust particles and other impurities,
• application of ventilated storage,
• labelling in case the poppy seeds need to undergo an additional treatment to reduce the
opium alkaloid content before human consumption,
• application of pretreatments and processing methods reducing the concentration of opium
alkaloids.
In addition, several countries have national legislation on the presence of opium alkaloids in poppy
seeds.
1.3.4.2. Narcotics
Among the three main international drug control conventions of the United Nations (UN), the Single
Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, includes the regulation on
poppy cultivation (beside coca bush and cannabis plant).5 It was established to achieve more effective,
co-ordinated and universal measures against drug abuse. This convention deﬁnes the methods and
rules of estimation of drug requirement (each for medical and scientiﬁc purposes as well as for
manufacture of other drugs) and providing statistics on production (both as quantity and area) and
stocks of these drugs, their consumption, export and import. The list of substances (among them
concentrate of poppy straw,6 opium, morphine, thebaine and derivatives of morphine and codeine)
underlying to this convention, is included in an addendum ‘ST/CND/1/Add.1’. The countries permitting
the cultivation of the opium poppy for the production of opium (alkaloids) shall maintain government
agencies to carry out the controlling functions deﬁned in the convention. Article 25 especially about
control of poppy straw stipulates that the country that permits the cultivation of the opium poppy for
purposes other than the production of opium shall take all measures necessary to ensure that opium is
not produced from such opium poppies; and that the manufacture of drugs from poppy straw is
adequately controlled.
1.3.5. Poppy seeds and opium poppy – botanical origin, ingredients, uses,
varieties and cultivation
The botanical origin, uses, varieties and cultivation of poppy seeds and opium poppy has been
extensively reviewed in the previous EFSA opinion on opium alkaloids (EFSA CONTAM Panel, 2011).
The following chapter is an updated excerpt of this review.
Poppy seed is an oilseed obtained from the opium poppy (Papaver somniferum L.) that is used as
food and to produce edible oil. P. somniferum L. is cultivated for production of alkaloids and opium for
pharmaceutical purposes. The alkaloids are synthesised, stored and metabolised in the latex (milky
sap). The latex permeates all parts of the plant other than the seeds and is to be found in particular in
the pericarp of the capsule. The ripened seeds do not contain milky sap and do not naturally contain
opium alkaloids. However, opium alkaloids can be present on the surface of the poppy seeds as a
result of contamination from dust of capsule walls during harvest and/or improper processing
(Fairbairn and El-Masry, 1968; Rochholz et al., 2004). Contamination may also result from insect
damage (weevil; Ceutorhynchus macula-alba) due to chewing of larvae on the unripe capsule wall
resulting in droplets of latex on the seed surface (Bernath and Nemeth, 2010). On the other hand, the
morphine content on the surface of the seeds can drastically be reduced by professional cleaning
5 Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol Convention on Psychotropic Substances of 1971
United Nations Convention against Illicit Trafﬁc in Narcotic Drugs and Psychotropic Substances of 1988 with ﬁnal acts and
resolutions. https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_
Control_Conventions_E.pdf
6 ‘The material arising when poppy straw has entered into a process for the concentration of its alkaloids when such material is
made available in trade’. This deﬁnition was taken from the addendum ST/CND/1/Add.1/Rev.3 ‘Schedules of the Single
Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol as at April 2017’. Available at https://documents-dds-
ny.un.org/doc/UNDOC/GEN/V17/032/70/PDF/V1703270.pdf?OpenElement
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machines and especially through washing (e.g. Lo and Chua, 1992; Andresen and Schmoldt, 2004;
Commission Recommendation 2014/662/EU7 – see Section 3.2.3).
There is a wide range of cultivars and ecotypes of P. somniferum grown all over the world that are
differing in morphological (e.g. growth, branching, ﬂower colour, capsule shape, etc.) and chemical
characteristics (level and spectrum of alkaloids) and furthermore in the length of vegetation cycle and
yield. Eighteen countries are authorised by the UN to produce poppy for pharmaceutical use (Austria,
Australia, China, France, Germany, Great Britain, Hungary, India, Japan, Macedonia, the Netherlands,
New Zealand, Poland, Romania, Slovakia, Spain, Turkey and Ukraine). To a large extent, this list
coincides with the countries that are reported by the Food and Agriculture Organization (FAO)8 as the
producers of poppy seed (Austria, Bulgaria, Croatia, the Czech Republic, France, Germany, Hungary,
Macedonia, the Netherlands, Occupied Palestinian Territory, Romania, Serbia, Slovakia, Spain, and
Turkey) (Lohr, 2017). In the European Union (EU), the main poppy seed producing country is the
Czech Republic (Figure 2). Other important producers are Spain, France and Hungary. Own production
of the Netherlands is relatively small but it is considered the largest centre of the world regarding
poppy seed trade. Globally, the biggest producer of poppy alkaloids is Australia followed by Turkey.
Recently, China has also emerged on the market. These three countries are also the main exporters to
the EU (Figure 3).
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Figure 2: Poppy seed production in EU countries in 2010–2016 (based on data extracted from
FAOSTAT)
7 Commission Recommendation 2014/662/EU of 10 September 2014 on good practices to prevent and to reduce the presence of
opium alkaloids in poppy seeds and poppy seed products. OJ L 271, 12.9.2014, p. 96–100.
8 http://www.fao.org/faostat/en/#home
Opium alkaloids in poppy seeds
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2018;16(5):5243
Poppy seeds are used in the food sector. They are used in bakery products, on top of dishes, in
ﬁllings of cakes and in desserts and to produce edible oil. The oil content in poppy seeds varies
between 32% and 57%. The oil is obtained by solvent or mechanical extraction and the remaining
poppy seed cake is crushed and used for cattle feed. Besides the seeds originating from varieties
particularly grown for food production, also seeds from varieties grown for pharmaceutical purposes
enter the food market (Fist, 2001).
The latex of the immature capsules is released by incisions and when dried is called opium. The
opium contains approximately 20–25% alkaloids of which around 50 alkaloids have been isolated in
pure form up to now. Poppy straw (i.e. capsules with the seeds removed and with 5–10 cm stem part)
contain the same active substances as opium but at a lower concentration (up to 3–4%; Nemeth-
Zambori et al., 2011; Desgagne-Penix et al., 2012). Both opium and poppy straw are used as raw
material by the pharmaceutical industry. Stems, leaves and roots accumulate much lower amounts of
alkaloids than the capsules, usually well below 1% and sometimes only in traces (Gessner and
Orzechowski, 1974; Gurkok et al., 2016).
Alkaloid accumulation in the poppy plant depends on both genetic factors and environmental/
cultivation conditions. On the one hand, breeding is focusing on the development of cultivars with high
and speciﬁc alkaloid content to fulﬁl the requirements of the pharmaceutical industry (Desgagne-Penix
et al., 2012; Chaturvedi et al., 2014) and on the other hand on cultivars with low alkaloid content for
seed/oil production (Bernath and Nemeth, 2009). In some European countries (e.g. Germany, the
Czech Republic), only ‘low-morphine’ varieties of P. somniferum are authorised for cultivation. They
have been selected for the production of seeds for food use or to produce oil. In some other countries,
only varieties for pharmaceutical use of the capsules are grown (e.g. Australia, France, Spain) while in
certain countries (e.g. Hungary, Slovakia) both culinary and pharmaceutical varieties are cultivated
(Lohr, 2017). A generally deﬁned borderline between the alkaloid contents of these two types of
varieties does not exist. However, in some countries (e.g. the Czech Republic9 and Hungary10) national
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Figure 3: Poppy seed import from third countries into the EU in 2011–2016 (based on data extracted
from FAOSTAT)
9 Regulation No 399/2013 of the Ministry of the Agriculture amending the Regulation of the Ministry of Agriculture No 329/1997
which implements Section 18 (a), (d), (h), (i), (j) and (k) of Act No 110/1997 on foodstuff and tobacco products and on the
change and completion of some related laws, for starch and starch products, legumes and oil seeds, as amended by the
Regulation No 418/2000.
10 19/2015 (II.16.) Government Decree on amendment of the Government Decree 162/2003. (X. 16.) on the regulation of
cultivation, trade and utilisation of narcotic plants and of the Government Decree 66/2012 (IV.2.) on the regulation of activities
with drugs and psychotropic agents and on the ofﬁcial registration and amendments of list of these compounds.
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legislation deﬁnes the alkaloid content of varieties for food use). Currently, 54 varieties are listed on
the EU Plant variety Catalogue.11 The OECD list contains 45 varieties, including 40 varieties in common
with the EU list, but also 5 Turkish genotypes.12 Unfortunately, these open databases do not offer
information on the alkaloid contents of the varieties. At the same time, several other, non-registered
strains/genotypes/accessions exist which have not been the target of ofﬁcial variety legislation as they
seem to be cultivated in closed areas for pharmaceutical industry only (Millgate et al., 2004;
Desgagne-Penix et al., 2012; Chaturvedi et al., 2014).
In course of time, the need of the pharmaceutical industry for speciﬁc opium alkaloid proﬁles has
changed with current demands for cultivars not only rich in morphine, but also in codeine, oripavine
thebaine or noscapine (Dang and Facchini, 2014).
Besides the genetics, environmental and cultivation conditions may also inﬂuence the alkaloid
content of the plant. Warm and sunny weather during capsule development and ripening contribute to
higher accumulation levels of morphine (Bernath, 1998), while the opposite effect has been reported
for noscapine (Kalman-Pal et al., 1987). Nitrogen fertilisation may enhance the accumulation of
alkaloids (Kadar et al., 2001); however, only under excessive light conditions (Bernath, 1986). Severe
drought stress may decrease the accumulation of morphinans (Bernath, 1986). Experimental data
showed that accumulation of heavy metals (Cd, Zn) – due to their higher concentrations in the soil –
correlates with higher noscapine levels in the seeds (Lachman et al., 2006). Heavy rain may cause a
wash out of alkaloids from mature capsules resulting in a marked drop in content. Morphine and
codeine are more easily washed out than thebaine or noscapine (Hofman and Menary, 1984a).
Pathogens, like viruses, may enhance the concentration of alkaloids in the plant (Zaim et al., 2014)
while on the other hand certain fungi can cause a considerable reduction of the morphine yield
(Hofman and Menary, 1984b).
The total alkaloid content changes during ontogenesis: it increases until the ﬂowering period and
then drops again (Kadar et al., 2001; Frohne and Pf€ander, 2004; Blaschek et al., 2006).
2. Data and methodologies
The CONTAM Panel applied the general principles for the assessment of chemicals in food as
described by WHO/IPCS (2009) and any EFSA guidance documents pertaining to risk assessment and
relevant for the present assessment (see Appendix C, Section C.4).
2.1. Supporting information for the assessment, and previously reported
occurrence data and dietary exposure
The CONTAM Panel issued a risk assessment on opium alkaloids in poppy seeds in 2011 and this
opinion was used as a starting point for drafting the supporting information. The data was summarised
in a narrative way based on expert knowledge/judgement and updated when new information had
become available (further details see Appendix C, Section C.1).
2.2. Hazard identiﬁcation and characterisation
2.2.1. Collection and selection of evidence
A comprehensive search for literature was conducted for peer-reviewed original research pertaining
to adverse health effects in experimental animals and humans. The search strategy was designed to
identify scientiﬁc literature dealing with toxicity, mode of action, toxicokinetics and human data on
morphine, codeine, thebaine, oripavine, papaverine and noscapine. Since this Scientiﬁc Opinion is an
update of the Scientiﬁc Opinion on the human health risks related to the presence of opium alkaloids
in poppy seeds published in 2011, the literature search was restricted to papers published in 2011 and
after. However, given the limited information available on thebaine and oripavine in the Scientiﬁc
Opinion published in 2011, no time restrictions were included in the literature search for these 2
substances. An overview of the search terms is given in Appendix C, Section C.2.
11 EU Database of registered plant varieties, http://ec.europa.eu/food/plant/plant_propagation_material/plant_variety_catalogues_
databases/search/public/index.cfm?event=SearchVariety&ctl_type=A&species_id=246&variety_name=&listed_in=0&show_current=
on&show_deleted, Accessed 29.3.2017.
12 OECD List of Varieties eligible for seed certiﬁcation http://www.oecd.org/tad/code/oecd-list-of-varieties-eligible-for-certification.
htm, Accessed 1.1.2018.
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The literature search was not restricted to publications in English. A ﬁrst literature search was
performed in February 2017 and has been updated until December 2017. Web of Science,13 PubMed14
and Embase were identiﬁed as databases appropriate for retrieving literature for the present evaluation.
The references obtained from the literature search were imported and saved using a software package
(EndNote15). The references obtained were screened using title and abstract to identify the relevant
literature and exclusion criteria are shown in Appendix C, Section C.3. For morphine, Distiller SR was
used to screen the title and abstract due to the high number of identiﬁed papers.
Additionally, reviews, relevant scientiﬁc evaluations by national or international bodies were
considered for the current risk assessment.
2.2.2. Appraisal of evidence
The information retrieved has been screened and evaluated by relevant domain experts from the
CONTAM Working Group (WG) on opium alkaloids and has been used for the present assessment. Any
limitations in the information used are documented in this Scientiﬁc Opinion.
Selection of the scientiﬁc papers for inclusion or exclusion was based on consideration of the extent to
which the study was relevant to the assessment or on general study quality considerations (e.g. sufﬁcient
details on the methodology, performance and outcome of the study, on dosing, substance studied and
route of administration and on statistical description of the results), irrespective of the results.
2.3. Occurrence data submitted to EFSA
2.3.1. Data collection and validation
At the moment of receiving the request for the update of the scientiﬁc opinion from the European
Commission, some occurrence data on opium alkaloids in food were already available in the EFSA
Chemical Occurrence database; part of those analytical data (2,678) were presented in the previous
opinion on opium alkaloids in poppy seeds (EFSA CONTAM Panel, 2011). In order to increase the
number of available data for the exposure assessment and to update the data set with more recent
data points, in 2017, the EFSA Evidence Management Unit (DATA Unit) alerted the data provider
network, requesting data on opium alkaloids in poppy seeds and food commodities. Data providers
were speciﬁcally invited to submit data on opium alkaloids as single chemicals rather than as sum of
opium alkaloids, with a speciﬁc focus on the following substances: morphine, codeine, papaverine,
noscapine, thebaine, oripavine and narceine. European national food authorities and similar bodies,
research institutions, academia and food business operators were invited to submit data through the
Call for continuous collection of chemical contaminants occurrence data in food and feed.16 Only data
submitted until October 2017 were considered for this Scientiﬁc Opinion.
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operating procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of food
consumption and occurrence data’.
2.3.2. Data analysis
Data were thoroughly evaluated, this including cleaning and validation steps. Special attention was
paid to the identiﬁcation of duplicates and to the accuracy of different parameters such as ‘Analytical
methods’, ‘Reporting unit’, ‘Sampling strategy’ and the codiﬁcation of the different samples under
FoodEx classiﬁcation. Upon identiﬁcation of potential inconsistencies, data providers were contacted to
provide further clariﬁcation. Among others, particular attention was also devoted to the ‘Country of
Origin’ and when this was not reported speciﬁc clariﬁcation request was sent to the data providers.
Details of data cleaning are reported in Annex A (Table A.1) while the outcome of the data analysis is
shown in Section 3.2.1.
13 Web of Science (WoS), formally ISI Web of Knowledge, Thomson Reuters. Available at: http://thomsonreuters.com/thomson-
reuters-web-of-science/
14 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI), National
Library of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health and
Human Services. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
15 EndNote X5, Thomson Reuters. Available at: http://endnote.com/
16 https://www.efsa.europa.eu/it/data/call/datex101217
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The left-censored data (analytical data reported below the LOD/limit of quantiﬁcation (LOQ)) were
treated by the substitution method as recommended in the ‘Principles and Methods for the Risk
Assessment of Chemicals in Food’ (WHO/IPCS, 2009). This method is also indicated in the EFSA
scientiﬁc report ‘Management of left-censored data in dietary exposure assessment of chemical
substances’ (EFSA, 2010b), as an option for the treatment of left-censored data. According to this
guidance the lower bound (LB) and upper bound (UB) approach should be used for chemicals likely to
be present in the food (e.g. naturally occurring contaminants, nutrients and mycotoxins). At the LB,
results below the LOQ or LOD were replaced by zero; at the UB, the results below the LOD were
replaced by the LOD and those below the LOQ were replaced by the value reported as LOQ.
Additionally, a middle bound (MB) approach was used by assigning a value of LOD/2 or LOQ/2 to the
left-censored data.
2.4. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (2011a). The latest version of
the Comprehensive Database contains results from a total of 51 different dietary surveys carried out in
23 different Member States covering 94,532 individuals.
The age classes considered in the EFSA Comprehensive European Food Consumption Database are
the following:
• Infants: < 12 months old
• Toddlers: ≥ 12 months to < 36 months old
• Other children: ≥ 36 months to < 10 years old
• Adolescents: ≥ 10 years to < 18 years old
• Adults: ≥ 18 years to < 65 years old
• Elderly: ≥ 65 years to < 75 years old
• Very elderly: ≥ 75 years old.
Overall, the food consumption data in the Comprehensive Database are the most complete and
detailed data currently available at EU level. Consumption data were collected using single or repeated
24- or 48-h dietary recalls, and dietary records covering from 3 to 7 days per subject. Owing to the
differences in the methods used for data collection, direct country-to-country comparisons can be
misleading. Detailed information on the different dietary surveys available in the EFSA Comprehensive
European Food Consumption Database (Comprehensive Database) can be found on the dedicated
page of the EFSA website.17
2.5. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food groups (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about
1,800 endpoints (food names or generic food names) at the fourth level.
In 2011, a new version of FoodEx, named FoodEx2 has been developed and is described in the
scientiﬁc document ‘Report on the development of a Food Classiﬁcation and Description System for
exposure assessment and guidance on its implementation and use’ (EFSA, 2011c). The last release of
FoodEx2 complements the previous hierarchical classiﬁcation system of basic codes with more detailed
food levels and gives the possibility of reporting additional information through the use of facets and
facet descriptors (EFSA, 2015).
2.6. Exposure assessment
The CONTAM Panel considered that only acute dietary exposure to opium alkaloids had to be
assessed as for the previous opinion (EFSA CONTAM Panel, 2011). Thus, for acute exposure
17 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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assessment, food consumption data were used from 41 different and most recent dietary surveys
carried out in 23 different European countries present in the latest version of the Comprehensive
Database (Annex B, Table B.1). Not for all countries consumption information is available for all age
groups.
In addition to the reporting of poppy seed consumption, reports on consumption of foods
containing poppy seeds were considered. Therefore, the original food descriptors for each of the foods
reported in the Comprehensive Database were searched for the term ‘poppy’. In this way, a larger
amount of eating occasions of food products containing poppy seeds as ingredient were identiﬁed. In
order to estimate the amount of poppy seeds in each of these food products, disaggregation factors
were worked out from the portfolio of recipes compiled in the 2011 opinion (EFSA CONTAM Panel,
2011). When it was possible to associate more than one recipe to a food product, the average content
of poppy seeds from the different recipes was used. Annex B, Table B.2 reports the average
disaggregation factors for each food product. Based on this approach, poppy seed consumption was
reported in 18 dietary surveys from 13 countries (Annex B, Table B.3).
Exposure estimates were calculated for each dietary survey and age class. Acute dietary exposures
were calculated by combining opium alkaloids mean, median, P75, P90, P95 and P99 concentrations in
poppy seed samples with the mean and P95 consumption of poppy seeds (expressed on a body
weight basis) per day.
All analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1).
2.7. Risk characterisation
The CONTAM Panel applied the general principles of the risk characterisation process for chemicals
in food as described by WHO/IPCS (2009) and the relevant EFSA guidance documents (see
Appendix C, Section C.4).
3. Assessment
3.1. Hazard identiﬁcation and characterisation
3.1.1. Toxicokinetics
3.1.1.1. ADME
The information on absorption, distribution, metabolism and excretion (ADME) of opium alkaloids
presented below, relates to humans unless speciﬁed differently.
Morphine
Morphine is extensively absorbed from the GI tract of humans and rats and is distributed
throughout the body. The oral bioavailability of morphine is reduced by both Phase I and II
presystemic metabolism in the GI tract and liver. Though the brain is its primary site of action,
morphine does not cross the blood–brain barrier easily. Morphine diffuses across the placenta, and
transfers into milk. Morphine is metabolised via N-demethylation and O-glucuronidation in the gut and
the liver. Glucuronidation is the predominant route of metabolism, producing approximately 60% of
morphine-3-glucuronide (M3G) and 5–10% of morphine-6-glucuronide (M6G). These reactions are
principally catalysed by uridine diphosphate-glucuronosyltransferase UGT2B7 and to a lesser extent
UGT1A8. Approximately 5% of morphine is N-demethylated to normorphine via the cytochromes P450
(CYP) enzymes CYP3A4 and CYP2C8. In addition, other minor metabolites are formed: morphine-3,6-
diglucuronide, codeine and morphine-3-sulfate. About 90% of morphine is excreted in the urine within
24 h mainly as M3G, M6G, and only 2–12% is excreted as morphine unchanged. The elimination half-
life of morphine is approximately 2 h in humans. Both morphine and M6G have a high afﬁnity to the
l-opioid receptor, whereas M3G has a very weak afﬁnity and is therefore considered as an inactive
metabolite (see Section 3.1.4) (EFSA CONTAM Panel, 2011).
Morphine has a low plasma protein binding of 35%, whereas the binding for M3G and M6G is even
lower: 10% and 15%, respectively (van Dongen et al., 1994). Higher plasma concentrations of M3G
and M6G have been measured in pharmacokinetic studies (Sawe et al., 1983). Penetration rate of M3G
and M6G across the blood–brain barrier is lower than for morphine itself (Yoshimura et al., 1973).
The rate and pathways of opioid metabolism may be inﬂuenced by genetic factors and medical
conditions (liver and kidney disease).
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More information on the ‘pharmacogenetics’ of transporters has become available since the
previous opinion. The distribution of morphine is under the control of several polymorphic genes,
which can account for part of the observed interindividual variation in morphine effects. For instance,
pain relief variability of morphine was associated with single-nucleotide polymorphism of the ABCB1
gene (coding for a P-glycoprotein transporter) (Campa et al., 2008) that may modify the ability of the
alkaloid to cross the blood–brain barrier. Similar results were obtained in a separate study when
fentanyl was used as analgesic (Dzambazovska-Trajkovska et al., 2016). The importance of the ABCB1
polymorphism was also conﬁrmed by investigating the risk of respiratory depression in response to
morphine administration (Sadhasivam et al., 2015). A similar role in inﬂuencing the risk of morphine
induced respiratory depression has been recently established for the gene ABCC3 (coding for a
transporter that facilitates hepatic morphine metabolite efﬂux) (Venkatasubramanian et al., 2014;
Sadhasivam et al., 2015; Chidambaran et al., 2017). OCT1, a member of the organic cation
transporters (OCTs) family, mediates cellular uptake of morphine into hepatocytes. Children with OCT1
homozygous genotypes have lower morphine clearance and have signiﬁcantly lower M3G and M6G
formation. Relatively high allelic frequencies of defective OCT1 variants among the Caucasian
population may explain their lower morphine clearance and higher frequencies of adverse effects
compared with African American children (Fukuda et al., 2013; Venkatasubramanian et al., 2014).
Genetic polymorphisms can lead to substantially low OCT1 activity in up to 9% of the Europeans
(Tzvetkov, 2017). Breastfed infants with mothers who have a low OCT1 transporter activity are also at
increased risk for toxicity (Tzvetkov, 2017).
In some studies, UGT2B7 polymorphism has been associated with interindividual variability in the
pharmacokinetics and/or adverse effects of morphine, while other studies have dismissed this
association (Kwara et al., 2009; Madadi et al., 2009; Fujita et al., 2010). Eissing et al. (2012) have
shown that increased UGT2B7 activity is associated with a decrease in active opioid exposure (lower
morphine and M6G plasma exposure); however, CYP3A4 (which catalyses the formation of norcodeine
and normorphine) inhibitors have only minor inﬂuences on active internal opioid exposure (increases of
approximately 10% in morphine and 15% M6G exposure).
Reduced renal function has been reported to increase the risk of adverse opioid effects. This may
be the consequence of the increase of M6G in case of renal impairment (Gasche et al., 2004; Klimas
and Mikus, 2014). However, according to other researchers, elimination of morphine is not signiﬁcantly
impaired in patients with renal dysfunction (Aitkenhead et al., 1984; Sawe et al., 1985; Woolner et al.,
1986; Eissing et al., 2012). Based on AUC data, there is a major contribution of M6G to the analgesic
effect of morphine (96.6% after oral administration of morphine). In patients with renal insufﬁciency,
97.6% of the analgesic effect is caused by M6G after oral administration of morphine (Klimas and
Mikus, 2014).
In newborns and young infants, morphine elimination is much slower because of immature liver
and kidney functions (Lynn and Slattery, 1987; Bhat et al., 1990; Osborne et al., 1993). The ontogeny
of UGT2B7 is comparatively slow, and adult activity levels are attained between 2 months and 3 years
of age (Strassburg et al., 2002; Edginton et al., 2006).
Codeine
Codeine (as codeine phosphate) is readily and extensively absorbed from the GI tract following oral
administration. The maximum plasma concentration is reached after about 1 h. Interindividual
variations in bioavailability (40–70%) have been shown. Codeine is distributed throughout the body. It
penetrates the placental barrier and enters fetal circulation. Oral bioavailability of codeine in humans is
approximately ﬁvefold greater than in rats; however, the amount of codeine converted to morphine is
approximately 30-fold greater in the rat. As a result, internal exposures to morphine from an oral dose
of codeine would be predicted to be approximately sevenfold lower in humans relative to rats. Codeine
and its metabolites are mainly excreted as glucuronides via the kidney. In healthy adults, the
elimination half-life is 3–5 h and between 9 and 18 h in the case of renal insufﬁciency. The elimination
of codeine is also slower in older people. In lactating women, it is excreted in breast milk and
concentrations are approximately 2.5-fold higher compared to maternal plasma concentrations (EFSA
CONTAM Panel, 2011).
The principal pathways for metabolism of codeine occur in the liver, although some metabolism
occurs in the intestine and brain. Approximately 50–70% of codeine is converted to codeine-6-
glucuronide (C6G) by UGT2B7, 10–15% of codeine is N-demethylated to norcodeine by CYP3A4 and
about 0–15% of codeine is O-demethylated to morphine, the most active metabolite, via CYP2D6 (Yue
et al., 1991; Caraco et al., 1996b; Coffman et al., 1997) (Figure 4). Norcodeine is then glucuronidated
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to norcodeine-6-glucuronide (N6G) and a minor part is O-demethylated to normorphine (Yue et al.,
1989; Yue and Sawe, 1997). The formed morphine is metabolised as described above. Codeine, C6G,
norcodeine and N6G have weak afﬁnity for the l-opioid receptor (Chen et al., 1991; Mignat et al.,
1995; Volpe et al., 2011 – see Section 3.1.4). O-demethylation is regarded to be the bioactivation
reaction essential for the analgesic activity of codeine.
Functional CYP2D6 activity is only weakly expressed in fetal liver but increases rapidly after birth.
There is considerable interindividual variability in CYP2D6 activity within the ﬁrst 2–4 weeks of life
(Crews et al., 2012).
Codeine metabolism to morphine is dependent of the CYP2D6 activity which relates to the phenotype
of the gene. In some cases, individuals have more than two copies of the CYP2D6 gene. CYP2D6 alleles
are characterised as wild type (normal function), reduced-function or non-functional alleles based on the
expected activity of the corresponding enzyme. Each allele is assigned an activity value between 0 and
1.0. If multiple copies of the gene are detected, the activity score is multiplied by the number of copies
of each allele present. The total CYP2D6 activity score typically ranges from 0 to 3.0 (sum of the values
assigned to each allele) (Crews et al., 2012). Individuals can be classiﬁed into poor metaboliser,
intermediate metaboliser, extensive metaboliser or ultra-rapid metaboliser as described in Table 1. As
reported, the extensive metabolisers represent the majority of the Caucasian population.
Codeine
Codeine-6-glucuronide
Norcodeine Morphine
Morphine-3-glucuronide
Morphine-6-glucuronide
Normorphine
CYP2D6
0–15%
UGT2B7
50–70%
CYP3A4
10–15%
UGT1A8
UGT2B7
60%
UGT1A8
UGT2B7
5–10%
CYP2C8
CYP3A4
5%
Norcodeine-6-glucuronide
Metabolites in pink colour indicate main active metabolites.
Figure 4: Codeine metabolism pathway in an individual with CYP2D6 extensive metabolism based on
Crews et al. (2014)
Table 1: Assignment of likely codeine metabolism phenotypes based on cytochrome P450 2D6
diplotypes – data of Crews et al. (2012, 2014)
Likely
phenotype(a)
Activity
score
Genotype
Ultra-rapid
metabolisers
(~ 1–2% of
population)
> 2.0 An individual carrying more than two copies of functional alleles
Extensive
metaboliser
(~ 77–92% of
population)
1.0–2.0 An individual carrying two alleles coding for a full or reduced function or one
full function allele together with either one non-functional or one reduced-
function allele
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The distribution of poor, extensive and ultra-rapid metabolisers differ signiﬁcantly between ethnic
groups (Ingelman-Sundberg et al., 2007). The highest frequency of ultra-rapid metabolisers in Europe
is in southern Europe (Greece, Italy, Portugal and Spain, about 5–10%) (Ingelman-Sundberg, 2005;
Kirchheiner et al., 2007). The highest frequency of ultra-rapid metabolisers (16–28%) occurs in the
North African, Ethiopian and Arab populations (Wong et al., 2012).
Kirchheiner et al. (2007) studied the pharmacokinetics of codeine and its metabolite morphine in
poor, extensive and ultra-rapid metabolisers after administration of a single oral dose of 30 mg
codeine. Signiﬁcant differences were detected between the groups in areas under the plasma
concentration vs time curves (AUCs) and the maximum plasma concentrations (Cmax) of morphine
(Table 2). So there is a very sharp increase in both morphine AUC and Cmax following codeine in
extensive/ultra-rapid metabolisers due to CYP2D6 duplications. The genotype-caused differences in
metabolism are also reﬂected in the metabolic ratio in urine.
Based on the available data, the CONTAM Panel concluded in 2011 that the maximal metabolic
conversion of codeine to morphine in CYP2D6 ultra-rapid metabolisers does not exceed 20%. Since
then, no new pharmacokinetic studies were identiﬁed that change this conclusion.
In addition to the subjects that are genetically deﬁcient in CYP2D6 (poor metabolisers), subjects
that ingest CYP2D6 inhibitors, such as quinidine (an anti-arrhythmic medication), form only negligible
amounts of the codeine metabolites, which results in a loss of pharmacological effect (Sindrup et al.,
1990; Desmeules et al., 1991; Otton et al., 1993a,b; Caraco et al., 1996a).
Overall, the documented abilities of active transport proteins, including the P-glycoprotein, and of
CYP2D6 phenotype to modify the pharmacological effects of morphine and/or codeine show that
genetic polymorphisms affect the sensitivity of humans to adverse effects of these opium alkaloids or
to develop addiction. The risk for opioid intoxication might be increased if other additional factors such
as reduction in renal function or further inhibition of other enzymes occur.
Thebaine, oripavine, noscapine and papaverine
Based on limited information, oral bioavailability of thebaine, oripavine, noscapine and papaverine
appears to be reduced due to presystemic metabolism in the GI tract and liver primarily involving
demethylation reactions but also glucuronidation (EFSA CONTAM Panel, 2011).
Tissue distribution studies on male Albino Wistar rats have shown that the uptake of 131I-thebaine
in the stomach, large intestine, spinal cord and prostate was higher than in the other tissues. The
clearance was via the urinary and hepatobiliary systems. The uptake of radiolabelled thebaine in the
brain was greater in the midbrain and hypothalamus (Enginar et al., 2013).
Kodaira and Spector (1988) have shown in vitro, that thebaine is transformed to oripavine, codeine,
and morphine by rat liver, kidney, and brain rat microsomes in the presence of an NADPH generating
system. Morphine biosynthesis from thebaine in mammalian tissues can occur by at least two routes:
Likely
phenotype(a)
Activity
score
Genotype
Intermediate
metaboliser
(~ 2–11% of
population)
0.5 An individual carrying one reduced and one non-functional alleles
Poor metaboliser
(~ 5–10% of
population)
0 An individual carrying no functional alleles
(a): The frequency estimates are based on data from Caucasians and may differ substantially for other ethnicities.
Table 2: Morphine area under the curve (AUC) and maximum plasma concentrations (Cmax) in
poor, extensive and ultra-rapid metabolisers following a single oral dose of 30 mg codeine
(Kirchheiner et al., 2007)
Metaboliser type AUC median (range) Cmax median (range)
Poor 0.5 (0.5–2.8) 0.05 (0.03–0.07)
Extensive 11 (5–17) 2.1 (0.6–4.3)
Ultra-rapid 16 (10–24) 2.6 (1.5–4.6)
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(i) via codeine: thebaine ? neopinone ? codeinone ? codeine ? morphine; and (ii) via oripavine:
thebaine ? oripavine ? 3-O-demethylated neopinone ? morphinone ? morphine. The presence of
morphine and codeine in mammalian tissue after dosing with thebaine can be explained by the fact
that these compounds are enzymatically synthesised there.
After subcutaneous (s.c.) injection, thebaine is extensively metabolised in the rat and eliminated in
urine as free and glucuronide metabolites. Thebaine was metabolised in the brain, intestine, liver,
kidney and blood. The metabolic pathways of thebaine in the rat appear to be O- and N-demethylation
as well as hydroxylation and glucuronide conjugation. Metabolites are oripavine, 14-hydroxycodeinone,
norcodeine, normorphine, codeine and morphine (Misra et al., 1974; Donnerer et al., 1986). Oripavine
appears to be the major metabolite in Sprague–Dawley rats. The conversion of thebaine to oripavine is
catalysed by CYP2D1, the rat orthologue to human CYP2D6 (Mikus et al., 1991).
After oral administration (150 mg dose of either rapidly dissolving tablets or a tablet containing ion
exchange resin-bound noscapine) to ﬁve human volunteers, noscapine was rapidly absorbed and gave a
maximum plasma concentration after 1 h. From then on, the noscapine levels declined with a half-life of
124 min (range 95–143 min). The absolute oral bioavailability was 30% (range 16–58%) (Dahlstr€om
et al., 1982). After gavage administration of noscapine hydrochloride salt (75, 150 and 300 mg/kg) to
mice, noscapine was easily and quickly absorbed at all dose levels (tmax < 2 h) and was distributed
rapidly and widely. The percent bioavailability was comparable at 75 and 300 mg/kg (between 22% and
27%); it was higher at 150 mg/kg (42–48%) for both males and females. Half-lives were 2.91/3.02 h,
1.47/0.99 h and 2.52/2.65 h in males and females, respectively (Aneja et al., 2007). Noscapine
undergoes extensive ‘ﬁrst pass’ metabolism mainly by C–C cleavage, O-demethylation and cleavage of
methylenedioxy group in rats, rabbits and humans (Tsunoda and Yoshimura, 1981). Noscapine’s
metabolism in mice has been shown to result in the formation of at least 20 or more metabolites including
a reactive intermediate that undergoes conjugation with glutathione (Fang et al., 2012). Phase I
metabolism of noscapine has been shown to result in more than 10 metabolites and Phase II metabolism
primarily produces at least 9 glucuronide conjugates (Fang et al., 2012). Several enzymes including CYP
and ﬂavin monooxygenases have been shown to catalyse the biotransformation of noscapine.
Several novel phase I metabolites of noscapine were detected after oral gavage of mice, including
an N-demethylated metabolite, two hydroxylated metabolites, one metabolite undergoing both
demethylation and cleavage of the methylenedioxy group and a bis-demethylated metabolite.
Additionally, several novel glucuronides were detected (Fang et al., 2012).
Iwase et al. (2017) have shown that papaverine, a GI drug, has an inhibitory effect on CYP3A4
activity in human liver microsomes. CYP3A4 is expressed in the liver and also in the small intestine. It
is considered that papaverine causes drug interactions mediated by CYP3A4 inhibition in the small
intestine rather than the liver.
3.1.1.2. Kinetic modelling
Various models that describe the link between pharmacokinetics (PK) and pharmacodynamics (PD)
of opioids and their metabolites have been developed and have been reviewed for adult (e.g. Lotsch,
2005a,b; Martini et al., 2011; Yassen et al., 2013) and paediatric data (Mahmood, 2011; Holford et al.,
2012; Krekels et al., 2012; Emoto et al., 2017). In adults, an obvious sex difference in morphine PD but
not PK is visible with greater opioid potency in women (Sarton et al., 2000; Niesters et al., 2010).
Interest in models that describe the PK and PD in infants and neonates is growing although the model
performance in most studies is limited (see review Krekels et al., 2012). Willmann et al. (2009)
described a model that relates morphine plasma concentration in mother and infant from maternal
codeine consumption in mothers who breastfed. The most critical factors for morphine accumulation in
the neonate are the mother’s codeine and morphine clearances and the neonate’s morphine clearance.
Considering the added effect of low neonatal elimination capacity for morphine, the authors reported
that potentially toxic morphine plasma concentrations can be reached within 4 days in the neonate after
repeated codeine dosing to the mother. CYP2D6 activity in neonates reaches ~ 3–5% of the adult level
activity during the ﬁrst week of life and increases signiﬁcantly thereafter. Neonates of extensive and
ultra-rapid metabolising mothers have comparable risks of opioid poisoning (Willmann et al., 2009).
Studies linking PK and PD of morphine action and the role of transporter systems are available in
experimental (rodent) and human models (Caraco et al., 1999; Zelcer et al., 2005; Borst et al., 2007;
Kalvass et al., 2007; van de Wetering et al., 2007; Emoto et al., 2017). In paediatric patients, changes
in cardiac output and age-dependent developmental changes need to be considered as well as key
determinants of variability in morphine clearance (Anderson and Holford, 2009; Vinks et al., 2015;
Emoto et al., 2017).
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Linares et al. (2015) developed a PK pathway model for codeine and its metabolites that
incorporate the effects of genetic polymorphisms of CYP2D6, using the data reported by Kirchheiner
et al. (2007) as the starting point for the modelling. According to their model, about 10% of a codeine
dose was converted to morphine in poor metabolisers, 40% in extensive metabolisers and 51% in
ultra-rapid metabolisers. The model indicated also that about 4% of morphine formed from codeine
was converted to M6G in poor metabolisers, 39% in extensive metabolisers and 58% in ultra-rapid
metabolisers; this is important since M6G has a similar or higher potency than morphine in terms of
efﬁcacy and opioid-related toxicities (overall effects on the central nervous system (CNS) and
respiratory depression; see Section 3.1.4). The CONTAM Panel noted substantial inconsistencies in
morphine and its glucuronides AUC in this paper compared to the experimental data presented by
Kirchheiner et al. (2007). The CONTAM Panel concluded that the paper by Linares et al. does not
provide a basis to change its previous conclusion from 2011 that the maximal metabolic conversion of
codeine into morphine does not exceed 20%.
3.1.2. Toxicity in experimental animals
3.1.2.1. Acute toxicity (single exposure)
No new data since the previous opinion were identiﬁed. Table 3 summarises the oral lethal doses
(LD50) reported in the literature for the different compounds (EFSA CONTAM Panel, 2011). Since not
for all compounds oral LD50 values were available, the CONTAM Panel also considered other routes of
administration for comparison of acute toxicity of the compounds (Table 4).
Table 3: Summary of oral LD50 values reported in scientiﬁc literature for the opium alkaloids
addressed in this Scientiﬁc Opinion
Substance Species LD50 (mg/kg bw)
(a)
Morphine Rat 335
Mouse 524
Codeine Rat 427
Mouse 250(b)
Codeine phosphate Rat 266
Thebaine Rat 114
Mouse 54
Oripavine No data
Noscapine Rat 1,520(b)
Mouse 853(b)–3,500
Papaverine Mouse 162(b)
bw: body weight; LD50: lethal dose for 50% of the subjects.
(a): LD50 values available from EFSA CONTAM Panel (2011) unless speciﬁed differently.
(b): LD50 values available from https://chem.nlm.nih.gov/chemidplus/
Table 4: Summary of subcutaneous and intraperitoneal LD50 values reported in scientiﬁc literature
for the opium alkaloids addressed in this Scientiﬁc Opinion
Substance Route of administration Species LD50 (mg/kg bw)
(a)
Morphine i.p. Rat 100
s.c. Rat 109
s.c. Rat 630(c)
i.p. Mouse 140/500(b)
s.c. Mouse 220
s.c. Mouse 430(c)
Codeine i.p. Rat 100
s.c. Rat 229
i.p. Mouse 60
s.c. Mouse 84.1
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Morphine and codeine
Morphine and codeine are potent pharmacologically active substances with their speciﬁc actions
usually mediated via the speciﬁc l-opioid receptor. The pattern of acute toxicity might be different
between animal species due to the speciﬁc distribution of several opioid receptors (l, j and d) (EFSA
CONTAM Panel, 2011).
Thebaine
Balint (1971) investigated the effects of thebaine administered intraperitoneal (i.p.) in mice. On
narcosis induced by hexobarbital sodium, thebaine produced a stronger potentiating effect than
morphine. Its analgesic effect is considerably inferior to that of morphine. In contrast to morphine, it
does not cause urine-retention. It was also shown that thebaine inhibits ‘orientation hypermobility’ and
spontaneous motility but it had no effect on hypermotility induced by cocaine and benzpropamine.
The dependence potential of thebaine is at least partially attributed to oripavine, which is one of
the principal metabolites of thebaine (WHO, 1980).
Oripavine
Oripavine possesses an analgesic potency comparable to morphine and much higher than that of
thebaine; however, it is not clinically useful due to severe toxicity and low therapeutic index (WHO
Advisory group, 1981). In both mice and rats, toxic doses caused tonic-clonic seizures of the limbs and
mouth followed by death, similar to thebaine (Gomez-Serranillos et al., 1998). Oripavine has a
potential for dependence, which is signiﬁcantly greater than that of thebaine but slightly less than that
of morphine (Toxnet18; Yeh, 1981).
The analgesic dose 50 (AD50) of oripavine and morphine after s.c. administration in the mouse
were 4.1 and 4.0 mg/kg bw, respectively. At doses above 7 mg oripavine/kg bw, convulsions were
observed in some mice. The analgesic potency of oripavine in the rat is less than that of morphine.
The AD50 of oripavine and morphine after s.c. administration in the rat were 7.7 and 4.5 mg/kg bw,
respectively. After administration of 10 mg oripavine/kg bw, convulsions were observed in 9/10 rats
and 1 animal died. The analgesic doses of oripavine in mice and rats are close to the lethal doses
(LD50 of 11 and 13 mg/kg bw for s.c. administration, respectively). This is not the case for morphine
where the LD50 were 430 and 630 mg/kg bw for s.c. administration, respectively (Yeh, 1981). In rats,
the physical dependence potential of oripavine at a dose of 4 mg/kg is almost comparable to that of
morphine at 0.5 mg/kg. Studies carried out on monkeys show that oripavine possesses weak
morphine-antagonist properties (WHO Advisory Group, 1981).
Clonic-tonic convulsions followed by death were observed in rats or mice after s.c. or i.p.
administration of oripavine (Yeh, 1981; Gomez-Serranillos et al., 1998). In mice, i.p. injection of
oripavine (6.5, 8.7 and 13 mg/kg bw) produced a decrease of the alert status, spontaneous activity
Substance Route of administration Species LD50 (mg/kg bw)
(a)
Thebaine i.p. Mouse 20
s.c. Mouse 31
Oripavine s.c. Rat 13
i.p. Mouse 26.1
s.c. Mouse 11
Noscapine i.p. Mouse 960
s.c. Mouse 725
Papaverine i.p. Rat 59.6
s.c. Rat 151
i.p. Mouse 91
s.c. Mouse 170
bw: body weight; i.p.: intraperitoneal; LD50: lethal dose for 50% of the subjects; s.c.: subcutaneous.
(a): s.c. and i.p. LD50 values available from https://chem.nlm.nih.gov/chemidplus/ unless speciﬁed differently.
(b): Gomez-Serranillos et al. (1998).
(c): Yeh (1981).
18 https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+8324
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and reactivity. It showed also CNS excitation as a sacrococcygeal dorsal muscle contraction and a
decrease in the respiratory rhythm.
Toxicity does not appear to be mediated at the opioid receptor. Oripavine showed some cross
tolerance with morphine, but did not suppress morphine abstinence in the mouse and rat (Yeh, 1981).
From the LD50 values by s.c. and i.p. administration, it can be concluded that thebaine and
oripavine are more toxic than morphine and codeine.
Noscapine
It is reported that noscapine is the least toxic of the opium alkaloids (Krueger et al., 1943 cited by
Winter and Flataker (1961)). Noscapine administered by gastric gavage of 800, 1,600 or 3,200 mg/kg
bw to fasting rats result in 0/5, 3/5 or 5/5 deaths, respectively. Death appeared to be due to asphyxia,
preceded by dyspnea and tonic convulsions. At autopsy the lungs were distended and ﬁlled with
mucus (Winter and Flataker, 1961).
Papaverine
Besides LD50 values, no data on the acute toxicity of papaverine were identiﬁed.
3.1.2.2. Short-term toxicity
No new data since the previous opinion were identiﬁed. The text below summarises the previous
information.
Morphine
Dietary studies in which rats were exposed to 100–200 mg/kg bw morphine for 4–6 weeks showed
clear opiate dependence, but no effects on body weight and feed intake. However, a clear decrease in
feed intake and body weight was observed when morphine was withdrawn as well as changes in
spontaneous locomotor activity (EFSA CONTAM Panel, 2011).
The data in rats and mice clearly show the dose dependency with marginal effects in rats at a serum
concentration of 200 ng/mL, resulting from an oral dose of 60 mg/kg bw (Van der Laan et al., 1988).
Codeine
Decreased body weights and body weight gains were observed in rats exposed to codeine in feed
(≥ 125 mg/kg bw per day after 14 days and ≥ 100 mg/kg bw per day after 13 weeks) and mice
(3,000 mg/kg bw per day after 14 days). No treatment-related gross or histopathological lesions were
observed (EFSA CONTAM Panel, 2011).
Thebaine
No data were identiﬁed.
Oripavine
No data were identiﬁed.
Noscapine
No toxic effects were observed in dogs given orally 30 mg noscapine/kg bw per day for 13 weeks
or in rats receiving up to 700 mg noscapine/kg bw per day (EFSA CONTAM Panel, 2011).
Papaverine
Oral administration of papaverine (50 and 100 mg/kg bw per day) to rats during 45 days was well
tolerated as no changes were reported. In a 6-month study in dogs, oral administration of 10 mg
papaverine/kg bw per day was tolerated without any adverse effects in clinical, biochemical, and
histopathological examinations (EFSA CONTAM Panel, 2011).
3.1.2.3. Long-term toxicity (including carcinogenicity)
Only limited new data were identiﬁed since the previous opinion. The text below summarises the
previous and new information.
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Morphine
No carcinogenicity study is available on morphine. However, based on the lack of carcinogenicity in
mice or rats of codeine, which is metabolised to morphine, the CONTAM Panel concluded that
morphine is unlikely to be carcinogenic (EFSA CONTAM Panel, 2011).
Tumour promotion effects were reported with s.c. administration of morphine in a transgenic mice
model with breast cancer (female transgenic mice carrying a rat C3(1) simian virus 40 large tumour
antigen fusion gene (called C3TAG mice) which causes highly invasive breast tumours) (Gupta et al.,
2002; Farooqui et al., 2007; Nguyen et al., 2014). Gach et al. (2011) observed both growth-promoting
and growth-inhibiting effects. The CONTAM Panel considered the data to be too limited to be further
considered in this Scientiﬁc Opinion.
Codeine
Long-term feeding toxicity studies in rats and mice showed no evidence of carcinogenic activity.
Exposure-related decreased body weight was noted in treated animals. In rats, at 2 years, there was
an exposure-related decrease in the incidences of adrenal medulla hyperplasia in both sexes, of benign
pheochromocytomas in males and of mammary gland ﬁbroadenomas and ﬁbroadenomas or
adenocarcinomas (combined). In mice, at 2 years, there was a signiﬁcant increased incidence of
thyroid gland follicular cell hyperplasia. The incidence of hepatocellular adenomas and adenomas or
carcinomas (combined) were signiﬁcantly lower at 400 mg/kg bw per day than in controls. The lower
incidence of tumours in high-dose animals of both species compared with control was considered to be
related to the suppression of body weight gain at this level. The no-observed-adverse-effect level
(NOAEL) for chronic toxicity was 15 mg/kg bw per day in rats and less than 100 mg/kg bw per day in
mice (EFSA CONTAM Panel, 2011).
Thebaine
No data were identiﬁed.
Oripavine
No data were identiﬁed.
Noscapine
No data were identiﬁed in the literature. The use of noscapine as an antitussive drug is intended to
be short-term, therefore not warranting life-time carcinogenicity studies in accordance with regulatory
guidelines (EFSA CONTAM Panel, 2011).
Papaverine
No data were identiﬁed.
3.1.2.4. Genotoxicity
Morphine
The CONTAM Panel concluded in 2011 that morphine is genotoxic only in vivo, most likely by a
non-DNA reactive and opioid receptor-mediated mechanism, which might be caused by species-speciﬁc
systems (EFSA CONTAM Panel, 2011). This conclusion was based on the following observations.
In vitro, morphine is not mutagenic in Salmonella spp. or yeast test systems or after short-term
exposure in hprt gene mutation assays. However, a highly signiﬁcant increase in the mutation frequency
at the hprt locus was observed after treatment of human T-cells for 3–4 days (Shafer et al., 1994). It did
not induce chromosomal aberrations in cultured human lymphocytes (Falek et al., 1972) or was
equivocal in one chromosomal aberration test (Snyder, 2009) and negative in an in vitro micronucleus
test in mouse splenocytes (without S9, 21 h exposure) (Sawant and Couch, 1995). It induced a
signiﬁcant, dose-dependent increase in DNA damage (single strand breaks, detected in a Comet assay) in
cultured human T cells (Shafer et al., 1994). In mice, i.p. injection of morphine induced an increase in the
frequency of micronuclei in splenocytes (Couch and Sawant, 1995; Sawant and Couch, 1995). Acute, but
not chronic, morphine administration has been shown to increase the frequency of chromosome
aberrations and micronuclei in mouse bone marrow cells (Swain et al., 1980; Das and Swain, 1982).
Studies show also that morphine induced DNA damage in germ cells of male mice might occur secondary
to hyperthermia (EFSA CONTAM Panel, 2011; Kirkland et al., 2011). More generally, it has been shown
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that chemically and environmentally induced changes in body temperature may be associated with
increased micronuclei in rodents (Asanami and Shimono, 1997, 2000; Shuey et al., 2007).
Codeine
In vitro, codeine was not mutagenic in Salmonella Typhimurium or Escherichia coli and it did not
induce chromosomal aberrations in Chinese hamster ovary (CHO) cells. It induces signiﬁcant increases
in sister chromatid exchanges (SCE) in CHO cells in the presence and in the absence of S9 mix. In one
study, increased frequencies of micronuclei were reported in cultured rat kidney ﬁbroblasts exposed to
a combination of codeine phosphate and paracetamol. However, this was probably due to the
treatment with paracetamol only. In vivo, negative results were reported in bone marrow micronucleus
test in mice after i.p. injection or gavage (EFSA CONTAM Panel, 2011).
Based on these observations, the CONTAM Panel concluded in 2011 that codeine is not genotoxic.
No new data were identiﬁed.
Thebaine
No data were identiﬁed.
Oripavine
No data were identiﬁed.
Noscapine
Since the previous opinion, several new studies have become available and the text below gives an
overview of previous and new data.
Several studies have shown that noscapine induces polyploidy and is an aneugen in vitro. To clarify
if noscapine would have an effect on germ cells in vivo, female mice were exposed by the oral route to
noscapine and oocytes were collected. Noscapine did not induce delay of the meiotic progression or
induction of chromosome malsegregation. No increases in polyploidy or hyperploid oocytes were found
(Tiveron et al., 1993; EFSA CONTAM Panel, 2011). An in vivo micronucleus test in mouse bone marrow
cells by i.p. injection was negative (Furukawa et al., 1989 – reported in an abstract only).
The difference between in vitro and in vivo results might be explained by the relatively long
treatment (24 h) necessary to induce polyploidy in vitro (Gatehouse et al., 1991; Mitchell et al., 1991).
Such a long exposure period at this level will never be reached in vivo because of the
pharmacokinetics of noscapine. It has been shown that after oral administration in healthy volunteers,
noscapine has a relatively low bioavailability because its systemic availability is greatly reduced by a
substantial ﬁrst-pass metabolism (Dahlstr€om et al., 1982). A risk of genotoxic damage caused by
noscapine in humans at therapeutic dosages is therefore very unlikely. Even after oral administration to
relatively high concentrations of noscapine, the GI tract is unlikely to be at risk because of the short
period that the cells are exposed to these concentrations (Rauws et al., 1997).
One possible therapeutic application of noscapine, i.e. as an oral effective anticancer drug, results
from its capacity to bind to tubulin, alter its conformation and assembly properties and interfere with
microtubule dynamics. In this way, noscapine arrests a variety of mammalian cells including drug-
resistant variants in mitosis targeting them for apoptosis. Noscapine inhibits progression of murine
melanoma, lymphoma, leukaemia, glioblastoma, colon cancer, ovarian carcinoma, non-small cell lung
cancer and prostate cancer cell lines and of human breast and bladder tumours implanted in nude
mice (Ye et al., 1998; Ke et al., 2000; Zhou et al., 2002; Landen et al., 2002, 2004; Jackson et al.,
2008; Mahmoudian and Rahimi-Moghaddam, 2009; Chougule et al., 2011a,b; Afzali et al., 2015). In
the in vivo studies, the toxicity to the kidney, heart, liver, bone marrow, spleen and small intestine was
low (Aneja et al., 2006; Afzali et al., 2015). These effects were seen in mice receiving 3 mg of
noscapine dissolved in 0.2 mL saline (120 mg/kg bw) by i.p. for 3 weeks (Ye et al., 1998) or orally fed
300 mg/kg bw for 80 days (Aneja et al., 2006). Harati et al. (2017) assessed the antiproliferative
effects of noscapine on human soft tissue sarcomas (STS) cells. Noscapine exhibited cytostatic effects
on STS cells, as assessed using the bromodeoxyuridine (BrdU) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) cell proliferation assays at 24 h; however, these effects could not
be validated by real-time cell analysis over a longer time period.
Fellows et al. (2011) tested the ability of the mouse lymphoma L5178Y TK+/– assay to detect
aneugens among which noscapine. Noscapine was negative in this test, but this test is not a standard
test to detect aneugens.
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The aneugenic potential of noscapine was evaluated in an in vitro micronucleus assay in TK6 cells.
In the ﬁrst experiment, cells were exposed continuously during 27 h to 0, 32.8, 41.0 and 64.0 lg/mL
in the absence of metabolic activation. A dose-related and statistically signiﬁcant increase in
micronuclei was observed. In a second experiment, cells were exposed during 4 h to 0, 98.4, 115.8,
160.3, 188.6 and 221.85 lg/mL in the absence of metabolic activation and harvested 40 h later.
Noscapine produced an equivocal response as it induced a statistically signiﬁcant increase in
micronuclei only at 188.6 lg/mL, the highest concentration considered acceptable according to the
study criteria regarding toxicity (Sobol et al., 2012).
Noscapine has been evaluated for its aneugenic properties in TK6 cells by ﬂow cytometry for
micronucleus induction. Cells were exposed continuously for 4 or 24 h to the solvent control (dimethyl
sulfoxide (DMSO), 1%) or noscapine (3.1–200 lM) without metabolic activation. Noscapine produced
dose-related increases in micronuclei at the 24-h time point (from 10 lM) but not at the 4-h time
point. In addition, noscapine treatment at 24 h induced a dose dependent increase in polyploidy
between 40 and 200 lM compared to DMSO. It was also shown that noscapine induced a dose-related
increase in the frequency of cells in mitosis while the percentage of cells in G0/G1 declined with dose
(Cheung et al., 2015).
Afzali et al. (2015) investigated the selective cytotoxic, genotoxic and apoptosis induction effects of
noscapine and papaverine on three human cancer cell lines: HT29 colorectal carcinoma, T47D breast
cancer cells and HT-1080 ﬁbrosarcoma cells. A non-cancerous mouse NIH-3T3 cell line was used to
compare the effects of the substances between cancerous and non-cancerous cells. Doxorubicin was
used as a positive control. Cells were treated with different concentrations of noscapine, papaverine
and doxorubicin and were incubated for 48 h. Cell viability was determined by the MTT assay. The
genotoxicity was tested with the comet assay (measure of the tail length). Noscapine and papaverine
had a dose-related cytotoxic effect on HT-29, T47D and HT-1080 cell lines, whereas no cytotoxic effect
was observed on the non-cancerous NIH-3T3 cell line. Doxorubicin induced cytotoxicity in all cell lines.
Noscapine and papaverine selectively enhanced DNA damage in cancerous cells compared to non-
cancerous cells, whereas, doxorubicin induced DNA damage in all cell lines.
In summary, noscapine is an aneugen in vitro most likely by a non-DNA reactive mechanism. No
in vivo genotoxicity test conducted on somatic cells, as recommended by the EFSA guidance (EFSA
Scientiﬁc Committee, 2011) has been identiﬁed, with the exception of one negative in vivo micronucleus
test in mouse bone marrow by i.p. reported in an abstract. Taking into account also its low systemic
availability, a risk of genetic damage caused by noscapine in vivo is very unlikely. The possible
therapeutic application of noscapine as an oral effective anticancer drug, results from its capacity to
bind to tubulin and interferes with microtubule dynamics. Noscapine arrests a variety of mammalian
cells, including drug-resistant variants, in mitosis targeting them for apoptosis. In this way, noscapine
inhibits progression of various tumours implanted in nude mice. It was also shown that, in vitro,
noscapine selectively enhanced DNA damage in cancerous cells compared to non-cancerous cells.
Papaverine
The selective cytotoxic, genotoxic and apoptosis induction effects of papaverine in human cancer
cell lines were reported in the section on noscapine above (Afzali et al., 2015). However, the data are
too limited to conclude on the genotoxic potential of papaverine.
3.1.2.5. Developmental and reproductive toxicity
Since the identiﬁed studies do not provide information on the oral dose-response relationship, they
cannot be used for the identiﬁcation of a reference point and therefore only few details are reported.
Morphine
Depressed sexual activity was observed in male rats treated with morphine. This effect is reversible
and results from lowering serum luteinising hormone and testosterone. Reduced testicular function and
spermatogenesis has been reported after prenatal administration of morphine. It was also shown that
morphine disrupted ovarian cyclicity, decrease pregnancy rate and increase still births (EFSA CONTAM
Panel, 2011).
More recently, Ghosian Moghaddam et al. (2013) reported that oral morphine exposure for 21 days
of adult male rats results in signiﬁcantly lower luteinising hormone level, testosterone level, oestrogen
level and progesterone level than the control group and a higher follicle-stimulating hormone level.
Developmental toxicity studies in experimental animal species are not conclusive. Subcutaneous
injection of high doses of morphine to hamster dams has been reported to cause CNS defects in the
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fetuses. Teratogenic effects, such as exencephaly and cryptorchidism were observed in mice but were
probably related to maternal toxicity. These effects could be blocked by administration of naloxone, the
opioid antagonist. The primary effect of morphine in rats and rabbits might be on food intake and
body weight rather than on organogenesis, causing miscarriages, low birth weight and decreases in
crown-to-rump length in the newborns. Morphine given late during pregnancy has been associated
with placental vasoconstriction with a potential for general fetal effects. Studies have also shown that
prenatal exposure of rats to morphine induces long-term alterations in the adult brain, changes in
morphology or effects on neural tube development (EFSA CONTAM Panel, 2011).
Recent publications have conﬁrmed that oral morphine exposure of pregnant rats affects the
normal development of the placenta: increased the placenta concentration of corticosterone, increased
the thickness of the maternal part of the placenta, and signiﬁcantly decreased the thickness of the
placenta and the lacuna number in the embryonic part (Kazemi et al., 2011, 2012; Dehghani et al.,
2013). Time-dependent effects of oral morphine exposure can inhibit the development and natural
functioning of cytotrophoblast and syncytiotrophoblast cells of the placental layers; morphine acting as
a mitogenic stimulus for cytotrophoblast cells. The defect in the normal development of placenta leads
to either abnormal fetal development or miscarriage (Dehghani et al., 2013).
The immature brain is particularly vulnerable to the actions of morphine. Morphine appears to
selectively accumulate in the nervous tissues of offspring because of increased permeability of the
blood-brain barrier. It may affect the development of the CNS and cause a variety of delays in
ontogeny. The delay effects of morphine on embryonic cells might be due to the stimulation of opioid
receptors in embryonic tissues (Nasiraei-Moghadam et al., 2005; Sadraie et al., 2008). Oral exposure
of pregnant rats to high doses of morphine induces suppression of cell proliferation in the cortical plate
and affects the migration and survival of neurons in the embryo which could lead to postnatal
neurological and behavioural deﬁcits in the animals (Sadraie et al., 2008). In mice, effects were
observed on cell cycle progression of both radial glia and progenitor cells in the developing cerebral
cortex (Sargeant et al., 2008). Several studies in rats indicated that oral administration of morphine
during pregnancy can delay the development of the neural tube and affect neural plate evolution, can
result in defects in the development of the cerebellum and reduce the development of frontal cortex in
the embryo (EFSA CONTAM Panel, 2011). Morphine can also affect growth and completion of the
spinal cord and decrease the embryos fronto-occipital length and the number of grey cells (Niknam
et al., 2013). Another study showed that the exposure to morphine disrupt the natural organisation of
the choroid plexus in the brain of the exposed rat embryos preventing them from functioning properly
in the future (Kazemi et al., 2009).
Haydari et al. (2014) showed that male pups from pregnant rats exposed to morphine during
pregnancy exhibited anxiogenic behaviour on post-natal day (PND) 35.
Nasiraei-Moghadam et al. (2013) studied the effects of prenatal morphine exposure (through
drinking water) on inhibitory avoidance memory performance in rat offsprings and whether these
deﬁcits are reversible during the postnatal development. Animals were dosed from gestational day 1 to
13 (group 1) or from gestational day 1 to 21 (group 2). Behavioural, molecular and histological studies
were conducted on PND 28 and 70, respectively, before and after puberty. Adolescent and adult
females failed in passive avoidance retention task in both groups. Adolescent and adult male offspring
were similar to control rats in group 1, however, in group 2, retention task was impaired in pre-
pubertal male offspring. This memory loss was repaired in post-pubertal stage.
Maternal morphine exposure prior to pregnancy can inﬂuence the development of future offspring
(Byrnes, 2005). Adolescent morphine exposure of female rats delays sexual maturation and long-lasting
alterations in adult gene expression are induced within the endogenous opioid system (Byrnes, 2008).
Potential changes in maternal care, communication and/or attachment were observed in the offsprings
of rats from mothers exposed to morphine during adolescence. Studies have shown that endogenous
opioids are implicated in the display of separation-induced distress calls and that these effects appear to
be opioid receptor speciﬁc. Daily s.c. injections of morphine in adolescent rats for 10 days resulted in a
signiﬁcant decrease in body weight and reduced number of distress calls elicited by separation from the
dam when compared to control offsprings. The same effects have been observed after saline injection.
However, only adolescent morphine exposure results in increased maternal potentiation (i.e. difference
between the number of ultrasonic vocalisations during ﬁrst and second separation) on PND 9 and PND
12. Signiﬁcant modiﬁcations in the functional activation and transcription of the l-opioid receptor
(OPRM1) and the dopamine D2 receptor are involved (Bodi et al., 2016).
In summary, depressed sexual activity, reduced testicular function and spermatogenesis, disruption
of ovarian cyclicity and decreased pregnancy rate have been observed in rats exposed to morphine.
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Oral morphine exposure of pregnant rats or mice affects the normal development of the placenta and
the brain. The effects on brain development of the embryo could lead to postnatal neurological and
behavioural deﬁcits in the animals including memory loss.
Codeine
Based on limited data it is concluded that oral administration of codeine did not result in
teratogenicity, even at doses inducing embryotoxicity. Embryotoxicity was observed in the presence of
maternal toxicity (EFSA CONTAM Panel, 2011).
Thebaine
Geber and Schramm (1975) have administered a single s.c. injection of thebaine (0, 110, 140 or
193 mg/kg bw) to hamster (20, 22 and 80 animals, respectively) on day 8 of gestation. A high
maternal mortality rate was produced at the two highest doses (10% and 75%, respectively). No
effect was noted on fetuses viability, however, a dose-related increase in the % of fetuses with
congenital malformations was observed (0%, 0%, 2.0% and 4.2%, respectively). Cranioschisis was the
most common anomaly observed, mainly at the highest dose (100% of the malformed fetuses). At
140 mg/kg bw, 80% of the malformed fetuses exhibited ‘other lesions’ (micro- or anophthalmia,
mylocoele, micrognathia, external liver and spina biﬁda).
Based on one study, it is concluded that s.c. injection of thebaine produces a teratogenic response,
but the results are limited by the marked maternal mortality.
Oripavine
No data were identiﬁed.
Noscapine
No data were identiﬁed.
Papaverine
No data were identiﬁed.
3.1.2.6. Neurotoxicity
Morphine
Morphine exerts many different effects, both in the CNS and peripheral nervous system by acting
on the opioid receptors. Most pharmacological effects are well characterised with regard not only to
their dose–response character but also to their development of tolerance induced by repeated
administration. Adverse effects include sedation, drowsiness, nausea and vomiting as well as
respiratory depression. Studies focused on neurobehavioural outcome showed that prenatal morphine
exposure induces long-term alterations in the adult brain, not restricted to a single brain area or a
single neurotransmitter. Altogether, there is evidence that persistent alterations in neurobehaviour can
be attributable to opioid effects on the developing nervous system (EFSA CONTAM Panel, 2011).
The effects of morphine on the nervous system have been largely investigated in experimental
animal models, mostly because of the concerns for side effects induced by the high doses used for
severe pain treatment (see Section 3.1.3 Observations in humans). Most of the studies are performed
using high doses administered s.c. or i.p., thus not relevant for the purpose of this opinion. No
neurotoxicity studies in adult animals based on oral administration of low doses were identiﬁed.
Studies on the effects of oral administration of morphine on the developing nervous system are
reported in the ‘Developmental and reproductive toxicity’ section (see Section 3.1.2.5).
Codeine
No data were identiﬁed.
Thebaine
The predominant effect of thebaine is CNS stimulation. Hyperirritability and increase in motor
activity as well as reﬂex excitability were observed in mice, rabbits, cats and dogs at doses around
2–10 mg/kg s.c. or intramuscular. In rabbits, thebaine antagonised the effects of phenobarbital and
potentiated those of caffeine. Convulsions were observed in mice, guinea pigs, rabbits, cats and dogs
after s.c. administration (WHO, 1980).
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Oripavine
No data were identiﬁed.
Noscapine
No data were identiﬁed.
Papaverine
Shehab-Eldeen et al. (2015) reported in an abstract that papaverine decreases viability of rat neural
progenitors’ neurospheres.
3.1.2.7. Immunotoxicity
Morphine
The CONTAM Panel concluded in 2011 that morphine causes immunosuppressive actions: effects on
macrophages, neutrophils, mast cells, depression of lymphocytes, decreased expression of the T-cell
E-receptors, suppression of antibody formation, decrease in spleen and thymus weight associated with
several changes in immune cells, decrease of B cells and T cells, lower natural killer cell activity,
alteration of cytokine expression, changes in mesenterial lymph node at dosages that induce also
physical dependence. These effects may be relevant for the sensitivity of opiate addicts to infectious
agents. The involvement of the l-opioid receptor was supported by the fact that the effects could be
antagonised by naloxone. The changes in immune function are also associated with increases of the
levels of corticosterone which is the ﬁnal effector hormone (Bryant et al., 1987, 1988; Sei et al., 1991;
Freier and Fuchs, 1993; Breslow et al., 2011; EFSA CONTAM Panel, 2011; Roy et al., 2011; Zhang
et al., 2011; Brown et al., 2012; Sacerdote et al., 2012; Plein and Rittner, 2017).
Since the previous opinion, only studies with s.c. pellet administration have been identiﬁed which
were considered to be of limited relevance for this opinion and are not described.
Codeine
Codeine may affect immunity responses both locally in the respiratory tract and systemically as shown
by immunotoxicological ﬁndings observed in immunised guinea pigs (EFSA CONTAM Panel, 2011).
Thebaine
No data were identiﬁed.
Oripavine
No data were identiﬁed.
Noscapine
No data were identiﬁed.
Papaverine
No data were identiﬁed.
3.1.3. Observations in humans
This section summarises and updates the human data presented in the ‘Scientiﬁc Opinion on the
risks for public health related to the presence of opium alkaloids in poppy seeds’ published in 2011
(EFSA CONTAM Panel, 2011).
In humans, opioids are able to bind to three types of receptors, the l-, d- and j-opioid receptors.
Morphine acts as an agonist and has high afﬁnity to the l-opioid receptor. Codeine is also able to bind
to the l-opioid receptor but with a much lower afﬁnity. More information on the interaction of opium
alkaloids with the opioid receptors is provided in Section 3.1.4. In addition, morphine and codeine are
endogenously formed but their physiological relevance is unknown (reviewed in Stefano et al., 2008).
Activation of the l-opioid receptor leads to analgesia, predominantly at the supraspinal level, euphoria,
dependence, cough calming, respiratory depression, obstipation and miosis,. Besides the supraspinal
level, also effects at the spinal level have been reported (Poeaknapo et al., 2004; BfR, 2005; Trescot
et al., 2008; Aktories et al., 2009).
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3.1.3.1. Morphine
In general, morphine is used for the treatment of severe pain and dyspnoea as morphine sulfate (in
the form of morphine sulfate pentahydrate) or as morphine hydrochloride (in the form of morphine
hydrochloride trihydrate) (Ph. Eur. 8, 2016; Martindale, 2017). Morphine primarily affects the CNS and
the GI system. Tolerance development as well as strong physical and psychological dependence occur
in conjunction with the chronic oral intake of morphine. The Panel concluded in 2011 that ‘with
sustained release forms in the oral dose range of 7.5–15 mg morphine per day (corresponding to
single doses of about 1.3–2.5 mg morphine taken every 4 h) side effects such as sedation, dizziness or
light-headedness occurred in the onset of therapy of opioid-na€ıve individuals. [. . ..] This dose range is
also associated with nausea, vomiting and obstipation’.
In 2011, the CONTAM Panel concluded that ‘Morphine has high afﬁnity for the l-opiate receptor as
an agonistic ligand. Activation of l-opiate receptors leads to analgesia, euphoria, dependence, miosis,
respiratory depression, cough calming and obstipation. Patients with pain tolerate, without severe side
effects, larger doses of morphine than pain-free patients. Therapeutic doses of morphine may also
impair the ability to drive or to operate machinery due to changes in attentiveness and reactive skills.
The lowest known single oral therapeutic dose reported is 1.9 mg morphine, corresponding to
31.7 lg/kg bw for an adult weighing 60 kg’
From the complex pharmaco- and toxicodynamic proﬁle of morphine described in detail in the 2011
opinion (EFSA CONTAM Panel, 2011), several aspects have been reviewed and updated in the newer
literature. Relevant information focussing on adverse effects associated with low doses of orally
administered morphine (up to 30 mg/day in adults) are summarised in the following (e.g. Caraceni
et al., 2012; Katz, 2013; Barton, 2016).
A. Pharmacodynamics, therapeutic applications and dosage
Treatment of severe pain
Newer reviews are reporting on studies on ‘pharmacogenetics’, the genetic variations affecting
receptors, metabolising enzymes and transporters, and thus the individual response to morphine by
their inﬂuence on pain perception, PK and PD, including development of adverse effects, such as
respiratory depression (e.g. Branford et al., 2012; Chidambaran and Sadhasivam, 2012; Sadhasivam
et al., 2015; Tzvetkov, 2012; Droney et al., 2013; Tzvetkov et al., 2013; Hajj et al., 2013; Rhodin
et al., 2013; Biesiada et al., 2014; Chidambaran et al., 2015; Ting and Schug, 2016; Aka et al., 2017;
Balyan et al., 2017; Obeng et al., 2017). However, recent knowledge does not yet allow personalised
therapies. Therapeutic morphine doses for pain therapy in children of different age and adults,
referring to oral immediate-release forms (aqueous solutions or tablets) as indicated in the 2011
opinion (EFSA CONTAM Panel, 2011) are still valid according to recent recommendations (Merck, 2016)
(Table 5).
Table 5: Examples of recommended doses for orally administered morphine for pain therapy in
children and adults (immediate release forms)
Age group (body
weight (kg))
Single dose
Morphine hydrochloride trihydrate
dosage (equivalent morphine dosage)
Total daily dose
Morphine hydrochloride trihydrate
dosage (equivalent morphine
dosage)
Dose (mg)
(Merck, 2016)
Dose
(mg/kg bw)(a)
Dose (mg)
(Merck, 2016)
Dose
(mg/kg bw
per day)(a)
Children up to 2 years
(up to 12.5 kg)
Up to 2.5
(Up to 1.9)
Up to 0.20
(Up to 0.15)
Up to 22.5
(Up to 17.1)
Up to 1.80
(Up to 1.37)
Children
2–6 years
(12.5–20 kg)
2.5–5
(1.9–3.8)
0.20–0.40
(0.15–0.30)
15–30
(11.4–22.8)
1.20–2.40
(0.91–1.82)
Children 6–12 years
(20–40 kg)
5–10
(3.8–7.6)
0.25–0.50
(0.19–0.38)
30–60
(22.8–45.6)
1.50–3.00
(1.14–2.28)
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According to new information, the British National Formulary for Children (BNF, 2017) indicates
lower dosage per kg bw for younger infants than for older infants. The following initial oral doses of
morphine are recommended according to children’s age, whereby doses should thereafter be adjusted
according to response:
• 1–2 months: 0.05–0.1 mg/kg bw every 4 h;
• 3–5 months: 0.1–0.15 mg/kg bw every 4 h;
• 6–11 months: 0.2 mg/kg bw every 4 h;
• 1 year: 0.2–0.3 mg/kg bw every 4 h;
• 2–11 years: 0.2–0.3 mg/kg bw every 4 h (maximum single dose per person: 10 mg);
• 12–17 years: 5–10 mg/person every 4 h.
It is assumed that the pharmacokinetics of morphine in children are similar to those of adults
(Martindale, 2017). Neonates, however, demonstrate signiﬁcantly altered pharmacokinetics and have a
longer half-life for morphine. They have lower plasma clearance, higher volume of distribution,
decreased protein binding, decreased hepatic clearance because of their immature CYP system and
decreased renal clearance compared to adults. Furthermore, they exhibit an immature blood-brain
barrier that can lead to elevated morphine concentrations in the brain and to increases of the
respiratory side effects of morphine (Kesavan, 2015). By 1 year of age, elimination of morphine is
almost at adult levels (Lyon and Njoku, 2015).
In general, in view of the risks of severe adverse effects, the paediatric indications for chronic
(> 3 month) daily administration of morphine for chronic pain treatment are primarily life-limiting
conditions (Berde et al., 2012).
Management of neonatal abstinence syndrome
Morphine is also used in the management of neonatal abstinence syndrome (NAS) under specialist
supervision (e.g. Dahan et al., 2011; Kraft and van den Anker, 2012; Kelly, 2014; Hall and Anand,
2014; Martindale, 2017). The British National Formulary for Children (BNF, 2017) recommends an initial
oral dose of 0.040 mg/kg bw every 4 h until symptoms are controlled and an increase of the dose if
necessary. The dosage frequency should be reduced gradually over 6–10 days until a dose of
0.040 mg/kg bw once daily is achieved after which the drug should be stopped (British National
Formulary for Children (BNF, 2017; Martindale, 2017). From the USA, a standard treatment consisting
of an initial dose of 0.4 mg/kg bw per day in six divided doses is reported (Kraft et al., 2011). A survey
of neonatal units in the United Kingdom revealed typical maximum doses up to 1.3 mg/kg bw per day
in the treatment of NAS (Kraft and van den Anker, 2012).
Treatment of dyspnoea
Morphine is used in the treatment for dyspnoea as a main symptom of several advanced lung or
heart diseases, because it is known to reduce ventilatory drive in response to carbon dioxide, hypoxia
and exercise (EFSA CONTAM Panel, 2011).
Age group (body
weight (kg))
Single dose
Morphine hydrochloride trihydrate
dosage (equivalent morphine dosage)
Total daily dose
Morphine hydrochloride trihydrate
dosage (equivalent morphine
dosage)
Dose (mg)
(Merck, 2016)
Dose
(mg/kg bw)(a)
Dose (mg)
(Merck, 2016)
Dose
(mg/kg bw
per day)(a)
Adolescents
12–16 years
(40–50 kg)
10–20
(7.6–15.2)
0.25–0.50
(0.19–0.38)
60–120
(45.6–91.1)
1.50–3.00
(1.14–2.28)
Adolescents
> 16 years and
adults (70 kg)
10–60
(7.6–45.6)
0.14–0.86
(0.11–0.65)
Up to 360
(Up to 273.3)
Up to 5.14
(Up to 3.90)
bw: body weight.
(a): Where dose ranges are shown, the dosage in mg/kg bw or mg/kg bw per day has been calculated using the lower body
weight shown in the ﬁrst column.
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In the treatment of dyspnoea, doses of morphine tend to be smaller than those used for pain relief.
Morphine sulfate may be given as an oral solution in carefully titrated doses, starting with as little as
2.5 mg morphine sulfate (equivalent to 1.9 mg morphine corresponding to 27.1 lg/kg bw for an adult
weighing 70 kg) every 4 h. For opioid-naive adult patients, 2.5 mg of morphine sulfate (equivalent to
1.9 mg morphine corresponding to 27.1 lg/kg bw for an adult weighing 70 kg) is recommended as
the lowest oral therapeutic single dose which could be applied every 4 h resulting in a daily dose of
11.4 mg morphine per day (Martindale, 2017). In the study of Rocker et al. (2013), therapy was even
started by increasing dosages from an initial dosage of 0.5 mg morphine sulfate twice daily, to
minimise the likelihood of adverse effects and taking a delay of any therapeutic effect into account.
However, since the authors did not report from which dosage onwards therapeutic and/or adverse
effects were observed, this study was not considered to be relevant for this risk assessment.
In the preceding opinion (EFSA CONTAM Panel, 2011), it was concluded that results obtained with
sustained release forms providing a mean of 12.4 mg morphine/day would be expected to be similar
to those obtained following the administration of an immediate release form with 1.9 mg morphine
applied every 4 h resulting in a daily dose of 11.4 mg morphine/day. Patients treated with sustained
release forms received doses as low as 10 mg morphine sulfate/day (corresponding to 7.52 mg
morphine/day). Dosage regimens, as presented in the opinion from the CONTAM Panel from 2011, are
conﬁrmed in recent reviews and monographs (e.g. Currow et al., 2014; Kohberg et al., 2016; Cabezon-
Gutierrez et al., 2016; Martindale, 2017). However, in newer literature, further research needs are
suggested to investigate upwards titration of dosages under aspects of therapeutical beneﬁts and
reduction of adverse effects (Currow et al., 2014; Verberkt et al., 2016).
B. Tolerance and dependence
Chronic oral intake of morphine may induce tolerance as well as strong physical and psychological
dependence. A short-term intake of morphine is not linked to any risk of dependence (EFSA CONTAM
Panel, 2011; Blaschek et al., 2015).
C. Adverse reactions
Adverse effects associated with the treatment of severe pain with morphine
Newer literature is in agreement with the reported side effects in the EFSA CONTAM Panel opinion
(2011).
Common adverse effects of morphine in the treatment of severe pain are bowel dysfunction and
spastic constipation, nausea and vomiting, pruritus, somnolence and cognitive impairment, dry mouth
and bladder dysfunction. A severe side effect of morphine in larger doses is respiratory depression.
Additional recognised adverse effects are endocrinopathies and sleep disorders. Furthermore
myoclonus and morphine induced hyperalgesia are described (Caraceni et al., 2012; Coluzzi et al.,
2012; Labianca et al., 2012; Jitpakdee and Mandee, 2014; Gyawali et al., 2015; Nelson and Camilleri,
2015; Riley et al., 2015; Harned and Sloan, 2016; Zecca et al., 2016; Hussain et al., 2016; Martindale,
2017).
Recent reviews describe opioid-induced respiratory depression as a potentially life-threatening
adverse effect in the treatment of severe acute and chronic pain with estimates of respiratory events
in the perioperative setting ranging from 0.5% to 2% (Boom et al., 2012; Dahan, 2013; Overdyk
et al., 2014). In the past, respiratory depression had been considered a transient morphine side effect
in the treatment of chronic pain to which tolerance quickly developed (e.g. Labianca et al., 2012).
However, the inﬂuence of morphine and other opioids on sleep-disordered breathing, including central
sleep apnoea, has recently been investigated more carefully (Zutler and Holty, 2011; Jungquist et al.,
2012; Javaheri et al., 2014; Rose et al., 2014; Harned and Sloan, 2016). A recent systematic review
found the overall prevalence of central sleep apnoea among patients taking chronic opioids to be 24%
(Correa et al., 2015). The risk appeared to be linearly related to escalating opioid doses, with the
morphine equivalent daily dose and risk of sleep disordered breathing being strongly associated. The
authors concluded that an morphine equivalent daily dose of 200 mg or greater was a risk factor for
severity of central sleep apnoea (Correa et al., 2015; Harned and Sloan, 2016).
Opioid-related CNS side effects can be separated into symptoms and signs associated with a lowering
level of consciousness (e.g. sedation, drowsiness), cognitive and psychomotor impairment (e.g.
impairment of memory, attention, reaction time, motor coordination), and hyperexcitability reactions
(hallucinations, myoclonus and hyperalgesia) (Caraceni et al., 2012; Højsted et al., 2012; Matzo and
Dawson, 2013). In a recent review on cognitive effects and sedation in chronic non-malignant pain
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populations receiving long-term opioid therapy, memory deﬁcits (73–81%), sleep disturbance (35–57%)
and fatigue (10%) are described as the most prevalent observations (Dhingra et al., 2015).
Baldo and Pham (2012) rediscuss the histamine-releasing and allergenic properties of opioid drugs
including morphine. Hypersensitivity reactions such as urticaria are frequently reported after oral intake
of morphine (Merck, 2016). The reported incidence of pruritus is 2–20% after oral administration of
opioids (Golembiewski, 2013). The pathogenesis of morphine induced pruritus is still not fully known.
It is primarily mediated by the binding of morphine to central l-opioid receptors in the brain and spinal
cord (Jitpakdee and Mandee, 2014). The incidence of other morphine induced dermatological side
effects such as exanthema is rare (Merck, 2016). However, a case of erythroderma associated with
administration of morphine sulfate to control severe pain has been published some years ago (Arai and
Mukai, 2011). Anaphylactoid reactions after administration of morphine are known but are uncommon
(AHFS, 2016; Merck, 2016).
In a study of Wiese et al. (2016) to investigate the immunosuppressive potential of opioids, their
use in patients with rheumatoid arthritis was associated with an increased risk of hospitalisation for
serious infections. Also, according to epidemiological studies, high doses and the initiation of opioid
therapy for non-malignant pain appear to correlate with a higher risk of infectious diseases such as
pneumonia. However, the clinical relevance of this observation has not yet been conﬁrmed in
controlled clinical studies (Plein and Rittner, 2017).
Disruption of physiological hormonal activity by chronic therapy with morphine and other opioids
has been well established and comprises all routes of opioid administration including oral application.
In addition to reduced testosterone and oestrogen levels, individuals taking opioid medications have
reduced levels of adrenal androgens, suggesting impairment of the hypothalamic–pituitary–adrenal axis
in addition to disruption of the hypothalamic–pituitary–gonadal axis. Recent reviews concluded that
especially hypogonadism is associated with chronic opioid use and that patients taking opioids
equivalent to ≥ 100 mg of morphine daily should be monitored regularly for symptoms of
hypogonadism (De Maddalena et al., 2012; Elliott et al., 2012; Brennan, 2013; Elliott and Fibuch,
2013; Inder et al., 2013; Valverde-Filho et al., 2015; Harned and Sloan, 2016; Girish and Rao, 2017).
A double-blind, placebo-controlled study was conducted in 21 participants with chronic low back pain
to investigate the potential of morphine to induce neuroplastic changes. In the treatment group (n = 11)
receiving a sustained-release oral formulation of morphine up to a maximum dosage of 120 mg/day for
1 month, decreases of grey matter volume in the right amygdala were observed, while no grey matter
decreases were observed in the placebo group (n = 10) (Lin et al., 2016). Reduced grey matter in the
right amygdala had also been observed in an earlier study following a month of oral morphine
administration via a sustained-release formulation with a ceiling of the dosage at 120 mg/day (Younger
et al., 2011).
Adverse effects associated with the treatment of dyspnoea or moderate cancer pain with morphine
(low-dose range)
In the EFSA CONTAM Panel opinion (2011), it was concluded from studies on the treatment of
dyspnoea, that with sustained release forms in the oral dose range of 7.5–15 mg morphine/day
(corresponding to single doses of about 1.3–2.5 mg morphine taken every 4 h) side effects such as
sedation, dizziness or light-headedness occurred in the onset of therapy of opioid-na€ıve individuals.
This dose range was also associated with nausea, vomiting and obstipation. Furthermore, a single low
sustained release morphine bedtime dose of 11.55 mg had been shown to signiﬁcantly affect sleep
architecture in healthy adults and lead to reductions in slow-wave sleep. A threshold for the onset of
these side effects was not described and it was not known if these side effects occur below the lowest
known single oral therapeutic dose of 1.9 mg morphine (EFSA CONTAM Panel, 2011).
According to newer literature, these conclusions are still valid. Raffa and Pergolizzi (2012) reviewed
the effects of morphine on sleep architecture without discussing dose–effect relationships: decrease in
the number and duration of rapid eye movement (REM) periods, delay in the onset of the ﬁrst REM
period and increase in the waking state and reduction in slow-wave sleep in healthy adults. According
to Kohberg et al. (2016), no severe adverse effects such as respiratory depression were reported from
studies on the treatment of dyspnoea, only constipation was reported as a common side effect. Also
Rocker et al. (2013) report that GI symptoms, primarily constipation, were the most frequent and
troubling adverse effects observed in the therapy of dyspnoea, besides of nausea, vomiting, bloating,
cramping in a few patients. Other adverse effects included sleepiness, itching, dry mouth, sweating,
dizziness and skin changes (Rocker et al., 2013). In a 28-day study by Bandieri et al. (2016) in
118 adults with moderate cancer pain, median doses of 30 mg morphine per day were well tolerated
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according to the authors. Tiredness, nausea, depression, anxiety, drowsiness, all in mild forms were
reported side effects, no shortness of breath being observed (Bandieri et al., 2016). In a study by
Navigante et al. (2010) 2 patients out of 30 required dose reduction because of excessive somnolence
to a lower dose of 3 mg morphine every 8 h for both patients (the dose causing the somnolence is not
reported). A case of angioedema with tongue and lip swelling has been reported in a 85-year-old
woman, receiving low dose sublingual morphine (2.5 mg every 4 h) (Kohli et al., 2011).
E. Interactions
The side effects of morphine, particularly respiratory depression, sedation, hypotonia or coma, may
be ampliﬁed by parallel administration of other central depressant drugs including other opioids and
alcohol (EFSA CONTAM Panel, 2011; Merck, 2016).
F. Speciﬁc groups (including contraindications)
Pregnant women, preterm infants
Morphine crosses the placental barrier. Adequate data are not available that would permit an
assessment of the possible teratogenic risk for humans (e.g. Brennan and Rayburn, 2012). However, it
has been reported on a possible association of morphine administration with an increased incidence of
hernia inguinalis (Merck, 2016).
Newborns of women addicted to morphine or related opioids, having prolonged in utero exposure
to the opioid, may develop the NAS exhibiting withdrawal symptoms during the ﬁrst days of life. It is
mainly characterised by signs of CNS and GI dysfunction (Bio et al., 2011; EFSA CONTAM Panel, 2011;
Kraft et al., 2011; Kraft and van den Anker, 2012; Brucknerova et al., 2015). Use of prescription
opioids including morphine during pregnancy is also associated with a risk of NAS, especially when
used long term or late in pregnancy (Desai et al., 2015; Dooley et al., 2015).
Prenatal exposure to morphine increases the number of opioid receptors in the substantia nigra,
subthalamic nucleus and the hippocampus, the structures involved in seizures. This corresponds to the
increased seizure activity, electroencephalogram (EEG) changes, and increased irritability observed in
children of opioid-abusing mothers (Kesavan, 2015).
Morphine analgesia in preterm neonates was associated with impaired cellular growth in the
neonatal period and smaller head circumference/cerebellar volume and poorer neurodevelopmental
outcome in early childhood (Ferguson et al., 2012; Steinhorn et al., 2015; Kocek et al., 2016; Zwicker
et al., 2016; McPherson, 2016). Opioid receptors are expressed early in the developing brain. Morphine
acts on the l-, d- and j-opioid receptors and activates multiple intracellular signalling pathways, which
are implicated in modulation of proliferation, survival and differentiation of neural stem cells, neurons,
and glia that express opioid receptors. Therefore, exposure to morphine during a critical period of
neuronal maturation may lead via complex mechanisms to permanent changes in the formation and
function of the CNS (Kesavan, 2015).
On the basis of the knowledge currently available, it is not possible to identify a threshold dose for
developmental and reproductive toxic effects of morphine in humans.
Breast feeding
Morphine is distributed into milk where it may reach higher levels than in the plasma of the mother
(AHFS, 2016; Merck, 2016). Hendrickson and McKeown (2012) analysed available data and concluded
that they did not identify any reports of suspected infant toxicity from maternal morphine use while
breast feeding. Recommendations in monographs are not consistent: while the American Academy of
Pediatrics has stated that the administration of morphine is usually compatible with lactation
(Martindale, 2017), others advise against breast feeding during oral treatment of the mother with
morphine (Merck, 2016).
Children
Morphine can cause signiﬁcant apnoea in newborn infants and is associated with seizure activity in
newborns. Respiratory depression due to morphine treatment is considered to be a main risk in all
children; however, neonates and infants under the age of 1 year have an enhanced risk to respiratory
depression. Morphine-associated respiratory depression is especially greater in premature born infants
due to the immaturity of their respiratory centre responses to hypoxia and hypercarbia (Kesavan,
2015; Merck, 2016; Martindale, 2017).
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Children with obstructive sleep apnoea and signiﬁcant previous recurrent hypoxemia during sleep
have been observed to have a higher sensitivity for morphine. This has been concluded from a study
in 22 children aged between 19 and 79 months treated postoperatively after adenotonsillectomy with
morphine intravenously (i.v.) (Brown et al., 2006).
In children episodes of recurrent hypoxia from sleep-disordered breathing, obstructive sleep apnoea
and/or tonsillitis are considered to increase sensitivity to morphine for respiratory depression and
analgesic effects (Brown et al., 2006; EFSA CONTAM Panel, 2011; Niesters et al., 2013).
Children between 2 and 12 years of age (n = 93), who underwent (adeno)tonsillectomy, were
discharged from the hospital on regular paracetamol and ibuprofen for 7 days and a single oral dose
of 0.2 mg morphine sulfate/kg bw on the mornings of days 3, 4 and 5 after tonsillectomy. Adverse
effects associated with morphine were only seen in 11 patients. There were no major adverse side
effects like respiratory depression recorded (Syed et al., 2016).
The elderly
Elder patients (over 75 years) may be more sensitive to morphine (Merck, 2016).
Individuals at higher risks due to certain health conditions
As described in the EFSA CONTAM Panel opinion (2011), individuals under special health conditions
may be at higher risks for development of side effects of morphine. For example, morphine has to be
avoided in patients at risk of paralytic ileus and has to be used only with caution in obstructive or
inﬂammatory bowel disorders and in patients with renal or hepatic impairment. Morphine is generally
contra-indicated in acute respiratory depression and obstructive airways disease, and must be used
with caution in patients with compromised respiratory function (e.g. emphysema, apnoea, severe
obesity) (e.g. AHFS, 2016). Also, in recent literature, it is reported that morphine is recognised to
worsen obstructive sleep apnoea (Rowsell et al., 2015, 2016) and that morphine treatment may be
associated with toxicity in renal insufﬁciency (Mallappallil et al., 2017).
G. Intoxications
Miosis, respiratory depression and unconsciousness (coma) are the three typical symptoms of acute
morphine intoxication. For non-opiate dependent adults, doses in the range from 200 to 1,100 mg
morphine may be acutely lethal. Toddlers and infants are far more sensitive (e.g. EFSA CONTAM Panel,
2011; Bracher et al., 2016; Merck, 2016).
Rivard et al. (2016) report on a case of intoxication of a 3-year-old child (bw: 15 kg), who
underwent adenoidectomy and tonsillectomy. At the day of surgery, he received three times a single
oral dose of 3 mg morphine and 225 mg paracetamol (corresponding to single doses of 0.2 mg
morphine and 15 mg paracetamol/kg bw). The day after he was given within 15 h two single oral
doses of 3 mg morphine and 225 mg paracetamol (corresponding to single doses of 0.2 mg morphine
and 15 mg paracetamol/kg bw) and by mistake two single oral doses of 15 mg morphine
(corresponding to single doses of 1 mg morphine/kg bw). Two hours after the last dose, the child
developed fever, somnolence, tachycardia, miosis, respiratory depression and convulsion. The child
survived after emergency treatment.
3.1.3.2. Codeine
Based on new data on the therapeutic use of codeine in humans, the CONTAM Panel has updated
the information from the previous opinion. Codeine is used for medicinal purposes as a monohydrate
or as a salt, e.g. codeine hydrochloride (in the form of a dihydrate) or codeine phosphate (in the form
of a hemihydrate or a sesquihydrate) (Ph. Eur. 8, 2016). From Swedish national register data, it was
concluded that codeine belongs to the most frequently used opioids (S€oderberg et al., 2013).
A. Pharmacodynamics, therapeutic applications and dosage
Codeine is used to treat mild to moderately severe pain (often in combination with a non-opioid
analgesic) and also to treat acute diarrhoea but its main use is for the symptomatic treatment of dry
coughs. The antitussive effect results from suppression of the cough reﬂex by acting on the medulla
oblongata in the cough centre. Additionally, codeine has slight sedating properties (Bracher et al.,
2016; Martindale, 2017).
Codeine is approximately one-twelfth less potent than morphine as an analgesic and has a
correspondingly lower dependence-liability than morphine (Vree et al., 2000). Codeine may be
considered a prodrug of the active compounds morphine and C6G (Srinivasan et al., 1997; Vree et al.,
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2000). Codeine has little analgesic effect in patients who are CYP2D6 poor metabolisers, whereas the
risk of morphine toxicity is higher in ultra-rapid metabolisers (see Section 3.1.1.1).
For the treatment of cough or pain, the following dose ranges shown in Table 6 are recommended
for adolescents over the age of 12 years and adults.
Observed life-threatening toxicity in paediatric patients given moderate doses of codeine has been
associated with the genotype predisposing to ultra-rapid metabolism of codeine into morphine by the
isoenzyme CYP2D6. Higher plasma morphine concentrations in the blood of ultra-rapid metabolisers lead
to a higher risk of side effects due to morphine’s action on the brain and respiratory centre (e.g. Gasche
et al., 2004; Ciszkowski et al., 2009; Kelly et al., 2012; Martindale, 2017). Therefore, medicinal uses of
codeine especially in children under 12 years have been restricted by responsible authorities (EMA,
2013a,b, 2015a,b; FDA, 2013; Health Canada, 2013; MHRA/CHM, 2013) (see Section 3.1.3.2.E).
According to Heintze and Fuchs (2015), in children, who are rapid or ultra-rapid metabolisers,
therapeutically used daily dose of codeine of 1–3 mg/kg bw may result in toxic accumulation of morphine
which may lead to respiratory depression and death (for details see Section 3.1.3.2.E Speciﬁc groups).
B. Tolerance and dependence
Codeine has dependence potential, with longer term use and high doses resulting in tolerance and
physical/psychological dependence. Codeine is subject to abuse, but produces less euphoria and
sedation than morphine. There is cross-tolerance with other opiates (Prescribing Information, 2015;
Martindale, 2017).
C. Adverse reactions
The adverse reactions to codeine are similar to those with morphine but seen to a lesser extent at
clinical doses. In the case of chronic administration in usual doses, the most frequent side effects are
nausea sometimes linked with vomiting (particularly at the beginning of treatment) and constipation
(Prescribing Information, 2015; Martindale, 2017).
Confusion is described as an unusual adverse effect, however has been observed recently in a
14-year-old girl after treatment with a cough suppressant over 15 days with daily doses of 30–45 mg
codeine/person (O’Reilly et al., 2015). The authors noted that the daily doses were within the
recommended dose range but the maximum recommended duration of dosage of 3 days was
exceeded (no genotyping for CYP2D6).
Codeine phosphate (50 mg/person) alone and with alcohol had a deleterious effect on driving skills
in a simulated driving test (Linnoila and Hakkinen, 1974; Martindale, 2017). Medications with codeine
have been associated with a signiﬁcant increase of risk for motor vehicle collisions (Rudisill et al., 2016).
Allergic reactions to codeine are known, as also shown by newly published case reports, but rarely
in a severe form (Fathallah et al., 2011; Deverriere et al., 2012; Ariosto, 2014; Yoo et al., 2014; Erfan
et al., 2015; Prescribing Information, 2015).
D. Interactions
Combined intake of codeine and other central depressants (e.g. sedatives, hypnotics,
psychotropics, antihistamines, antihypertensives) can amplify the sedating or respiratory depressive
effect of codeine. In addition, the combination of alcohol with codeine may reduce the psychomotor
abilities (supra-additive effect of individual components) (Prescribing Information, 2015; Bracher et al.,
2016; Martindale, 2017).
Table 6: Recommended single and total daily doses for orally administered codeine salts presented
as doses of codeine to treat dry cough (Prescribing Information, 2015; Bracher et al.,
2016)
Age group Single dose mg codeine(a)
Total daily dose
mg codeine
Adolescents over the age of
12 years and adults
15–44 mg, can be repeated every 6–8 h; in individual
cases up to 100 mg
Up to 200 mg
(a): Anhydrous codeine base, CAS No 76-57-3, MW: 299.36 g/mol.
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E. Speciﬁc groups (including contraindications)
Pregnant women
As summarised by the CONTAM Panel in 2011, codeine crosses the placental barrier. While codeine
administration during the ﬁrst trimester was statistically signiﬁcantly associated with respiratory and
heart malformations, data on other malformations were inconclusive. Furthermore, studies on the use
of codeine to treat pain and ‘high temperature’ during pregnancy did not reveal any elevated risk of
malformation. This was conﬁrmed by the outcome of ‘The Norwegian Mother and Child Cohort Study’
(Nezvalova-Henriksen et al., 2011, 2012; Nordeng et al., 2014). In this study, pregnancy outcomes of
2,666 women who used codeine during pregnancy were compared with 65,316 women without opioids
use during pregnancy by logistic regression analyses. Between codeine exposed and unexposed infants
no signiﬁcant differences were found in the survival rate (adjusted odds ratio 0.9, 95% conﬁdence
interval (CI) 0.6–1.5) or the congenital malformation rate (adjusted odds ratio 0.9, 95% CI 0.8–1.1).
However, third-trimester maternal codeine intake was associated for the mothers with acute Caesarean
delivery (adjusted odds ratio 1.5, 95% CI 1.3–1.8; p < 0.0001) and postpartum haemorrhage
(adjusted odds ratio 1.3, 95% CI 1.1–1.5; p < 0.0001).
In a neonate whose mother had taken about 90 mg of codeine daily during the last 2 months of
pregnancy, symptoms characteristic of the NAS associated with narcotic withdrawal were seen (Khan
and Chang, 1997). Thomas and Wolff (2016) recently reported another case, in which symptoms such
as hypoglycaemia, poor feeding, GI disturbance and respiratory distress have been associated with
NAS due to oral therapy during pregnancy with codeine in daily doses of 180 mg combined with the
analgesic tramadol, which is a synthetic opioid.
The identiﬁcation of threshold doses for developmental and reproductive toxic effects is not
possible on the basis of the knowledge currently available.
CYP2D6 ultra-rapid metabolisers, breast feeding, children
Several cases of life-threatening toxicity in patients (and breastfed infants of mothers) given orally
moderate doses of codeine were associated with an increased metabolism of codeine resulting in
excessive blood levels of morphine in ultra-rapid metabolisers. The prevalence of ultra-rapid
metabolisers varies by ethnic origin and ranges from 1% to 2% for Northern Europeans up to 29% for
Africans (e.g. Crankshaw, 2011; MHRA/CHM, 2013; Tremlett, 2013; Crews et al., 2014; Prescribing
Information, 2015; Martindale, 2017). Niesters et al. (2013) noted in their review on opioid induced
respiratory depression in paediatrics, that below the age of 6 months the CYP2D6-dependent
conversion of codeine into morphine is predominant since alternative pathways of codeine metabolism
are not fully developed. An additional risk factor to develop respiratory depression is seen in recurrent
hypoxic episodes from sleep-disordered breathing, obstructive sleep apnoea and/or tonsillitis. Episodes
of recurrent hypoxia are considered to increase sensitivity to opioids (Brown et al., 2006; EFSA
CONTAM Panel, 2011; Niesters et al., 2013).
Lactating mothers and breastfed infants
Codeine and its metabolite morphine are distributed into breast milk. If the mother is an ultra-rapid
metaboliser of codeine, breastfed infants are at high risks of severe adverse effects from its metabolite,
morphine. CNS depressions including a case of respiratory arrest resulting in death have been reported
for breastfed infants of mothers receiving codeine e.g. in the treatment of post-labour pain (Koren et al.,
2006; Madadi et al., 2007, 2009; van den Anker, 2012; Juurlink et al., 2012; Lam et al., 2012, 2013;
Berlin and van den Anker, 2013; Prescribing Information, 2015; Anderson et al., 2016; Martindale, 2017).
A newborn male infant was found cyanotic and without vital signs on day 13 after birth.
Resuscitation was unsuccessful. Full post-mortem analysis failed to identify an anatomic cause of
death. The mother had been taking orally single dosages of 30 or 60 mg codeine twice daily (initially
60 mg every 12 h, reduced to half that dose from postpartum day 2 because of somnolence and
constipation) as part of a combination preparation with paracetamol for about 2 weeks. Assayed
morphine concentrations in the mother’s breast milk were found to be 87 ng/mL. Post-mortem
toxicological testing of the infants’ blood revealed a blood concentration of morphine at 70 ng/mL.
Neonates receiving morphine for analgesia have been reported to have serum concentrations of
morphine at 10–12 ng/mL. Later investigations found that the mother’s genotype for CYP2D6 classiﬁed
her as an ultra-rapid metaboliser of codeine (Koren et al., 2006; Madadi et al., 2007, 2009).
Madadi et al. (2009) reported an additional case of severe neonatal toxicity in a breastfed infant
whose mother was a CYP2D6 ultra-rapid metaboliser. After childbirth, the mother took 120 mg
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codeine/day in form of a combination product with paracetamol to treat severe muscle pain. During
the period, she was taking codeine, she reported feeling sedated, nauseous, dizzy, and weak. Her
breastfed infant was described extremely drowsy and feeding poorly. Due to feeding difﬁculties, breast
milk was supplemented with formula. After completely replacing breast milk by formula feeding at
7 days after delivery, the mother noted complete reversal of the infant’s symptoms in the following
days. Furthermore, the authors examined characteristics of mothers and infants with or without signs
of CNS depression following codeine exposure while breastfeeding in a case–control study. They
showed that mothers of symptomatic infants (n = 17) consumed a mean 59% higher codeine dose
than mothers of asymptomatic infants (n = 55) (1.62  0.79 mg/kg bw per day vs 1.02  0.54 mg/kg
bw per day; p = 0.004). Comparison of neonatal and maternal CNS depression exhibited a
concordance of 71%. Ultra-rapid metabolisers were identiﬁed in 2 (11.8%) cases. According to the
authors the lowest maternal dose of codeine associated with symptoms in the infant was 0.63 mg/kg
bw per day corresponding to 44 mg codeine for a 70-kg woman (Madadi et al., 2009).
Administration to children
Serious adverse effects due to central nervous depression have been repeatedly reported after oral
administration of codeine to infants or children after hospital discharge in the management of pain due
to surgery or in the therapy of cough (EMA, 2013a, 2015a, Niesters et al., 2013; Subramanyam et al.,
2013; Wong et al., 2012). Especially after oral codeine treatment following tonsillectomy, apnoeas
partly with fatal outcome have been observed in children who were diagnosed (or suspected of being)
extensive or ultra-rapid metabolisers of codeine (e.g. Voronov et al., 2007; Ciszkowski et al., 2009;
Kelly et al., 2011, 2012).
Voronov et al. (2007) described a case of a 29-month-old boy (bw: 13.7 kg) who experienced
apnoea resulting in brain injury following oral treatment with paracetamol combined with codeine
2 days after adenotonsillectomy. After the surgery, the patient spent 5 h in the hospital and received
two oral doses of codeine (1.75 mg/kg bw per dose). At home during postoperative day 1, four doses
of codeine and one extra codeine dose during the night were administered to the boy (1.75 mg/kg bw
per dose). Four hours later, his mother found him unresponsive and apnoeic. The emergency medical
service noted upon arrival that the child was spontaneously breathing, unresponsive and with pinpoint
pupils. A quantity of 1.4 mg naloxone was administered leading to some improvement. He came to the
intensive care unit with stable vital signs. Magnetic resonance imaging of the head showed bilateral
parasagittal watershed infarcts involving the white matter and cerebral cortex. He was discharged from
the hospital on post-operative day 13 with stable conditions. Genotyping was performed and the
results interpreted by the authors as indication of extensive metabolism.19
Ciszkowski et al. (2009) report on the case of a healthy 2-year-old boy (bw: 13 kg), who
underwent adenotonsillectomy. After surgery, instructions were to administer at home orally 10–
12.5 mg of codeine and 120 mg paracetamol every 4–6 h as needed (corresponding to single doses of
0.77–0.96 mg codeine/kg bw and about 3–6 mg/kg bw per day). On the second evening after surgery,
the child developed fever and wheezing and on the next morning, the boy’s vital signs were absent.
Post-mortem examination showed evidence of bronchopneumonia. Analysis of femoral blood resulted
in 700 ng codeine/mL and 32 ng morphine/mL without evidence of other drugs or metabolites being
present. CYP2D6 genotyping revealed ultra-rapid metaboliser phenotype. According to the authors’
explanation, the given dose of codeine was within the recommended range of 1–3 mg/kg bw per day.
However, respiratory depression has been shown in other young children with serum morphine
concentrations exceeding 20 ng/mL. The authors also noted that the existing bronchopneumonia may
have enhanced the risk of hypoxemia and recurrent episodes of hypoxemia may lead to alterations in
the l-opioid receptor and increased sensitivity to morphine.
Two fatalities and a case of severe respiratory depression following the oral use of codeine in three
young overweight children, aged 3–5 years, for pain following adenotonsillectomy have been published
by the same group of authors (Kelly et al., 2012). The three children were receiving doses within the
recommended weight-adjusted dose of 0.5–1 mg codeine/kg bw every 4–6 h (maximum 6 mg
codeine/kg bw per day). Two of the children had CYP2D6 polymorphisms for extensive or ultra-rapid
metabolism phenotypes (which can overlap), and this was suspected in the third child in view of the
high morphine blood concentrations found relative to those of codeine. As morphine sparsely
19 However, it was noted that the authors described it as well as ultra-rapid metabolism in the title of their report (Voronov
et al., 2007). In consequence, the report was repeatedly commented (de Leon, 2008; Lerman, 2008; Stamer and Stuber,
2008; de Wildt and Koren, 2008).
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distributes to fatty tissue, the authors considered that dosing in the three overweight patients based
on total body weight instead of lean mass might have partially contributed to morphine accumulation.
Friedrichsdorf et al. (2013) describe the deaths of three children aged 4–10 years after oral
administration of codeine at home in the recommended dose ranges. All three children were
overweight or obese and were given codeine after tonsillectomy, orthopaedic surgery or as cough
suppressant. They received codeine every 4 h as needed in single oral doses of 0.29 mg/kg bw
(tonsillectomy; co-administration: valproate; death occurred after 4 single doses of codeine); 0.22–
0.44 mg/kg bw (respiratory infection; co-administration: guaifenesin, azithromycin; death occurred
after 3 single doses of codeine); or 0.45–0.9 mg/kg bw (orthopaedic surgery; reactive airway disease;
co-administration: diazepam; death occurred after 3 single doses of codeine). In the last case, co-
administration of benzodiazepine and the reactive airway disease were regarded as possible
contributing factors by the authors. Testing for CYP2D6 ultra-rapid metabolism was undertaken in only
one of the three cases presented with negative result (no indication which case).
Hermanns-Clausen et al. (2009) report on the intoxication of 3-year-old male twins after the oral use
of codeine as an antitussive agent. Further medication consisted of acetaminophen, ibuprofen, an ivy
extract. One of the twins with a body weight of 13.4 kg was found lying in vomit and apnoeic at night.
He was re-animated and survived after transfer to an intensive care unit. Two and a half hours later, his
twin brother (body weight: 14 kg) was found dead in his bed at home and autopsy showed massive
aspiration of gastric content. The monozygotic twins had been given both a codeine solution at a dose of
‘10 drops per day’ for 6 days for the treatment of an upper respiratory tract infection lasting for several
days. The weight of ‘10 drops’ was determined experimentally and was found to range from 494 to
940 mg. Thus, the highest possible dose administered was 23.5 mg codeine/day (corresponding to
1.75 mg codeine/kg bw per day based on a body weight of 13.4 kg) instead of the recommended 10 mg
codeine/day. The twins had identical CYP2D6 gene polymorphisms of the ‘extensive metaboliser’ type.
An episode of an apparent life-threatening event with recurrent apnoea was observed in a 17-day-
old Chinese female neonate born at full-term, who was treated for mild cough and nasal blockage with
chlorpheniramine and a cough suppressant syrup containing 6 mg codeine/2.5 mL (single dose).
According to the authors, the patient was given a dose of 6.6 mg codeine/kg bw per day, which
exceeded the published dosage recommendation at that time for codeine in children of 1 mg/kg bw
per day. At the second day of treatment, the girl experienced a ﬁrst attack of cyanosis with a decrease
in responsiveness and breathing effort 2 h after the last administration of the dose which took place at
noon. The attack lasted for 1 min and the patient gradually recovered. The second attack of apnoea
occurred 1 h later while the patient was waiting at the emergency department. The patient recovered
after treatment in hospital. No CYP2D6 genotyping was performed (Tong and Ng, 2001).
Magnani and Evans (1999) report on a case of codeine intoxication in an infant at 29 days of age, in
which codeine was prescribed for cough control in the form of a medicinal preparation. Each 5-mL of the
preparation contained 30 mg of pseudoephedrine hydrochloride, 10 mg of codeine phosphate, 2 mg of
chlorpheniramine maleate, and 5% alcohol. The infant received twice 1 mL of the preparation within 6 h,
corresponding to a total of 4 mg of codeine phosphate or 1.26 mg of codeine phosphate/kg bw within a
6-h period. Two hours after the administration of the last dose the mother noted that the baby was not
breathing. Despite lifesaving measures, the infant died. No CYP2D6 genotyping was performed.
Near-fatal consequences were described after oral administration of a medicinal preparation,
containing triprolidine, pseudoephedrine hydrochloride and codeine phosphate to a 3-month-old boy
with a body weight of 3.0 kg for the treatment of an upper respiratory tract infection. Within 24 h
after administering the single dose of 5 mL containing 10 mg codeine phosphate twice (total intake:
6.6 mg codeine phosphate/kg bw), his mother noted he was sleepy, breathing heavily, and had small
pupils. On arrival in the hospital the baby was collapsed, cold, and semi-comatose with pin-point pupils
and Cheyne–Stokes breathing. He recovered after i.v. treatment with naloxone. No CYP2D6 genotyping
was performed. The authors noted that the total intake of codeine was well above the at that time
recommended dose of 1–2 mg codeine/kg bw per day (Wilkes et al., 1981).
The CONTAM Panel noted that therapeutical oral administration of single doses of codeine as low as
0.22–0.44 mg/kg bw, repeated every 4 h as needed, has led to death in children. Case reports and
pharmacovigilance data for codeine show that individuals who have CYP2D6 polymorphisms for
extensive or ultra-rapid metabolism phenotypes exhibit higher sensitivity to codeine toxicity compared
to their poor or intermediate metabolising counterparts. Especially affected are breastfed infants from
ultra-rapid metabolising mothers and ultra-rapid metabolising infants and children. In addition
breathing problems such as recurrent hypoxic episodes from sleep-disordered breathing, obstructive
sleep apnoea and/or tonsillitis may increase the risk for codeine toxicity.
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Current recommendations
Although morphine-induced side effects after administration of oral codeine may occur at all ages,
current evidence suggests that children below 12 years are at special risk of life-threatening respiratory
depression with codeine. EMA considered that the way codeine is converted into morphine in children
below 12 years is more variable and unpredictable, making this population at special risk of such side
effects (EMA, 2015b). A particular risk is seen in those paediatric patients who might already have
compromised airways and who require pain relief following tonsillectomy and/or adenoidectomy (EMA,
2013a,b, 2015a,b; FDA, 2013; Health Canada, 2013; MHRA/CHM, 2013; Prescribing Information, 2015;
Martindale, 2017).
Following reviews by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), which
investigated reports of serious and fatal respiratory depression in children after taking codeine, some of
the children being ultra-rapid metabolisers of codeine, EMA (EMA, 2013a,b, 2015a,b) recommended that:
• “Codeine-containing medicines should only be used to treat acute (short-lived) moderate pain
in children above 12 years of age, and only if it cannot be relieved by other painkillers such as
paracetamol or ibuprofen, because of the risk of respiratory depression associated with
codeine use.”
• “Codeine should not be used at all in children (aged below 18 years) who undergo surgery for
the removal of the tonsils or adenoids to treat obstructive sleep apnoea, as these patients are
more susceptible to respiratory problems.”
• “Use of codeine for cough and cold is contraindicated in children below 12 years.”
• “Use of codeine for cough and cold is not recommended in children and adolescents between
12 and 18 years who have breathing problems.”
• Codeine should not be used in breastfeeding mothers.
• Codeine should not be used in people of any age who are known to be ultra-rapid metabolisers
of codeine.
Similar recommendations were given by other authorities (FDA, 2013; Health Canada, 2013; MHRA/
CHM, 2013; Stingl and Rotthauwe, 2015).
The elderly
In elder patients, elimination of codeine may be prolonged (Prescribing Information, 2015).
Individuals at higher risks due to certain health conditions
It is known that patients with certain diseases and individuals under special health conditions are at
higher risks for development of side effects of codeine, consequently precautionary measures or
contraindications are recommended in the medical ﬁeld due to corresponding known side effects of codeine.
Codeine is generally contraindicated in acute respiratory depression. Codeine must be used with
caution in patients with obstructive airways disease, asthma and impaired renal function (Prescribing
Information, 2015; Martindale, 2017).
F. Intoxications
Codeine intoxication leads to similar symptoms as morphine intoxication; reﬂecting the metabolism
of codeine to morphine. The most frequently reported symptoms are extreme respiratory depression
and pulmonary oedema. Other symptoms are extreme sleepiness, stupor, coma, miosis, vomiting,
headaches, urine and faeces retention, cyanosis, hypoxia, cold skin, skeletal muscle tone loss and
areﬂexia and, in some cases, with bradycardia, syncopes and a drop in blood pressure. It is to be
noted that in children only cramps occur (BfR, 2005; Dillon et al., 2013; Prescribing Information, 2015;
Bracher et al., 2016).
3.1.3.3. Thebaine, oripavine, noscapine and papaverine
Thebaine
Since thebaine is not used pharmaceutically, but only as a starting substance for pharmaceutic
synthesis, no information is available about its effects in humans after oral or parental exposure as
already noted in the previous opinion in 2011 (EFSA CONTAM Panel, 2011).
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Oripavine
Since oripavine is not used pharmaceutically, but only as a starting substance for pharmaceutic
synthesis, no information is available about its effects in humans after oral exposure.
Noscapine
As summarised by the CONTAM Panel in 2011, noscapine which is used as centrally acting
antitussive compound, does not bind to opioid receptors and has neither an analgesic, respiratory
depressive nor obstipating effect. For adults, the oral therapeutic dose of noscapine is 25–50 mg
(corresponding to 0.36–0.71 mg/kg bw for an adult weighing 70 kg) three times daily, for children
aged between 3 and 12 years 12–25 mg (corresponding to 0.52–1.09 mg/kg bw assuming a body
weight of 23 kg20) three times daily and for children aged between 6 months and 3 years 6–12 mg
(corresponding to 0.67–1.33 mg/kg bw assuming a body weight of 9 kg or 0.5–1.0 mg/kg bw
assuming a body weight of 12 kg21) two to three times daily. Slight sleepiness, light-headedness,
dizziness, headaches, nausea and erythema are indicated as adverse reactions. Very rarely
anaphylactic reactions and Steven-Johnson syndrome may occur.
As already referred to by the CONTAM Panel in 2011, investigations regarding the use of noscapine
and its derivatives as anti-mitotic and tubulin-binding anti-cancer agents are still a subject of reviewing
articles (e.g. DeBono et al., 2015; Rida et al., 2015; Tomar et al., 2017). From new literature, it is
known that the Netherlands Pharmacovigilance Centre received 10 reports of angioedema associated
with the use of noscapine between 1987 and 2013.22 Furthermore, two cases of erythema occurring in
Japan after noscapine administration have been published (Ishiguro et al., 2011).
Papaverine
Papaverine is normally used pharmaceutically as a smooth muscle relaxant in the form of
papaverine hydrochloride (Ph. Eur. 8, 2016) in the treatment of GI disorders and coughs. Orally, 150–
300 mg papaverine hydrochloride (equivalent to 135–270 mg papaverine) is administered two to three
times daily. The maximum daily dose is indicated as 600 mg papaverine hydrochloride (equivalent to
540 mg papaverine) (Bracher et al., 2016; Martindale, 2017).
In 2011, the CONTAM Panel concluded that papaverine does not show opiate-like pharmacology since
it acts as a smooth muscle relaxant that is most pronounced on blood vessels. The side effects of
papaverine, reported after oral administration, are dizziness, drowsiness, headache, tiredness, GI
disturbance, tachycardia, skin rash, sweating and hypotonia. After long-term administration, eosinophilia,
icterus and liver enzyme changes (reversible) have been reported (BfR, 2005). Overdosage may lead to
seizures.
3.1.3.4. Opium
Opium is the dried latex obtained from the unripe capsules of P. somniferum L. The toxicity of
opium is mainly attributed to the toxic effect of morphine and can be increased by codeine. The
paralysing effect of opium on the CNS, particularly on the respiratory centre, is described to be lower
compared to morphine due to the antagonistic effect of thebaine (Blaschek et al., 2013). Noscapine
also has a minor stimulatory effect on respiration (Blaschek et al., 2013).
Mainly the peripheral GI effects of opium are used therapeutically. According to the European
Pharmacopoeia (Ph. Eur. 8, 2016), ‘raw opium’ should contain not less than 10% of morphine
(anhydrous), not less than 2% of codeine (anhydrous), and not more than 3% of thebaine
(anhydrous). ‘Raw opium’ is intended only as the starting material for the manufacture of ‘standardised
opium dry extract’, ‘prepared opium’ or ‘standardised opium tincture’, which are orally used in the
treatment of severe diarrhoea associated with chronic inﬂammatory GI diseases. The relaxing action of
papaverine and noscapine on intestinal muscle makes the opium preparations more constipating than
morphine. They decrease in the number and frequency of bowel movements and slow down intestinal
movements (Blaschek et al., 2013; Bracher et al., 2016; Martindale, 2017).
‘Standardised opium tincture’ contains 0.95–1.05% morphine (anhydrous), not less than 0.1% of
codeine (anhydrous) and not more than 0.3% of thebaine (anhydrous). In the treatment of pain for
adults, single dosages range from 0.5 g to a maximum 1.5 g of tincture, the maximum daily dosage
20 Mean body weight for children from 3 to 10 years old (EFSA Scientiﬁc Committee, 2012).
21 The mean body weight of infants from 6 to 12 months old is 8.8 kg and the default body weight for European toddlers (aged
1–3 years) is 12 kg (EFSA Scientiﬁc Committee, 2012).
22 https://www.lareb.nl/en/news/noscapine-and-angioedema/
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being 5 g of tincture. In the treatment of diarrhoea, the tincture is administered in single dosage of
0.15–0.33 g, given three times daily, the daily dosage being 0.45–1 g/day. This corresponds to single
dosages of about 1.5–3.3 mg morphine, not less than 0.15–0.33 mg codeine and not more than 0.45–
1 mg thebaine and daily dosages of 4.5–10 mg morphine, not less than mg 0.45–1 mg codeine and
not more than 1.35–3 mg thebaine for adults. This calculation informs about the maximum doses of
thebaine, which are tolerated by humans in the therapeutic uses of mixtures of opium alkaloids in the
treatment of diarrhoea associated with chronic inﬂammatory GI diseases.
Thus, as noted by the CONTAM Panel in 2011, since the high alkaloid content in poppy seeds is
considered to be caused by contamination with the latex, opium alkaloids adhering to poppy seeds
may have a distribution pattern similar to that found in opium. In consequence, combined effects
reported for the alkaloids in opium may be relevant for alkaloid-contaminated poppy seeds originating
from cultivars traditionally used in opium production. However, the available analytical results show
that the alkaloid proﬁle in poppy seed samples may largely deviate from the proﬁle of opium as
deﬁned in the European Pharmacopoeia.
3.1.3.5. Poppy seeds
The CONTAM Panel summarised in 2011 one case of intoxication after food use of a consumer
reporting an ‘uneasy feeling’ in her head, vomiting and she felt like she had a hangover the next day.
Symptoms of intoxications following misuse of poppy seeds included respiratory depression in a
6-week-old baby and tonic-clonic seizures and hallucinations in a 26-year-old adult. From studies with
healthy subjects, nausea, vomiting, constipation and some system on the CNS like dizziness,
headache, and difﬁculties to concentrate were reported after intake of contaminated poppy seeds.
Since 2011, some cases of intoxications after consumption of homemade tea from poppy seeds,
store-bought or purchased on the Internet, for ‘relaxation’ or ‘treatment of chronic anxiety’ or ‘natural
pain control’ have been reported (Castelli and Hendrickson, 2017; Rinner et al., 2017; Spyres and Van
Wijk, 2017). Authors associate the intoxications with intake of opioid overdoses via the poppy seed tea
without specifying the exposure doses of the opioids.
Schuppener and Corliss (2018) describe a case of a 54-year-old woman who had consumed ‘large
quantities’ of raw poppy seeds prior to the development of intractable vomiting and death. A cast-like
large bowel obstruction composed of brown-black poppy seeds (approximately 900 g) was identiﬁed at
autopsy. The authors report that the post-mortem blood morphine level was < 10 ng/mL and
considered the level to be well below that needed to cause acute opioid toxicity or even intoxication.
The codeine level in the blood was below the LOD. Complications of a bowel obstruction, secondary to
poppy seed ingestion, were determined to be the cause of death which was not associated with opioid
toxicity.
As outlined in the 2011 opinion, immediate-type allergy (Type I, immunoglobulin E (IgE)-mediated)
and anaphylaxis caused by poppy seeds are well known (EFSA CONTAM Panel, 2011). This is also
reﬂected in the newer literature which includes case reports, studies on cross-reactivity and reviews (e. g.
Armentia et al., 2014; Lavine and Ben-Shoshan, 2015; van Gasse et al., 2015; Patel and Bahna, 2016).
3.1.4. Mode of action
3.1.4.1. Interaction with opioid receptors: afﬁnity, agonistic/antagonistic effects
The pharmacological effects of opioid drugs derive from their ability to interact with three different
G protein coupled receptors namely the l-, d- and j-opioid receptors. Opioid receptors are present in
both the CNS as well as peripheral tissues throughout the body. All the opioid drugs which are
currently used in the clinic display high afﬁnity for the l-opioid receptor. The crucial role played by this
receptor in opioid induced analgesia but also in the unwanted actions of opioids has been clearly
documented in receptor knockout studies (Kieffer, 1999). Opioid receptors are coupled with Gi/o
proteins, thus their activation reduces cyclic adenosine monophosphate (cAMP) levels, increases
potassium conductance and reduces calcium currents. These cellular actions promote a reduction in
neuronal ﬁring when the receptors are located post-synaptically or a reduction in neurotransmitter
release when the receptors are located presynaptically. These mechanisms associated with the
expression of opioid receptors along the nociceptive neuronal pathways (nociceptors, dorsal horn of
the spinal cord, periaqueductal gray, thalamus and limbic system) account for the profound analgesic
actions obtained in response to opioid drugs. Opioids drugs used in the clinic act as opioid receptor
agonists (eventually with different efﬁcacy). Pure antagonists such as naloxone are used to treat opioid
overdose.
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The gene coding for the l-opioid receptor, OPRM1, is highly polymorphic and OPRM1 polymorphism
may alter the activity of the receptor and explain to some extent the interindividual variation in efﬁcacy of
opioids in the treatment of pain and their implication in dependence. It has been hypothesised that
polymorphism of catechol-amino transferase (COMT), the enzyme that modulates the neurotransmission
of dopamine and norepinephrine, may have a similar effect on the efﬁcacy of opioids. However, there is a
lack of evidence linking COMT polymorphism to interindividual variation in opioid dose requirement (Lloyd
et al., 2017; Obeng et al., 2017).
A large amount of data from the recent years demonstrated that G protein-coupled receptor ligands
can couple with different efﬁcacies to the multiple pathways activated by a given receptor, a
phenomenon most commonly known as functional selectivity or biased agonism (Kenakin, 2015). As
far as opioid receptors are concerned, previous studies have demonstrated that the analgesic response
to opioid drugs entirely depends on G protein signalling while the interaction between the l-opioid
receptor and beta-arrestin-2 promotes the unwanted side effects of opioid drugs (Siuda et al., 2017).
For example, beta-arrestin-2 knockout mice display enhanced and prolonged morphine analgesia while
being protected from morphine induced respiratory suppression (Bohn et al., 1999).
In receptor binding experiments, morphine displayed the following values of afﬁnity (Ki) 14 nM,
538 nM and > 1,000 nM at the l-, d- and j-opioid receptor, respectively (Raynor et al., 1994).
Nikolaev et al. (2007) reported the following values of afﬁnity at the human l-opioid receptor for
natural alkaloids: morphine 4 nM, codeine 6,300 nM, oripavine 286 nM and thebaine 7,400 nM. A large
difference between morphine and codeine afﬁnity was also reported (1.8 nM for morphine vs 350 nM
for codeine) in guinea pig brain membranes by Mignat et al. (1995). No indication has been found that
the effects of noscapine and papaverine are mediated via opioid receptors.
The pharmacological effects of codeine, oripavine and thebaine in comparison with morphine were
investigated by Zhang et al. (2012) in cells coexpressing the human opioid receptors and chimeric G
proteins that force the receptors to signal via the calcium pathway and by Nikolaev et al. (2007) by
measuring l-mediated activation of Gi with a ﬂuorescence resonance energy transfer assay. The
results obtained in the two studies were highly consistent and can be summarised as follows:
• Morphine behaved as a potent full agonist at the l-opioid receptor, as a potent partial agonist
at the j-opioid receptor, while at the d-opioid receptor it displayed low efﬁcacy associated to
very low potency.
• Codeine displayed very low potency (200- to 1,600-fold less than morphine) associated with
low efﬁcacy both at the l- and j-opioid receptors, while being inactive at the d-opioid
receptor.
• Oripavine displayed moderate potency (30- to 70-fold less than morphine) at the l-opioid
receptor. At j- and d-opioid receptors, oripavine produced similar effects as morphine.
• Thebaine was able to stimulate opioid receptors only at very high concentrations (micromolar
range).
The morphine metabolites M3G and M6G are able to bind the l-opioid receptor. M6G displays
values of afﬁnity similar to morphine or higher, while M3G is more than 100-fold less potent (Frances
et al., 1992; Mignat et al., 1995; Klimas and Mikus, 2014). Interestingly, morphine and M6G displayed
similar analgesic potency after s.c. injection in mice, although M6G exhibited a much higher
antinociceptive potency (longer lasting effect) after intracerebroventricular injection (Frances et al.,
1992). More information on M6G is available in the review by Dahan et al. (2008). Knockout studies
demonstrated that both the desired (antinociceptive) and undesired (respiratory depression) effects of
M6G and morphine are due to the l-opioid receptor (Romberg et al., 2003). The codeine metabolites
C6G, norcodeine and N6G have weak afﬁnity for the l-opioid receptor (Chen et al., 1991; Mignat
et al., 1995; Volpe et al., 2011; Frost et al., 2012).
3.1.4.2. Apoptosis
Morphine
Apoptotic cell death can be induced by morphine in both adult and developing nervous system.
Several in vivo and in vitro studies have shown occurrence of apoptotic cell death in neuronal cells
after morphine administration. Apoptotic cells have been observed in several areas including parietal,
frontal, temporal, occipital, pyriform and enthorinal cortex, hippocampus and spinal cord. Changes in
the levels of Bax and Bcl-2 as well as activation of caspase 3 have been reported after exposure in
adulthood as well as after prenatal exposure. The involvement of Bcl-2 and Bax, with subsequent
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activation of caspase 3, suggests that the mitochondrial-mediated pathway may be a major player in
morphine-induced apoptosis. The studies are presented in more detail in Appendix D.
Codeine
No data were identiﬁed.
Thebaine
No data were identiﬁed.
Oripavine
No data were identiﬁed.
Noscapine
The selective cytotoxic and apoptosis induction effects of noscapine and papaverine were studied in
three human cancer cells lines: HT29 colorectal carcinoma, T47D breast cancer cells and HT-1080
ﬁbrosarcoma cells. Non-cancerous mouse NIH-3T3 cell line was used to compare the effects of the
substances between cancerous and non-cancerous cells. Noscapine and papaverine had a dose-related
cytotoxic effect on HT-29, T47D and HT-1080 cell lines, whereas no cytotoxic effect was observed on the
non-cancerous NIH-3T3 cell line. Noscapine and papaverine induced apoptosis in HT-29 and T47D
without any signiﬁcant effect on NIH-3T3 cell line. Noscapine increase caspase activity, which was not the
case for papaverine. The authors concluded that their results may indicate that caspase-independent
apoptosis pathways are involved in the programmed cell death related to papaverine (Afzali et al., 2015).
Papaverine
See previous paragraph on noscapine.
Opium
Asiabanha et al. (2011) examined the inﬂuence of opium exposure by i.p. on brain and liver cells
apoptosis in male and female diabetic and non-diabetic rats. Apoptosis was evaluated by TUNEL
(terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-X nick end labelling) and DNA
fragmentation assays. Brain and liver cells from normal opium-exposed and diabetic opium-exposed
rats had a signiﬁcantly higher incidence of apoptosis as compared to cells from unexposed animals.
Apoptosis in brain cells was signiﬁcantly higher in opium-exposed and diabetic opium-exposed males
than in females, whereas apoptosis in liver cells was signiﬁcantly higher in opium-exposed and diabetic
opium-exposed females than in males. The authors concluded that opium probably plays an important
role in brain and liver cell apoptosis, leading to neurotoxicity and hepatotoxicity and that there is a
difference in susceptibility between males and females for induction of apoptosis by opium in brain or
liver cells.
3.1.4.3. Other effects
Administration of morphine (s.c. or i.p) has been shown to change the expression of genes related
to mitochondria, cytoskeleton, secretory vesicle and cell adhesion. These modiﬁcations are considered
to be linked to intracellular adaptation processes. In certain brain areas, such as nucleus accumbens,
locus coeruleus or caudate putamen, alterations in gene expression occur and they may have a role in
adaptive response to chronic morphine and dependence.
Altogether, the reported changes in gene expression in the brain are consistent with the
observations that morphine affects a wide range of cellular and molecular targets including
neurotransmitters, neuromodulators, signalling pathways involved in neuronal plasticity, proliferation
and apoptosis. The studies are presented in more detail in Appendix D.
3.1.5. Considerations of critical effects and dose–response analysis
3.1.5.1. Considerations of critical effects
The CONTAM Panel previously concluded that the chronic and developmental toxicity of morphine
have not been systematically evaluated, but based on the lack of carcinogenicity of codeine, which is
metabolised to morphine, it is unlikely that morphine is carcinogenic (EFSA CONTAM Panel, 2011).
Furthermore, morphine is genotoxic in vivo but not in vitro, most likely by a non-DNA reactive mode of
action. Recent studies in rats and mice add to the weight of evidence that morphine has reproductive
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and developmental effects. These effects include depressed sexual activity, reduced testicular function
and spermatogenesis, disruption of ovarian cyclicity and decreased pregnancy rate. Oral morphine
exposure to pregnant rats or mice affects the normal development of the placenta and the brain,
which could lead to postnatal neurological and behavioural deﬁcits in the animals including memory
loss. Some evidence from newborns of mothers who were opioid-addicted or used prescription opioids
during pregnancy demonstrates that the CNS of the human fetus can also be affected by morphine.
There is also evidence of immunosuppressive effects in humans. These data do not allow assessment
of dose–response relationships in support of the risk assessment for opioids in food.
The CONTAM Panel conﬁrms its previous conclusion that the critical effects of morphine are on the
CNS, mediated by its high afﬁnity to the l-opioid receptor as an agonistic ligand. These effects
included analgesia, euphoria, dependence, miosis, respiratory depression, cough calming and
obstipation. Therapeutic doses of morphine may also reduce attentiveness and reactive skills, with
potential impact on driving and operating machinery.
From data on humans and experimental animals, it is clear that morphine can interfere with brain
development of the fetus resulting in behavioural effects at later life-stages; however, data are too
limited to derive a dose–response relationship.
The critical effects of codeine are the same as those of morphine, because morphine is the active
metabolite of codeine. Codeine has some direct activity at the l-opioid receptor, but with a much
lower potency than morphine, and therefore a direct effect of codeine is negligible compared to the
effect of its metabolite morphine.
The toxicological properties of thebaine have not been well characterised. It demonstrates little or
no activity with opioid receptors. Limited information is available regarding the metabolism of thebaine.
However, there are indications that thebaine is metabolised into several metabolites including oripavine
and morphine, which act as agonists to the l-opioid receptor. Therefore, a contribution to morphine-
like toxicity may occur, but is expected to be small. Lower LD50 values have been reported for thebaine
compared to morphine, both by oral and parenteral routes indicating that thebaine is more acutely
toxic than morphine. However, no other data on the oral toxicity of thebaine were identiﬁed and
therefore its critical effects are unknown.
Oripavine also acts as an agonist to the l-opioid receptor, with a lower activity than morphine and a
higher activity than codeine. No oral LD50 values have been reported, but lower i.p. and s.c. LD50 values
have been reported for oripavine than for morphine, indicating that oripavine is more acutely toxic than
morphine. Apart from one study showing convulsions following i.p. and s.c. administration, no other data
on the toxicity of oripavine were identiﬁed. Therefore, the toxicological proﬁle of oripavine is unclear.
High LD50 values for noscapine, following both oral and parenteral administration, indicate a lower
acute toxicity compared to the other opioid alkaloids. EFSA’s CONTAM Panel (2011) noted that
noscapine is used as a centrally acting antitussive compound, does not bind to opioid receptors and
has neither an analgesic, respiratory depressive nor obstipating effect. Although its toxicological
properties have not been characterised, less severe adverse effects (e.g. headache, dizziness; see
Section 3.1.3) are known from the therapeutic uses in humans.
For papaverine, the LD50 values, by oral and parenteral administration are similar to those for
morphine. However, evidence of toxicity was not seen following oral administration of papaverine
(50 and 100 mg/kg bw per day) to rats for 45 days and to dogs at 10 mg papaverine/kg bw per day
(EFSA CONTAM Panel, 2011). Therefore, the critical effects of papaverine are unclear. No data on
receptor binding were identiﬁed; however, EFSA’s CONTAM Panel (2011) concluded that papaverine
does not show opiate-like pharmacology since it acts as a smooth muscle relaxant that is most
pronounced on blood vessels. The side effects of papaverine, reported after oral administration, are
dizziness, drowsiness, headache, tiredness, GI disturbance, tachycardia, skin rash, sweating and
hypotonia. After long-term administration eosinophilia, icterus and liver enzyme changes (reversible)
have been reported (BfR, 2005). Overdosage may lead to seizures.
3.1.5.2. Dose–response analysis
For morphine, the CONTAM Panel selected again the lowest oral therapeutic dose of morphine
(1.9 mg morphine/person) in adults to derive a reference point. Applying the default body weight of
70 kg (EFSA Scientiﬁc Committee, 2012), this dose corresponds to 27 lg/kg bw per day or 30 lg/kg
bw per day when rounded to one signiﬁcant ﬁgure. This conclusion also relates to codeine because
morphine is the active metabolite of codeine.
For thebaine, oripavine, noscapine and papaverine, critical effects have not been established and
the available data from studies in experimental animals are insufﬁcient for dose-response analysis.
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However, based on the very limited available data in experimental animals, it appears that noscapine is
less toxic than the other alkaloids discussed in this opinion.
Noscapine is used as a centrally acting antitussive compound. For adults, the oral dosage of
noscapine is 25–50 mg (corresponding to 0.36–0.71 mg/kg bw for an adult weighing 70 kg) three
times daily, for children aged between 3 and 12 years 12–25 mg (corresponding to 0.52–1.09 mg/kg
bw assuming a body weight of 23 kg20) three times daily and for children aged between 6 months and
3 years 6–12 mg (corresponding to 0.67–1.33 mg/kg bw assuming a body weight of 9 kg or 0.5–
1.0 mg/kg bw assuming a body weight of 12 kg21) two to three times daily.
Pharmaceutically, papaverine hydrochloride is used orally as a myotropic spasmolytic agent in single
dosages of 150–300 mg (equivalent to 135–270 mg papaverine) (corresponding to 1.93–3.85 mg/kg
bw for an adult weighing 70 kg) two to three times daily. The maximum daily dose is indicated as
600 mg papaverine hydrochloride (equivalent to 540 mg papaverine; corresponding to 7.71 mg/kg bw
per day for an adult weighing 70 kg).
The therapeutic uses of noscapine and papaverine may be accompanied by adverse effects (e.g.
dizziness, headache) which are considered less severe compared to those known from the
pharmaceutical uses of morphine.
3.1.6. Derivation of a health-based guidance value
The CONTAM Panel previously concluded that the establishment of an ARfD was required for
morphine because of the short-term nature of its effects, and that ensuring exposure is below the ARfD
would also protect against possible effects of repeated exposure. An ARfD of 10 lg/kg bw was derived
from the lowest known single oral therapeutic dose of morphine, which was regarded as a LOEL, with
application of an uncertainty factor of 3. The more recently available data do not provide a basis for
revising the 2011 conclusions and therefore the CONTAM Panel conﬁrms the ARfD of 10 lg/kg bw. This
is the dose of morphine from foods for which a person would not be expected to experience adverse
effects following consumption of a single meal, or from total consumption over the course of a day.
The CONTAM Panel previously considered whether morphine-equivalents should be estimated based
on combined exposure to morphine and codeine from poppy seed-containing foods. However, at that
time, it was concluded that codeine has a minor impact based on an analysis of the relative
concentrations of morphine and codeine in poppy seed samples, using an equivalence factor of 0.2 for
codeine (see Table 8 of EFSA CONTAM Panel, 2011). The factor of 0.2 assumes that ≤ 20% of codeine
is converted to morphine in ultra-rapid metabolisers which was primarily based on the data of
Kirchheiner et al. (2007). Since 2011, no new data have become available regarding the conversion of
codeine to morphine. The CONTAM Panel noted that Linares et al. (2015) had performed
pharmacokinetic modelling of the data of Kirchheiner et al. (2007), which suggested that about 51% of
codeine is converted to morphine in ultra-rapid metabolisers. However, there are inconsistencies in the
outcome of the modelling, relating to the much larger AUCs for morphine and its glucuronides. The
CONTAM Panel therefore concluded that the results of the pharmacokinetic modelling did not provide a
robust basis for revising its previous conclusion that the equivalence factor of 0.2 is appropriate.
However, the occurrence data currently available demonstrate that the concentration of codeine can
be much higher than that of morphine in some poppy seed samples on the European market (see
Section 3.2.1.5). The CONTAM Panel therefore now concludes that the concentration of codeine in the
poppy seed samples should be taken into account in the exposure assessment and risk
characterisation by converting to morphine equivalents, using a factor of 0.2, in order to express
exposure in morphine equivalents. The ARfD is therefore a group ARfD for morphine and codeine,
expressed in morphine equivalents. It relates to the risk assessment of opium alkaloids in poppy seed-
containing foods and not to therapeutic uses of these opioids, which also take into account the
beneﬁts of therapeutic use.
Thebaine is exhibiting in rats and mice a higher oral acute toxicity than morphine based on lower
LD50 values. Thebaine stimulates the l-opioid receptor only at very high concentrations, however due
to possible metabolism into morphine and oripavine, a contribution to morphine-like toxicity may occur,
but is expected to be small. However, the available data are insufﬁcient to identify a factor for
conversion to morphine equivalents, or to propose a health-based guidance value (HBGV), or to
identify a reference point for calculating margins of exposure. The CONTAM Panel noted that no
conclusions could be drawn regarding whether thebaine would enhance narcotic morphine effects as
described for hexobarbital in mice.
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Oripavine also has the potential to elicit morphine-like effects, and therefore in principle should be
considered for inclusion in the group ARfD. However, the available data are insufﬁcient to characterise
the hazard or to identify a factor for conversion to morphine equivalents.
The modes of action of noscapine and papaverine differ from that of morphine, and therefore,
these alkaloids cannot be converted to morphine equivalents and are not included in the group ARfD.
The available data are insufﬁcient to propose HBGVs. Based on the very limited data available, it
appears that noscapine and papaverine are less toxic than the other alkaloids discussed in this opinion.
3.2. Occurrence data
3.2.1. Occurrence data on food submitted to EFSA
3.2.1.1. Overview on analytical results submitted to EFSA before and after 2011
A ﬁrst batch of 2,678 analytical results on occurrence of opium alkaloids in food and poppy seeds
(Table 7) was collected by EFSA until 2011 and these data were already presented in the previous
opinion of EFSA’s CONTAM Panel on opium alkaloids in poppy seeds (EFSA CONTAM Panel, 2011). The
2011 data set is used in the current document for comparison with occurrence data on opium alkaloids
provided to EFSA after the previous opinion was published. The data set available for the 2011 opinion
contained 181 analytical results, belonging to 55 Australian poppy seed samples, which were
presented in the opinion but not used for dietary exposure assessment. This was due to their opium
alkaloid proﬁle that was considered different from poppy seed samples available on the EU market at
that time.
Between November 2012 and October 2017, new occurrence data were submitted to EFSA. This
second batch of data contained a total of 5,040 analytical results on opium alkaloids in different foods.
The overall data set was carefully evaluated and data cleaning procedures were applied before the
estimation of dietary exposure to opium alkaloids. In particular, 49 analytical records were excluded
because the reported analyte was indicated as ‘sum of morphine alkaloids’ and could not be included
in any of the considered single opium alkaloids used for this opinion; details and criteria for data
cleaning and the outcome of clariﬁcation requests to data providers are detailed in Annex A, Table A.1.
After cleaning, a total of 4,991 analytical results on opium alkaloids in food, submitted by institutions
from 10 different EU countries, were available in the second batch (Table 7). Moreover within the
second batch, two analytical results on morphine were submitted by an EU food business association.
It should be noted that the country of sampling did not necessarily correspond to the country of
reporting, since some institutions collected samples abroad. The data set contains analytical results on
morphine, codeine, thebaine, oripavine, noscapine and papaverine, as well as a small number of
analytical results on narceine (n = 44) and acetylcodeine (n = 43) (Table 7).
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Table 7: Number of analytical results on opium alkaloids in poppy seeds and other food types collected by EFSA
Reporting country/institution
Substance
Morphine Codeine Thebaine Oripavine Noscapine Papaverine Narceine Acetylcodeine Total
1st batch(a)
Australia 55 43 47 43 0 0 0 0 188
Austria 45 45 0 0 45 45 0 0 180
Germany 561 374 143 0 87 90 0 0 1,255
Hungary 231 231 231 0 231 0 0 0 924
Netherlands 131 0 0 0 0 0 0 0 131
Total 1,023 693 421 43 363 135 0 0 2,678
2nd batch(b)
Austria 9 9 0 0 9 9 0 0 36
Czech Republic 146 145 145 0 145 145 0 0 726
EU food business association 2 0 0 0 0 0 0 0 2
France 63 63 63 0 0 0 0 0 189
Germany 173 234 181 90 132 182 0 0 992
Hungary 516 517 518 0 518 0 0 0 2,069
Luxembourg 17 16 0 0 0 0 0 0 33
Malta 5 0 0 0 0 0 0 0 5
Spain 253 50 50 0 0 0 0 0 353
Netherlands 44 44 44 44 44 44 44 0 308
United Kingdom 81 68 0 0 43 43 0 43 278
Total 1,309 1,146 1,001 134 891 423 44 43 4,991
(a): Collected by EFSA until 2011; these results were already presented in the previous opinion from EFSA’s CONTAM Panel on opium alkaloids in poppy seeds (EFSA CONTAM Panel, 2011).
(b): Collected by EFSA from 2012 to 2017; presented data show the number of samples after cleaning (see Annex A, Table A.1 for further details regarding data cleaning).
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3.2.1.2. Distribution of analytical results across different food types
For consistency with the previous opinion on opium alkaloids (ﬁrst batch) and since some single
food categories at the level 4 of the FoodEx classiﬁcation contained too few analytical results, certain
food groups were reclassiﬁed. The aggregated food groups are detailed in Annex A, Table A.3, while
Annex A, Table A.2 presents for both batches the number of analytical results per substance and
reporting country for the aggregated food categories. The three main food categories in the second
batch of data were represented by poppy seeds (4,206 analytical results for 1,190 samples), bakery
products (599 analytical results for 131 samples) and baking ingredients (106 analytical results for 20
samples). Apart from the three main food categories, some data on other types of food were
submitted in the second batch: ﬁsh snack product (1 sample), cereal-based food for infants and young
children (2 samples), honey (1 sample), (non-chocolate) confectionery (3 samples), tap water (40
samples) and well water (11 samples).
In both batches, the vast majority of data was reported on poppy seed samples (Figure 5) and
mainly for morphine, followed by codeine, thebaine and noscapine.
3.2.1.3. Analytical methods and limits of quantiﬁcation
Within the second batch, 3,694 analytical results were generated by LC–MS-based methods, 309 by
HPLC with UV–Vis or ﬂuorescence detection, while for 988 data points no information was provided.
This is in accordance with the analytical methods reported for the ﬁrst batch (see Figure 3 in EFSA
CONTAM Panel, 2011).
Table 8 provides an overview of the reported LOQs for poppy seed samples (second batch only)
while LODs and LOQs for all matrix types are reported in Annex A, Table A.4. Similar LODs were
reported for the ﬁrst batch (see EFSA CONTAM Panel, 2011 for further details). The LOQs reported for
morphine in poppy seed samples in the second batch varied from 0.010 to 7.5 mg/kg and 2% of the
data on morphine were left-censored. The maximum reported LOQ was 27 mg/kg for thebaine; this
LOQ was reported for a set of 35 samples measured by HPLC-UV. However, all samples were
quantiﬁed and had a thebaine concentration well above the LOQ.
On the left: analytical results collected until 2011 and presented in the EFSA Scientiﬁc Opinion of 2011 (1st batch);
on the right: analytical results collected from November 2012 until October 2017 (2nd batch).
Figure 5: Number of analytical results on opium alkaloids in food available to EFSA according to main
food groups and substance
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3.2.1.4. Occurrence data in poppy seed samples: a critical comparison between ﬁrst and
second batch
In total, for both batches, 7,669 analytical results on the occurrence of opium alkaloids in various
foods were available. Considering the limited amount of data on food categories other than poppy
seeds, the CONTAM Panel decided to evaluate the alkaloid proﬁle based on poppy seed samples only.
For the latter, a total of 6,369 analytical results related to 1,975 samples, collected throughout the
years 1981–2017, were available. A total of 4,206 analytical results (corresponding to 1,190 samples)
were submitted to EFSA in the second batch as compared to 2,163 analytical results (corresponding to
785 samples) in the ﬁrst batch. Annex A, Table A.5 presents an overview of the number of analytical
results divided by batch, sampling year and reporting country/organisation.
Table 9 summarises the descriptive statistics for all poppy seed samples and the percentage of left-
censored data. The Australian data collected until 2011 have not been excluded to allow a comparison
with the second batch. All data on acetylcodeine were left-censored and therefore not used in the
present opinion. Only one institution provided a limited number of analytical results on narceine
(41 samples) and 54% were left-censored. Therefore, this compound was not included in the risk
assessment.
The comparison between the ﬁrst and second batch revealed that the latter had a higher mean
morphine concentration than the ﬁrst. However, in both data sets, samples with very high morphine
concentrations were found, and the 95th percentile exceeded 200 mg/kg in both batches. This is
accordance with the fact that poppy seeds from poppy varieties with high alkaloid content, bred for
pharmaceutical purposes, are used as a by-product for food purposes.
The mean oripavine concentration was considerably lower in the second batch of reported data
compared to the data presented for the previous opinion, but in both cases statistics have been
calculated on a limited number of observations (about 40).
Table 8: Descriptive statistics of reported limits of quantiﬁcation for poppy seed samples (mg/kg;
whole weight) and proportion of left-censored (LC) data (%) for analytical results
submitted from 2012 until 2017 (2nd batch)
Substance N % LC Minimum P25 Mean P75 Maximum
Morphine 1,164 2 0.010 0.10 2.7 6.9 7.5
Codeine 962 25 0.010 0.050 0.60 1.0 1.8
Thebaine 869 31 0.040 0.050 2.35 1.0 27
Oripavine 41 63 0.10 0.10 0.10 0.10 0.10
Noscapine 782 60 0.050 0.10 0.65 1.0 1.0
Papaverine 304 71 0.040 0.050 0.17 0.10 1.0
Narceine 41 54 0.10 0.10 0.10 0.10 0.10
Acetylcodeine 43 100 0.10 0.10 0.10 0.10 0.10
N: number of samples; P: percentile.
Table 9: Summary statistics of the concentration (mg/kg; whole weight) of opium alkaloids in poppy
seed samples collected until 2011 (1st batch)(a) and collected after 2011 (2nd batch)
Substance Batch N
LC
(%)
Concentration (mg/kg)
Median Mean P95(b) Maximum
LB UB LB UB LB UB LB UB
Morphine 1st 775 11 10.0 10.0 38.2 38.6 202 202 630 630
2nd 1,164 2 13.6 13.6 57.8 57.8 253 253 596 596
Codeine 1st 557 32 1.40 1.40 4.95 5.23 14.9 14.9 827 827
2nd 962 25 1.40 1.40 5.93 6.15 28.0 28.0 298 298
Thebaine 1st 356 19 2.00 2.00 15.7 15.8 101 101 783 783
2nd 869 31 1.20 1.20 12.4 12.6 64.0 64.0 455 455
Oripavine 1st 43 42 4.00 4.00 20.8 21.3 n.a. n.a. 233 233
2nd 41 63 0 0.100 1.78 1.85 n.a. n.a. 27.5 27.5
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The CONTAM Panel identiﬁed large differences in the concentration of opium alkaloids in relation to
the country of origin of the poppy seed samples (Figure 6 and Annex A, Table A.6). The Spanish
poppy seed samples collected in the second batch contained a higher median concentration of
morphine, codeine and thebaine than those of any other reported country of origin. The median UB
morphine concentration in Spanish poppy seeds was 156 mg/kg. Upon a clariﬁcation request, the data
provider conﬁrmed that ‘analyses were made by the producer on commercial batches for the food
industry. It is very important to remark that these poppy seeds are from a variety of plant also
cultivated for the pharmaceutical industry’.
In the second batch, apart from Spanish samples, also poppy seed samples originating from France
(69.6 mg/kg), Australia (53.4 mg/kg), the UK (37.6 mg/kg) and China (32.1 mg/kg) had a high
median morphine content (at the UB) compared to samples originating from other countries. Moreover
French poppy seed samples had a relatively high median codeine (9.6 mg/kg at the UB) and thebaine
(17.9 mg/kg at the UB) concentration compared to other countries of origin, although the number of
reported samples was limited (n = 15). Likewise, the Australian poppy seed samples showed a higher
codeine and thebaine concentration compared to the other samples and this was in line with the data
presented in the ﬁrst batch. However, it should be noted that only a limited number of Australian
samples (n = 4) was present in the second data set.
The CONTAM Panel considered the following points:
1) the high median morphine concentration in poppy seeds originating from Australia in the
ﬁrst batch was conﬁrmed by the samples originating from Australia in the second batch;
2) high morphine concentrations were reported in the second batch for samples originating
from China, France, Spain and the UK, for which no data were available in the ﬁrst batch
(Annex A, Table A.6 and Figure 6);
3) the concentration of morphine was lower in poppy seeds originating from the other
countries (e.g. Austria, the Czech Republic, Germany, Hungary and the Netherlands) with
little variation between data from the ﬁrst and second batch.
Based on these considerations, the CONTAM Panel concluded that the proﬁles in the two batches
are comparable. In addition, the proﬁle in the Australian poppy seeds is compatible with the proﬁle in
the European poppy seeds. Therefore, the Australian data were included in the data set and the two
batches of data submitted to EFSA were merged. Based on the observed differences in median
morphine concentrations between different countries of origin, the CONTAM Panel decided to divide
the samples in three groups:
• poppy seed samples originating from Australia, China, France, Spain and the UK which are
assumed to represent primarily poppy seeds from varieties grown for pharmaceutical use which
are used as a by-product for food purposes; hereafter referred to as ‘high-morphine’ group;
• poppy seed samples originating from other countries which are assumed to represent varieties
grown for food use; hereafter referred to as ‘low-morphine’ group. However, it is known that
some of these countries produce also varieties for pharmaceutical purposes and this is also
represented by the high maximum morphine concentrations as reported in Annex A, Table A.6;
• poppy seed samples with unknown origin.
Substance Batch N
LC
(%)
Concentration (mg/kg)
Median Mean P95(b) Maximum
LB UB LB UB LB UB LB UB
Noscapine 1st 330 69 0 1.00 1.02 1.70 4.20 4.20 39.2 39.2
2nd 782 60 0 1.00 1.84 2.34 6.30 6.30 86.9 86.9
Papaverine 1st 102 81 0 0.750 0.090 0.590 0.400 1.00 1.79 1.79
2nd 304 71 0 0.100 0.150 0.250 1.15 1.15 3.20 3.20
Narceine 2nd 41 54 0 0.100 0.230 0.290 n.a. n.a. 1.61 1.61
Acetylcodeine 2nd 43 100 0 0.100 0 0.100 n.a. n.a. 0 0.100
N: number of samples; LB: lower bound; LC: left-censored; n.r.: not applicable; P95: 95th percentile; UB: upper bound.
(a): Discrepancies in the descriptive statistics of the 1st batch of data compared to the 2011 opinion are due to the way of handling
left-censored data. In the present report, analytical results showing a concentration below the reported limit of quantiﬁcation
(LOQ) were considered as LC irrespectively of whether or not it was speciﬁed by the data provider as below the LOQ.
(b): The 95th percentile with less than 60 observations may not be statistically robust (EFSA, 2011b) and is therefore not calculated.
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Besides the fact that countries may produce varieties for both food and pharmaceutical use, the
application of cleaning practices might reduce the level of morphine in the poppy seed samples.
Furthermore, seeds of different poppy varieties (data providers did not report information on poppy
seeds varieties) may be mixed before entering the food market. These factors introduce some
uncertainty in the applied division.
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Figure 6: Box plots representing the upper bound concentration (mg/kg whole weight) of morphine
(top) and thebaine (down) in poppy seed samples according to country of origin for the 1st
(left) and 2nd batch (right) of data
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Table 10 presents the results for the occurrence data set divided into the above-mentioned groups.
Considering the low percentage of left-censored data, and consequently the small difference between
LB, MB and UB concentrations for morphine, codeine and thebaine, only the MB concentrations are
shown in Table 10. LB and UB concentrations are presented in Annex A, Table A.7. Due to the higher
percentage of left-censored data for oripavine, noscapine and papaverine, also the LB and UB
concentrations were considered for these opium alkaloids (see discussion below; Annex A, Table A.7).
The median morphine concentration in poppy seed samples of the ‘high-morphine’ group was
15 times higher than in the ‘low-morphine’ group. Moreover, the median concentration for codeine,
thebaine and oripavine in the ‘high-morphine’ group was 4, 43 and 70 times, respectively, higher
compared to the ‘low-morphine’ group. Similar trends were observed at the P75. The here presented
data therefore indicate that seeds from poppy varieties relatively rich in morphine, codeine and
thebaine might be used for culinary purpose in Europe. Poppy seed samples with a high morphine,
codeine and/or thebaine concentration were also occasionally present in the ‘low-morphine’ group and
in the unknown group. The available information regarding country of origin and country of sampling
shows that although poppy seeds grown in one country are mainly sampled in the same country, a
part is also sampled and consequently consumed in other EU countries.
As explained in Section 3.1.6, the CONTAM Panel concluded to take the combined exposure to
morphine and codeine into account in the risk assessment, by converting the codeine concentration
into morphine equivalents, using a factor of 0.2. In 1,485 poppy seed samples, both morphine and
codeine were analysed, while in 454 samples only morphine was analysed. In order to use the same
data set for the calculation of the exposure to morphine and morphine equivalents, an imputation of
the codeine concentration was performed for these samples. After selection of the not left-censored
data for codeine and morphine, the proportion of codeine to morphine was calculated (expressed as
percentage). The median proportion was 15% for both the ‘high-’ and ‘low-morphine’ group. This
proportion was used for the samples in which codeine was not analysed. Morphine equivalents were
calculated using the following formula:
½Morphine equivalents ¼ ½Morphine þ ½Codeine  0:2:
Morphine equivalents were very similar to the morphine concentrations (Table 10) since in the
majority of the samples codeine is contributing little to the morphine equivalents.
Table 10: Descriptive statistics of opium alkaloids MB concentrations (mg/kg whole weight) in
poppy seed samples
Substance Group N Mean Min P25 P50 P75 P95(a) Max
Morphine ‘High-morphine’ 362 147 0.05 48.3 129 212 383 596
‘Low-morphine’ 1,210 16.4 0.02 4.50 8.37 15.6 52.8 458
Unknown 367 64.8 0.05 5.90 16.7 71.0 309 630
Total 1,939 50.1 0.02 5.20 11.9 41.4 240 630
Codeine ‘High-morphine’ 144 22.7 0.02 0.50 4.77 25.3 52.0 827
‘Low-morphine’ 1,097 2.88 0.03 0.50 1.20 2.50 9.30 202
Unknown 278 7.95 0.02 0.60 1.90 3.90 26.8 262
Total 1,519 5.82 0.02 1.00 1.40 3.14 21.0 827
Morphine
equivalents
‘High-morphine’ 362 152 0.05 49.7 133 218 390 614
‘Low-morphine’ 1,210 16.9 0.02 4.70 8.60 16.2 55.3 479
Unknown 367 67.2 0.05 6.18 17.4 73.1 318 649
Total 1,939 51.7 0.02 5.2 12.3 43.0 247 649
Thebaine ‘High-morphine’ 123 92.5 0.03 11.0 52.0 121 334 783
‘Low-morphine’ 940 3.92 0.01 0.50 1.20 3.00 12.3 373
Unknown 162 8.56 0.01 0.29 0.86 4.20 54.9 128
Total 1,225 13.5 0.01 1.00 1.40 4.10 68.4 783
Oripavine ‘High-morphine’ 46 20.0 0.05 0.50 3.50 23.0 n.a. 233
‘Low-morphine’ 15 2.14 0.05 0.05 0.05 0.18 n.a. 27.5
Unknown 23 1.19 0.05 0.05 0.05 2.52 n.a. 7.00
Total 84 11.8 0.10 0.10 1.00 5.00 55.0 233
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For oripavine, noscapine and papaverine, the percentage of left-censored data was higher and
consequently the difference between LB and UB concentrations was larger. The mean oripavine
concentration in poppy seed samples (n = 84) was 11.5–11.8 mg/kg (LB–UB) and the P95 was
55.0 mg/kg (LB = UB). The mean noscapine concentration in poppy seed samples (n = 1,112) was
1.59–2.15 mg/kg (LB–UB) and the P95 was 5.1 mg/kg (LB = UB). The mean papaverine concentration
in poppy seed samples (n = 406) was 0.14–0.34 mg/kg (LB–UB) and the P95 was 1.00 mg/kg
(LB = UB).
3.2.1.5. Proﬁles of opium alkaloids in poppy seeds – Ratios to morphine
Variations in the alkaloid proﬁles in poppy seed samples were explored by calculating the ratio of
single opium alkaloids to morphine. Concentrations were expressed as mmol/kg at the UB. It was
noted that not all laboratories reported results on the full set of opium alkaloids, and morphine was
the most frequently reported substance in poppy seeds (n = 1,939). The overall results (Table 11 –
line Total) showed a large variation in the ratios among poppy seed samples.
In general, morphine was the predominant alkaloid in poppy seed samples as shown by the median
ratios being smaller than 1 for the overall data set (Table 11). However in the ‘high-morphine’ group,
several samples had a thebaine, codeine or oripavine ratio to morphine that was greater than 1, which
was not observed for the ‘low-morphine’ and the unknown group. At the P95, the codeine ratio
exceeded 1 in the ‘high-morphine’ group, while this was not observed for the ‘low-morphine’ group. In
the ‘high-morphine’ group, a sample (with origin Australia) was reported with a very high
concentration of codeine and a ratio to morphine of > 700-fold. At the P75, the thebaine concentration
was 14 times higher than the morphine concentration in the ‘high-morphine’ group, while in the ‘low-
morphine’ group the ratio was 0.22. At the P75, oripavine was over 4 times higher than morphine in
the ‘high-morphine’ group versus a ratio of 0.02 in the ‘low-morphine’ group. Ratios according to the
country of origin of the poppy seed samples can be found in Annex A, Table A.8.
Substance Group N Mean Min P25 P50 P75 P95(a) Max
Noscapine ‘High-morphine’ 26 0.13 0.03 0.03 0.05 0.05 n.a. 1.80
‘Low-morphine’ 943 2.08 0.02 0.50 0.50 1.00 6.30 86.9
Unknown 143 0.78 0.02 0.05 0.50 0.50 2.68 27.0
Total 1,112 2.15 0.02 1.00 1.00 1.00 5.10 86.9
Papaverine ‘High-morphine’ 26 0.09 0.03 0.03 0.05 0.05 n.a. 1.30
‘Low-morphine’ 273 0.27 0.01 0.03 0.09 0.50 1.15 2.60
Unknown 107 0.19 0.01 0.03 0.05 0.07 0.92 3.20
Total 406 0.34 0.01 0.05 0.10 0.50 1.00 3.20
N: number of samples; n.a.: not applicable; Max: maximum; Min: minimum; P: percentile.
(a): The 95th percentile with less than 60 observations may not be statistically robust (EFSA, 2011b) and is therefore not calculated.
Table 11: Opium alkaloids ratios in poppy seed samples compared to morphine
Substance Origin N
Ratio to morphine(a)
Min P25 Median P75 P95(b) Max
Codeine ‘High-morphine’ 142 < 0.01 0.04 0.14 0.29 1.08 713
‘Low-morphine’ 1,086 0.01 0.10 0.14 0.20 0.51 0.97
Unknown 257 0.01 0.09 0.15 0.27 0.67 2.33
Total 1,485 < 0.01 0.10 0.14 0.21 0.75 713
Thebaine ‘High-morphine’ 123 0.01 0.11 0.29 14.0 135 227
‘Low-morphine’ 936 < 0.01 0.08 0.14 0.22 0.48 1.86
Unknown 143 < 0.01 0.07 0.12 0.19 0.52 1.10
Total 1,202 < 0.01 0.08 0.14 0.24 0.84 227
Oripavine ‘High-morphine’ 46 < 0.01 0.01 0.87 4.34 n.a. 43.4
‘Low-morphine’ 15 < 0.01 0.01 0.01 0.02 n.a. 0.47
Unknown 23 < 0.01 0.01 0.02 0.05 n.a. 0.21
Total 84 < 0.01 0.01 0.04 0.87 19.9 43.4
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3.2.1.6. Proportion of alkaloid content in poppy seed samples
For a total of 1,197 poppy seed samples, the concentration of morphine, codeine and thebaine was
available. For these samples the proportion of each alkaloid to the total opium alkaloid content was
calculated, corrected for molecular weight (Table 12). Annex A, Table A.9 shows the proportion per
country of origin.
Morphine was overall the main of the three considered opium alkaloids in poppy seeds; for all
samples combined the average proportion is 74%, followed by thebaine (15%) and codeine (11%).
Morphine was also the largest contributor of the three (51% on average) to the sum of morphine,
codeine and thebaine for the ‘high-morphine’ group. However, thebaine was also an important
contributor (41% on average). For the ‘low-morphine’ group, morphine contributed on average 76% to
the sum, with thebaine and codeine both contributing on average 12%.
3.2.1.7. Occurrence data for matrices other than poppy seeds
Descriptive statistics of the concentration of opium alkaloids in food other than poppy seeds are
shown in Annex A (Table A.10) according to the food categories described in Section 3.2.1.2,
Substance Origin N
Ratio to morphine(a)
Min P25 Median P75 P95(b) Max
Noscapine ‘High-morphine’ 26 < 0.01 < 0.01 < 0.01 < 0.01 n.a. 0.75
‘Low-morphine’ 939 < 0.01 0.04 0.07 0.14 0.62 6.75
Unknown 127 < 0.01 0.01 0.05 0.09 0.23 0.48
Total 1,092 < 0.01 0.03 0.07 0.13 0.57 6.75
Papaverine ‘High-morphine’ 26 < 0.01 < 0.01 < 0.01 < 0.01 n.a. 0.76
‘Low-morphine’ 272 < 0.01 0.01 0.02 0.11 0.76 0.76
Unknown 87 < 0.01 < 0.01 0.01 0.05 n.a. 0.76
Total 385 < 0.01 0.01 0.02 0.09 0.76 0.76
N: number of samples; n.a.: not applicable; Max: maximum; Min: minimum; P: percentile.
(a): Calculated by dividing the opium alkaloid upper bound concentration by the morphine upper bound concentration.
Concentrations were expressed as mmol/kg.
(b): The 95th percentile with less than 60 observations may not be statistically robust (EFSA, 2011b) and is therefore not
calculated.
Table 12: Percentage(a) of the opium alkaloid to the sum of morphine, codeine and thebaine per
sample
Substance Origin N
Percentage(a) of the opium alkaloid to the sum
Mean Min P25 Median P75 P95 Max
Morphine ‘High-morphine’ 119 50.6 0.13 6.6 70.0 80.0 97.6 98.5
‘Low-morphine’ 935 76.4 28.4 71.0 78.5 83.8 91.7 97.4
Unknown 143 77.3 22.6 74.3 79.8 84.4 92.2 97.1
Total 1,197 73.9 0.13 70.3 78.0 83.9 92.6 98.5
Codeine ‘High-morphine’ 119 8.88 0.1 0.7 4.0 10.6 19.9 92.6
‘Low-morphine’ 935 11.6 0.8 8.1 10.5 13.9 22.7 35.7
Unknown 143 11.6 1.7 6.7 9.3 12.9 32.0 52.7
Total 1,197 11.3 0.1 7.6 10.2 13.5 22.8 92.6
Thebaine ‘High-morphine’ 119 40.5 1.26 9.7 19.2 89.4 98.6 99.4
‘Low-morphine’ 935 12.1 0.12 6.8 10.5 15.9 26.0 58.0
Unknown 143 11.1 < 0.1 6.4 10.0 14.2 24.7 32.6
Total 1,197 14.8 < 0.1 6.8 10.8 16.6 37.2 99.4
N: number of samples; Max: maximum; Min: minimum; P: percentile.
(a): Calculated by dividing the opium alkaloid upper bound concentration by the sum of the upper bound concentration of
morphine, codeine and thebaine, per sample morphine upper bound concentration. Concentrations were expressed as
mmol/kg.
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substance and batch of data collection. The following general considerations on data from other food
categories were made:
• Bakery products: a limited number of analytical results were available to EFSA for this food
category. Bakery products represent a heterogeneous category since it consists of different
types of products containing different amounts of poppy seeds. In general, the mean opium
alkaloids concentrations were in the same order of magnitude in the ﬁrst and second batch,
with a mean UB concentration of 1 mg/kg or below. Oripavine was reported only in the second
batch, but with 94% of left-censored data. The three bakery products analysed for narceine
were left-censored.
• Baking ingredients: a limited number of analytical results were available for this category.
Under the UB scenario, the average morphine concentration in the ﬁrst and secnd batch was
3.64 and 1.10 mg/kg, respectively, for codeine 1.19 and 0.17 mg/kg, for thebaine 0.23 and
0.21 mg/kg, and for papaverine 0.18 and 0.11 mg/kg. Noscapine levels were comparable in
the ﬁrst and second batch of data. Oripavine was reported only in the second batch, but 96%
of the data were left-censored.
• Other types of food: In the second batch, results on food types other than bakery products
and ingredients were reported. Three confectionary products were found to contain morphine
(average concentration of 6.60 mg/kg). Tap and well water samples (n = 51) were only
analysed for codeine and all samples were left-censored. Other food categories for which
analytical results were reported (honey, cereal-based food for infants and young children,
snack food) had a minor, or negligible, opium alkaloids content. Further details are reported in
Annex A, Table A.10.
3.2.2. Previously reported occurrence data in the open literature
In this section, an overview is presented on the reported occurrence data in the open literature. It
should be noted that part of the data published may also have been submitted to EFSA and may have
been included in the EFSA occurrence data set described in Section 3.2.1.
A summary on the older data on occurrence of opium alkaloids in poppy seeds and baking ingredients
(poppy seed ﬁllings) can be found in the report from the Bundesinstitut f€ur Risikobewertung (the
German Federal Institute for Risk Assessment; BfR) from 2005 (BfR, 2005). The reported values in
(unground) poppy seeds range from 0.1 to 620 mg/kg for morphine, from 0.1 to 57.1 mg/kg for
codeine, from 0.3 to 41 mg/kg for thebaine, from 0.84 to 230 mg/kg for noscapine and from < LOQ to
67 mg/kg for papaverine. With respect to the occurrence of morphine in poppy seeds, data were
provided for 72 samples, ranging in content from 0.5 to 620 mg/kg. Nineteen samples contained at least
100 mg/kg morphine, while 23 samples contained less than 10 mg/kg morphine. A study conducted by
the Bavarian Regional Ofﬁce for Health and Food Safety on the content of morphine and codeine in 48
poppy seed samples showed for morphine a range of 3.1–330 mg/kg and for codeine a range of < LOQ
to 23.7 mg/kg.
BVL (Bundesamt f€ur Verbraucherschutz und Lebensmittelsicherheit) reported on two German surveys
held in 2007 on the occurrence of morphine in a total of 446 samples of poppy seeds and poppy seed
containing food products collected on the German retail market. Of the 201 samples of unground poppy
seeds, 62 (30.8%) contained only low levels (≤ 4 mg/kg) of morphine, 114 (56.7%) contained between
4 and 20 mg/kg, and 25 (12.4%) contained more than 20 mg/kg. The ground poppy seeds (46 samples)
tended to have slightly lower concentrations of morphine: 21 (45.7%) contained ≤ 4 mg/kg, 19 (41.3%)
between 4 and 20 mg/kg, and 6 samples (13.0%) contained more than 20 mg/kg. The poppy seed
containing food products could be divided into baking products (poppy seed cake, rolls, 143 samples)
and baking ingredients (ready-to-use ﬁllings, 56 samples). The large majority of the pastry samples
(140, 97.9%) contained ≤4 mg/kg morphine, while 3 samples contained between 4 and 10 mg/kg.
Regarding the ready-to-use ﬁllings, 45 (80.3%) contained ≤ 4 mg/kg morphine, 10 (17.9%) contained
between 4 and 20 mg/kg while one sample exceeded 20 mg/kg (BVL, 2007).
In the previous opinion, the occurrence data were presented that had been submitted to EFSA up
to early 2011 (EFSA CONTAM Panel, 2011). Data had been submitted by ﬁve different countries for in
total six alkaloids (morphine, codeine, thebaine, oripavine, noscapine and papaverine) in poppy seeds,
bakery products and baking ingredients. However, the number of analytical results per individual
alkaloid differed signiﬁcantly, from 43 results for oripavine to 1,023 results for morphine. The majority
of submitted data (2,163, results, 80.8%) was on poppy seeds, and smaller contributions were made
for bakery products (373 results, 13.9%) and baking ingredients (142 results, 5.3%). The CONTAM
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Panel noted that only one country (Germany) submitted results for bakery products and ingredients.
Regarding the poppy seeds, morphine (775 results) was present in the highest concentrations (based
on LB approach): 10.0, 38.2, 202 and 630 mg/kg for the median, mean, P95 and maximum,
respectively. For codeine (557 results) the values were: 1.4, 5.0, 14.9 and 827 mg/kg, respectively,
and for thebaine (356 results): 2.0, 15.6, 101 and 783 mg/kg, respectively. Data on oripavine were
based on a relatively small number of samples (43): resulting in the following values: 4.0, 20.8, 68.0
and 233 mg/kg, respectively. For noscapine (330 results): 0.0, 1.0, 4.2 and 39.2 mg/kg, respectively,
and for papaverine (102 results): 0.0, 0.1, 0.4 and 1.8 mg/kg, respectively. The percentage of data
below the LOQ (varying between 0.1 and 10 mg/kg) varied from 9% for morphine to 80% for
papaverine. In general, morphine was the dominant alkaloid in poppy seed samples, followed by
codeine and thebaine. Only in a small number of samples (9 out of 547) codeine was present in a
higher concentration than morphine. A notable exception formed the poppy seed data submitted by
Australia, in which thebaine was often present in higher concentrations than morphine (29 out of 43).
This was presumably due to use of different cultivars selected for use in the pharmaceutical industry.
The concentration of opium alkaloids in bakery products and baking ingredients was generally lower:
The maximum concentration reported was 8.2 mg/kg morphine in bakery products and 28.8 mg/kg
morphine in baking ingredients, while the mean concentrations were 0.5 and 3.2 mg/kg, respectively.
The other alkaloids were found at even lower concentrations.
In the framework of an exposure study of consumers in Hungary to opium alkaloids in poppy seeds,
Zentai et al. (2012) reported the results obtained for 737 poppy seed samples collected from the
Hungarian retail market. Samples were collected during 2001–2010 and were analysed for morphine,
codeine, thebaine and noscapine. Morphine was detected above the LOQ (ranging from 1 to 2 mg/kg)
in all but one of the samples. Codeine (61.3%) and thebaine (63.0%) were often present, but
noscapine was detected only in 6.2% of the samples. With respect to individual alkaloids, morphine was
present in the highest concentrations: 11.0, 18.7, 57.6, and 533 mg/kg for the median, mean, P95 and
maximum, respectively. For codeine the values were: 2.0, 3.6, 17.2, and 60 mg/kg, respectively and for
thebaine: 2.0, 4.0, 15.8, and 120 mg/kg, respectively. Noscapine was the least prominent alkaloid
analysed in Hungarian poppy seed samples, with values of 1.2, 1.2, 1.6, and 40 mg/kg, respectively.
Recently, Lopez et al. (2018) reported the results obtained for 35 retail samples of blue and white
poppy seeds collected in the Netherlands and for three samples of ground seeds and three ready-to-
eat products sampled in Germany. Samples were analysed for six alkaloids (morphine, codeine,
thebaine, noscapine, papaverine and narceine). Regarding the 32 blue poppy seed samples the
following concentrations for the median, mean, P90 and maximum were reported: morphine: 6.7,
39.4, 125 and 241 mg/kg, respectively. For codeine the values were: 1.6, 48.6, 202 and 348 mg/kg,
respectively, and for thebaine: 0.8, 20.4, 76.5 and 106 mg/kg, respectively. Levels reported for
noscapine, papaverine and narceine were much lower, with maximum concentrations of 6.0, 2.1 and
2.1 mg/kg, respectively. In the poppy seed samples, morphine was generally present in the highest
concentration, but in seven samples codeine was dominant and in one sample thebaine was the major
alkaloid. Ground poppy seeds, white poppy seeds and the ready-to-eat products contained much lower
concentrations of alkaloids (maximum for morphine was 19.6 mg/kg in a sample of white poppy seeds.
Within the period covering 2005–2017, the Rapid Alert System for Food and Feed (RASFF) has
reported 20 occurrences of high levels of morphine in poppy seeds (Appendix B). Fourteen notiﬁcations
were based on ofﬁcial control on the market, while six notiﬁcations were done by the producing or
trading company. The reported values ranged from 40 to 228 mg/kg morphine in (unground) poppy
seeds. One sample of ground poppy seeds was reported to contain 59.13 mg/kg morphine. The
countries of origin were Hungary (5 reports), the Czech Republic (4), France (3), Australia (2), Slovak
Republic (2), Austria (1), the Netherlands (1) and for two consignments the country of origin was not
known. In most cases, the products concerned were withdrawn from the market or prevented from
entering the market. It should be noted that only three countries have issued reports on the occurrence
of high morphine levels in poppy seeds: Hungary and Germany have issued a total of 14 reports in the
period 2005–2010, while the Czech Republic has made six notiﬁcations in the period 2014–2015.
In conclusion, opium alkaloids are often present in poppy seeds and in bakery products or ingredients
containing poppy seeds. In general, morphine is the dominant alkaloid detected, followed by codeine and
thebaine. However, in a smaller proportion of samples thebaine or codeine is the dominant alkaloid
instead of morphine. Although the majority of raw poppy seed samples contain individual alkaloid levels
below 50 mg/kg, a smaller proportion (possibly 5–20%) can contain levels between 100 and 1,000 mg/
kg. Bakery products and ingredients contain signiﬁcantly lower levels of alkaloids, with the large majority
of samples well below 20 mg/kg. The CONTAM Panel noted that for these two categories of products only
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data have been reported for products obtained from the German retail market, which may not be
representative for the EU as a whole. Overall, the concentration of opium alkaloids in poppy seeds
identiﬁed from the open literature and the data submitted to EFSA are in agreement.
3.2.3. Food processing
The reduction of the alkaloid content of poppy seed samples by means of pretreatment and food
processing has been reviewed in detail in the previous EFSA opinion on opium alkaloids (EFSA
CONTAM Panel, 2011).
Based on this review, the European Commission published in 2014 an overview of recommended
pre-treatments and processing methods reducing the alkaloid content of poppy seeds and poppy seed
products as part of a recommendation on good practices to prevent and to reduce the presence of
opium alkaloids in poppy seeds and poppy seed products4 (see Section 1.3.4 for further details).
Little new work has been published since then. The following paragraph is an ‘excerpt’ of the
information provided in the previous EFSA opinion.
The alkaloid content of poppy seed samples can be reduced by several means of pretreatment and food
processing. Washing or soaking of poppy seeds with cold water may reduce morphine levels by 40–75%,
and reductions close to 100% can be reached using hot or boiling water (Bjerver et al., 1982; Sproll et al.,
2007). Grinding of the seeds results in a moderate reduction (25–34%) in morphine content (Sproll et al.,
2007). Baking/heating of poppy seeds gives a reduction in morphine content of around 30% at moderate
baking temperatures (135°C) and of 80–90% at high temperatures (220°C) (General et al., 2007).
Combination of poppy seed pretreatment and food preparation (baking) has been shown to result in an
overall reduction of 80–100% in the ﬁnal food product (General et al., 2007; Lachenmeier et al., 2010).
It should be noted that the above-mentioned studies focussed only on the fate of morphine while
the stability of other opium alkaloids was not assessed. Leaching from mature capsules due to rainfall
was more signiﬁcant for morphine and codeine than for thebaine, suggesting a lower water solubility
of the latter alkaloid (Hofman and Menary, 1984a). This is also reﬂected in the slightly lower logP
values for morphine (0.89) and codeine (1.19) compared to thebaine (1.53) and oripavine (1.46)
(Figure 1). So, it could be assumed that reduction by washing or soaking is more effective for
morphine and codeine than for thebaine and oripavine. Reactivity to oxygen upon grinding and
thermal stability during baking may resemble that of morphine. Nevertheless, experimental data on the
fate of other opium alkaloids than morphine during pretreatment and food processing will be required
for a better estimate of the reduction that can be obtained during food processing.
3.3. Dietary exposure assessment for humans
Acute dietary exposure to opium alkaloids from poppy seeds was estimated across the European
Union following the methodology described in Section 2.6. A total of 41 dietary surveys, carried out in 23
different Member States, were available for this assessment (Annex B, Table B.1). The consumption of
poppy seeds (or poppy seed-containing foods) was reported at least once in 18 dietary surveys
(corresponding to 44 population groups23) from 13 different Member States. Poppy seed consumption
was reported for up to about 5% of the days covered by the survey. The ﬁve population groups most
frequently consuming poppy seeds (more than 3% of the days) were other children from the Czech
Republic, very elderly from Denmark, adults from Slovakia, adolescents from the Czech Republic and
other children from Austria. Among poppy seed consumers, average consumption ranged from 0.5
(Other children, Sweden) to 25 g poppy seeds/day (Adults, Hungary). Only in seven population groups, it
was possible to calculate the 95th percentile, which ranged from 1 (Other children, Sweden) to 55 g
poppy seeds/day (Adults, Germany). Poppy seeds consumption data are reported in Annex B (Table B.3).
In some dietary surveys, consumption of poppy seed-containing foods was reported. The
disaggregation strategy described in Section 2.6 was used to convert the consumed amount of poppy
seed-containing foods into the corresponding amount of consumed poppy seeds. This disaggregation
strategy did not take into consideration any possible reduction of morphine (and other opium
alkaloids) due to the processing of poppy seeds, such as heating or milling.
The CONTAM Panel veriﬁed the disaggregation strategy by comparing calculated morphine
concentrations in bread to reported concentrations in bread. Within the second batch, Germany
reported analytical results for morphine both in poppy seeds (58 samples) and in white wheat rolls
containing poppy seeds (70 samples). The reported median and maximum levels of morphine in white
23 Age class within a country.
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wheat rolls were 0.19 and 6.3 mg/kg, respectively. These reported values were in line with the
morphine concentrations for white wheat rolls calculated from the concentrations in poppy seeds. In
fact, the calculated median and maximum concentrations of morphine in bread containing 4% of poppy
seeds were 0.20 and 10.9 mg/kg, based on the median and maximum level of morphine in poppy seed
samples from Germany (5.1 and 272 mg/kg, respectively). This backward calculation suggests that the
used approach is in line with the submitted data on the occurrence in bakery products.
3.3.1. Mean and high dietary exposure
Acute dietary exposure estimates to opium alkaloids were based on two different occurrence data
sets: the ‘high-morphine’ and ‘low-morphine’ groups. It is assumed that the ﬁrst represents primarily
poppy seeds from varieties grown for pharmaceutical use of which the seeds are used as a by-product
for food purposes, and the second primarily varieties grown for food use (Section 3.2.1.4). In the text
and tables below, the mean exposure (based on the mean consumption and mean occurrence) and
the 95th exposure (based on 95th percentile consumption and 95th percentile occurrence) are
presented. Hereafter, they are just referred to as mean exposure and P95 exposure respectively.
Detailed exposure results, including the exposure calculated using other occurrence percentiles are
presented in Annex B (Tables B.4 until B.9). Acute dietary exposure estimates are presented for
consumers of poppy seeds only, and under the MB (for morphine, codeine, thebaine and morphine
equivalents) or LB and UB (papaverine and noscapine) scenario.
A clear difference in the exposure to morphine (Table 13; Annex B, Table B.4) emerges between the
‘high-’ and the ‘low-morphine’ scenario: based on the ‘high-morphine’ data set ‘other children’ displayed
the highest mean exposure, while the corresponding exposure for the ‘low-morphine’ group was about 10
times lower. The mean exposure was also high for ‘toddlers’ for the ‘high-morphine’ group ranging from
25.7 to 55.3 lg/kg bw per day, however only two surveys were available. The CONTAM Panel noted that
the P95 exposure of the ‘low-morphine’ group was similar to the mean exposure for the ‘high-morphine’
group; the reason for this is likely due to the already mentioned the presence of poppy seeds with high
morphine content in both groups.
Table 13: Summary statistics of acute dietary exposure to morphine (lg/kg bw per day) estimated
at the middle bound across dietary surveys for consumers only
Group(a) Population class
Mean exposure(b) P95 exposure(c)
N Min Median Max N Min Median Max
‘High-morphine’ Infants 2 14.9 n.a. 37.9 0 n.a. n.a. n.a.
Toddlers 2 25.7 n.a. 55.3 1 330 n.a. 330
Other children 9 3.81 40.9 99.5 2 20.6 n.a. 284
Adolescents 8 2.31 27.2 56.1 0 n.a. n.a. n.a.
Adults 11 4.91 28.1 53.8 4 82.3 257 326
Elderly 8 2.07 25.1 41.3 0 n.a. n.a. n.a.
Very elderly 4 8.99 28.7 40.6 0 n.a. n.a. n.a.
‘Low-morphine’ Infants 2 1.66 n.a. 4.22 0 n.a. n.a. n.a.
Toddlers 2 2.86 n.a. 6.17 1 45.6 n.a. 45.6
Other children 9 0.42 4.56 11.1 2 2.84 n.a. 39.2
Adolescents 8 0.26 3.03 6.25 0 n.a. n.a. n.a.
Adults 11 0.55 3.14 6.00 4 11.4 35.5 45.1
Elderly 8 0.23 2.79 4.60 0 n.a. n.a. n.a.
Very elderly 4 1.00 3.20 4.53 0 n.a. n.a. n.a.
bw: body weight; Max: maximum; Min: minimum; N: number of surveys; n.a. not applicable; P95: 95th percentile.
(a): Group of poppy seed samples. The ‘high-morphine’ group refers to poppy seed samples originating from Australia, China,
France, Spain and the UK which are assumed to represent primarily varieties grown for pharmaceutical use. The ‘low-
morphine’ group refers to poppy seed samples originating from other countries which are assumed to represent varieties
grown for food use. See Section 3.2.1.4 for further details.
(b): Mean exposure calculated from the mean consumption of poppy seeds and the mean occurrence of morphine in poppy seed
samples.
(c): P95 exposure calculated from the P95 consumption of poppy seeds and the P95 occurrence of morphine in poppy seed
samples. The P95 exposure estimates for surveys with less than 60 observations may not be statistically robust and are
therefore not calculated.
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Acute dietary exposure to codeine (Table 14) is an order of magnitude lower compared to the
exposure to morphine. Also in the case of codeine, there is a large difference between the ‘high-’ and
the ‘low-morphine’ scenario, with the highest mean exposure found for the other children and toddlers
in both scenarios. Detailed summary statistics on the exposure estimates calculated for each dietary
survey are presented in Annex B, Table B.5.
Table 15 summarises the acute dietary exposure estimates for morphine and codeine, expressed as
morphine equivalents. Detailed summary statistics on the exposure estimates calculated for each
dietary survey are presented in Annex B, Table B.6. Overall, similar results as for morphine alone were
obtained and the data show that codeine makes a minor contribution to the morphine equivalents.
Table 14: Summary statistics of acute dietary exposure to codeine (lg/kg bw per day) estimated at
the middle bound across dietary surveys for consumers only
Group(a) Population class
Mean exposure(b) P95 exposure(c)
N Min Median Max N Min Median Max
‘High-morphine’ Infants 2 2.30 n.a. 5.85 0 n.a. n.a. n.a.
Toddlers 2 3.96 n.a. 8.54 1 44.9 n.a. 44.9
Other children 9 0.59 6.31 15.4 2 2.80 n.a. 38.6
Adolescents 8 0.36 4.19 8.65 0 n.a. n.a. n.a.
Adults 11 0.76 4.34 8.31 4 11.2 35.0 44.4
Elderly 8 0.32 3.87 6.37 0 n.a. n.a. n.a.
Very elderly 4 1.39 4.43 6.27 0 n.a. n.a. n.a.
‘Low-morphine’ Infants 2 0.29 n.a. 0.74 0 n.a. n.a. n.a.
Toddlers 2 0.50 n.a. 1.08 1 8.03 n.a. 8.03
Other children 9 0.07 0.80 1.95 2 0.50 n.a. 6.90
Adolescents 8 0.05 0.53 1.10 0 n.a. n.a. n.a.
Adults 11 0.10 0.55 1.05 4 2.00 6.25 7.93
Elderly 8 0.04 0.49 0.81 0 n.a. n.a. n.a.
Very elderly 4 0.18 0.56 0.80 0 n.a. n.a. n.a.
bw: body weight; max: maximum; min: minimum; N: number of surveys; n.a. not applicable; P95: 95th percentile
(a): Group of poppy seed samples. The ‘high-morphine’ group refers to poppy seed samples originating from Australia, China,
France, Spain and the UK which are assumed to represent primarily varieties grown for pharmaceutical use. The ‘low-
morphine’ group refers to poppy seed samples originating from other countries which are assumed to represent varieties
grown for food use. See Section 3.2.1.4 for further details.
(b): Mean exposure calculated from the mean consumption of poppy seeds and the mean occurrence of codeine in poppy seed
samples.
(c): P95 exposure calculated from the P95 consumption of poppy seeds and the P95 occurrence of morphine in poppy seed
samples. The P95 exposure estimates for surveys with less than 60 observations may not be statistically robust and are
therefore not calculated.
Table 15: Summary statistics of acute dietary exposure to morphine and codeine, expressed as
morphine equivalents (lg/kg bw per day) estimated at the middle bound across dietary
surveys for consumers only
Group(a) Population class
Mean exposure(b) P95 exposure(c)
N Min Median Max N Min Median Max
‘High-morphine’ Infants 2 15.4 n.a. 39.2 0 n.a. n.a. n.a.
Toddlers 2 26.5 n.a. 57.2 1 336 n.a. 336
Other children 9 3.94 42.3 103 2 21.0 n.a. 289
Adolescents 8 5.08 29.1 55.7 0 n.a. n.a. n.a.
Adults 11 2.38 28.1 57.9 4 83.8 262 332
Elderly 8 2.14 25.9 42.7 0 n.a. n.a. n.a.
Very elderly 4 9.29 29.7 42.0 0 n.a. n.a. n.a.
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Acute dietary exposure to thebaine (Table 16) is lower compared to the sum of morphine and
codeine, expressed as morphine equivalents, in the ‘low-morphine’ group and slightly lower in the ‘high-
morphine’ group. Compared to the exposure to codeine, the acute dietary exposure to thebaine is higher
in both groups. The mean dietary exposure to thebaine calculated for the ‘high-morphine’ group ranged
from 1.3 to 62.5 lg/kg bw per day across dietary surveys and age groups and was the highest for other
children. For the ‘low-morphine’ group, the acute mean dietary exposure ranged from 0.06 to 2.65 lg/kg
bw per day across dietary surveys and age groups. The P95 acute dietary exposure was only calculated
for 7 dietary surveys, with exposures ranging from 18.0 to 288 lg/kg bw per day for the ‘high-morphine’
group and from 0.66 to 10.6 lg/kg bw per day for the ‘low-morphine’ group. Detailed summary statistics
on the exposure estimates calculated for each dietary survey are presented in Annex B, Table B.7.
Group(a) Population class
Mean exposure(b) P95 exposure(c)
N Min Median Max N Min Median Max
‘Low-morphine’ Infants 2 1.71 n.a. 4.36 0 n.a. n.a. n.a.
Toddlers 2 2.95 n.a. 6.36 1 47.7 n.a. 47.7
Other children 9 0.44 4.70 11.4 2 2.98 n.a. 41.0
Adolescents 8 0.56 3.24 6.19 0 n.a. n.a. n.a.
Adults 11 0.27 3.13 6.44 4 11.9 37.2 47.2
Elderly 8 0.24 2.88 4.75 0 n.a. n.a. n.a.
Very elderly 4 1.03 3.30 4.67 0 n.a. n.a. n.a.
bw: body weight; Max: maximum; Min: minimum; N: number of surveys; n.a. not applicable; P95: 95th percentile
(a): Group of poppy seed samples. The ‘high-morphine’ group refers to poppy seed samples originating from Australia, China,
France, Spain and the UK which are assumed to represent primarily varieties grown for pharmaceutical use. The ‘low-
morphine’ group refers to poppy seed samples originating from other countries which are assumed to represent varieties
grown for food use. See Section 3.2.1.4 for further details.
(b): Mean exposure calculated from the mean consumption of poppy seeds and the mean occurrence of morphine and codeine,
expressed as morphine equivalents, in poppy seed samples.
(c): P95 exposure calculated from the P95 consumption of poppy seeds and the P95 occurrence of morphine and codeine,
expressed as morphine equivalents, in poppy seed samples. The P95 exposure estimates for surveys with less than 60
observations may not be statistically robust and are therefore not calculated.
Table 16: Summary statistics of acute dietary exposure to thebaine (lg/kg bw per day) estimated
at the middle bound across dietary surveys for consumers only
Group(a) Population class
Mean exposure(b) P95 exposure(c)
N Min Median Max N Min Median Max
‘High-morphine’ Infants 2 9.34 n.a. 23.8 0 n.a. n.a. n.a.
Toddlers 2 16.1 n.a. 34.7 1 288 n.a. 288
Other children 9 2.39 25.7 62.5 2 18.0 n.a. 248
Adolescents 8 1.45 17.1 35.2 0 n.a. n.a. n.a.
Adults 11 3.08 17.7 33.8 4 71.9 225 285
Elderly 8 1.30 15.7 25.9 0 n.a. n.a. n.a.
Very elderly 4 5.64 18.0 25.5 0 n.a. n.a. n.a.
‘Low-morphine’ Infants 2 0.40 n.a. 1.01 0 n.a. n.a. n.a.
Toddlers 2 0.68 n.a. 1.47 1 10.6 n.a. 10.6
Other children 9 0.10 1.09 2.65 2 0.66 n.a. 9.09
Adolescents 8 0.06 0.72 1.49 0 n.a. n.a. n.a.
Adults 11 0.13 0.75 1.43 4 2.63 8.24 10.5
Elderly 8 0.06 0.67 1.10 0 n.a. n.a. n.a.
Very elderly 4 0.24 0.76 1.08 0 n.a. n.a. n.a.
bw: body weight; max: maximum; min: minimum; N: number of surveys; n.a. not applicable; P95: 95th percentile.
(a): Group of poppy seed samples. The ‘high-morphine’ group refers to poppy seed samples originating from Australia, China,
France, Spain and the UK which are assumed to represent primarily varieties grown for pharmaceutical use. The ‘low-
morphine’ group refers to poppy seed samples originating from other countries which are assumed to represent varieties
grown for food use. See Section 3.2.1.4 for further details.
(b): Mean exposure calculated from the mean consumption of poppy seeds and the mean occurrence of thebaine in poppy seed samples.
(c): P95 exposure calculated from the P95 consumption of poppy seeds and the P95 occurrence of thebaine in poppy seed
samples. The P95 exposure estimates for surveys with less than 60 observations may not be statistically robust and are
therefore not calculated.
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For oripavine, no calculation of the exposure assessment was performed because of the insufﬁcient
amount of occurrence data.
In the case of noscapine and papaverine, dietary exposure was not calculated for the ‘high-’ and
‘low-morphine’ group separately, because of the small amount of samples per subgroup. Due to the
higher percentage of left-censored data, acute dietary exposure is presented in Tables 17 and 18 for
both the LB and UB. Detailed summary statistics on the exposure estimates calculated for each dietary
survey are presented in Annex B, Table B.8 and B.9. For noscapine, the mean dietary exposure ranged
from 0.02 to 1.45 lg/kg bw per day (min LB–max UB) across dietary surveys and age groups and was
the highest for other children. The P95 acute dietary exposure ranged from 0.27 to 4.40 lg/kg bw per
day (min LB–max UB) across dietary surveys and age groups. Among the opium alkaloids considered
in this Scientiﬁc Opinion, acute dietary exposure was the lowest for papaverine. The mean dietary
exposure to papaverine ranged from 0.002 to 0.27 lg/kg bw per day (min LB–max UB) across dietary
surveys and age groups and was the highest for other children. The P95 acute dietary exposure
ranged from 0.06 to 0.99 lg/kg bw per day (min LB–max UB) across dietary surveys and age groups.
Table 17: Summary statistics of acute dietary exposure to noscapine (lg/kg bw per day) estimated
at the lower and upper bound across dietary surveys for consumers only
Age group
Mean exposure(a) P95 exposure(b)
N Min Median Max N Min Median Max
Infants LB 2 0.161 n.a. 0.410 0 n.a. n.a. n.a.
UB 2 0.217 n.a. 0.552 0 n.a. n.a. n.a.
Toddlers LB 2 0.278 n.a. 0.599 1 4.40 n.a. 4.40
UB 2 0.374 n.a. 0.806 1 4.40 n.a. 4.40
Other children LB 9 0.041 0.442 1.076 2 0.27 n.a. 3.78
UB 9 0.056 0.596 1.449 2 0.27 n.a. 3.78
Adolescents LB 8 0.025 0.294 0.606 0 n.a. n.a. n.a.
UB 8 0.034 0.396 0.817 0 n.a. n.a. n.a.
Adults LB 11 0.053 0.304 0.582 4 1.10 3.43 4.35
UB 11 0.072 0.410 0.784 4 1.10 3.43 4.35
Elderly LB 8 0.022 0.271 0.447 0 n.a. n.a. n.a.
UB 8 0.030 0.365 0.602 0 n.a. n.a. n.a.
Very elderly LB 4 0.097 0.310 0.440 0 n.a. n.a. n.a.
UB 4 0.131 0.418 0.592 0 n.a. n.a. n.a.
bw: body weight; max: maximum; min: minimum; N: number of surveys; n.a. not applicable; P95: 95th percentile.
(a): Mean exposure calculated from the mean consumption of poppy seeds and the mean occurrence of noscapine in poppy seed
samples.
(b): P95 exposure calculated from the P95 consumption of poppy seeds and the P95 occurrence of noscapine in poppy seed
samples. The P95 exposure estimates for surveys with less than 60 observations may not be statistically robust and are
therefore not calculated.
Table 18: Summary statistics of acute dietary exposure to papaverine (lg/kg bw per day)
estimated at the lower and upper bound across dietary surveys for consumers only
Age group
Mean exposure(a) P95 exposure(b)
N Min Median Max N Min Median Max
Infants LB 2 0.014 n.a. 0.035 0 n.a. n.a. n.a.
UB 2 0.041 n.a. 0.104 0 n.a. n.a. n.a.
Toddlers LB 2 0.024 n.a. 0.051 1 0.99 n.a. 0.99
UB 2 0.070 n.a. 0.151 1 0.99 n.a. 0.99
Other children LB 9 0.004 0.038 0.092 2 0.06 n.a. 0.85
UB 9 0.010 0.112 0.272 2 0.06 n.a. 0.85
Adolescents LB 8 0.002 0.025 0.052 0 n.a. n.a. n.a.
UB 8 0.006 0.074 0.153 0 n.a. n.a. n.a.
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3.3.2. Previously reported dietary exposure
In the previous opinion, a dietary exposure assessment was performed based on the available
occurrence data that had been submitted to EFSA up to early 2011 and the data available on poppy
seed consumption in the Comprehensive European Food Consumption Database (EFSA CONTAM Panel,
2011). Only acute dietary exposure was considered relevant and, based on the relative prevalence of
the alkaloids present in the poppy seed and food samples combined with the pharmacological potency
of the opium alkaloids, it was concluded that the exposure assessment could be focused on morphine
alone. It was also considered that the consumption of food products containing substantial amounts of
poppy seeds is mainly restricted to countries in Central and Eastern Europe. In the other European
countries, poppy seeds are mostly used as decoration or condiment.
Poppy seed consumption data were available from only ﬁve different EU Member States (Austria,
the Czech Republic, Germany, Hungary and Slovakia). However, of these, only three countries (the
Czech Republic, Hungary and Slovakia) had more than 10 consumption days per survey. Based on
these limited data the average reported poppy seed consumption for these three countries was used
to estimate the dietary exposure to morphine, using lower and upper bound concentrations. For
adults, the exposure ranged from 3.1 to 17.4 lg/kg bw per day using the mean morphine
concentration in poppy seeds and from 16.4 to 90.9 lg/kg bw per day taking the P95 concentration in
poppy seeds. For children in the age range 3–10 years the exposure was lower: 9.2 and 48.3 lg/kg
bw per day for the mean and P95 concentration, respectively.
The CONTAM Panel concluded that the lack of available consumption data could lead to a possible
underestimation of the true poppy seed intake. To compensate for this, scenarios were developed,
using recipes for the preparation of poppy seed containing food products (bread, pastries, biscuits,
main dishes, desserts, poppy seed ﬁllings), to estimate the acute exposure for a hypothetical single
portion of foods with high poppy seed content. The exposure (UB) to morphine ranged from 37.8
(mean morphine concentration) to 200 lg/kg bw per day for adults (P95 level). For children of the age
group of 3–10 years, the exposure ranged from 47.8 to 252 lg/kg bw per day, respectively.
As a worse-case approach, occurrence data of morphine in poppy seed samples and consumption of
bread or ﬁne bakery ware with estimated high or low level poppy seed contents were used, assuming
that all bread or ﬁne bakery ware that were consumed on one day contained poppy seeds. Estimated
exposure from bread was lower than from ﬁne bakery ware. For adult consumers of foods with high
poppy seed content, the estimated dietary exposure to morphine via ﬁne bakery ware ranged from 2.48
to 375 lg morphine/kg bw per day. The estimated dietary exposure was the highest for children of age
3–10 years at 10.2–753 lg morphine/kg bw per day. For adult consumers of low poppy seed content
foods, the estimated dietary exposure to morphine via ﬁne bakery ware ranged from 0.05 to 16.9 lg
morphine/kg bw per day. The estimated dietary exposure for children age 3–10 years, ranged from 0.16
to 33.6 lg morphine/kg bw per day.
A ﬁnal exposure assessment was made in which occurrence data was used that had been
submitted by Germany on morphine levels measured in ﬁne bakery ware. Using LB and UB
concentrations for P95 morphine levels in the occurrence data, the exposure for adults ranged from
0.50 to 14.6 lg/kg bw per day. The exposure was the highest for children in the age of 3–10 years,
ranging from 1.88 to 30.7 lg/kg bw per day.
Age group
Mean exposure(a) P95 exposure(b)
N Min Median Max N Min Median Max
Adults LB 11 0.005 0.026 0.050 4 0.25 0.77 0.98
UB 11 0.013 0.077 0.147 4 0.25 0.77 0.98
Elderly LB 8 0.002 0.023 0.038 0 n.a. n.a. n.a.
UB 8 0.006 0.069 0.113 0 n.a. n.a. n.a.
Very elderly LB 4 0.008 0.027 0.038 0 n.a. n.a. n.a.
UB 4 0.025 0.078 0.111 0 n.a. n.a. n.a.
bw: body weight; max: maximum; min: minimum; N: number of surveys; n.a. not applicable; P95: 95th percentile.
(a): Mean exposure calculated from the mean consumption of poppy seeds and the mean occurrence of papaverine in poppy
seed samples.
(b): P95 exposure calculated from the P95 consumption of poppy seeds and the P95 occurrence of noscapine in poppy seed
samples. The P95 exposure estimates for surveys with less than 60 observations may not be statistically robust and are
therefore not calculated.
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Except for the ﬁnal approach in which the German occurrence data in ﬁne bakery was used, the
effects of processing had not been taken into account in the exposure assessments. The CONTAM
Panel noted that food processing steps (washing, grinding, baking) may reduce the alkaloid content in
raw poppy seeds by up to 90% in the ﬁnal product. However, due to the lack of consumption data on
poppy seeds and the products as consumed, processing was not taken into account.
From the different exposure scenarios. it could be concluded that children of age 3–10 are the most
exposed age group on a body weight basis.
Zentai et al. (2012) conducted a dietary exposure assessment on morphine, focussing on
Hungarian consumers. Occurrence data for the period 2001–2010 on morphine, codeine, thebaine and
noscapine in poppy seeds sold on the Hungarian market were used and consumption data were
available from two 3-day surveys conducted in Hungary in 2003 and 2009, respectively. The 2003
survey contained consumption data for adults only, while the 2009 survey included also children and
adolescents. The overall percentage of poppy seed consumption days was 1.94% in 2003 and 2.18%
in 2009. Consumption of poppy seeds was somewhat more frequent in the age group below 18
(2.81%). The 2009 survey provided information on the type of product that was consumed, i.e. 65%
of poppy seeds was consumed as ground and 35% was consumed as baked and ground in the form of
baked cakes. The effect of processing could therefore be taken into account, including grinding and
baking steps while washing was considered not relevant for the Hungarian situation. Processing factors
were deﬁned as 0.71 for grinding, 0.31 for baking and 0.22 for the combination of grinding and
baking.
Based on the infrequent use of poppy seeds, only the acute exposure was considered relevant.
Point estimates for acute exposure were made, taking the 97.5 percentile of daily poppy seed
consumption in combination with the 97.5 percentile of the morphine content. Based on the available
occurrence data the following P97.5 concentrations in poppy seeds were calculated: 84.8 mg/kg
morphine; 25.7 mg/kg codeine; 23.9 mg/kg thebaine and 4.7 mg/kg noscapine. Based on the 2009
survey, the P97.5 for poppy seed consumption (on consumption days) was estimated as 1.26 g/kg bw
per day, while the average consumption was 0.44 g/kg bw per day. Ground poppy seeds were
consumed about twice as often as baked poppy seeds, resulting in an average consumption of 0.52 g
ground poppy seeds/kg bw per day and 0.30 g baked poppy seeds/kg bw per day. The point
estimates for the acute exposure at the P97.5, based on raw poppy seeds, for adults and children
were 116.7 and 164.7 lg/kg bw per day, respectively. Taking processing into account, the P97.5 values
were 78.6 and 116.9 lg/kg bw per day, a decrease of approximately 30%.
The authors also used different probabilistic methods to estimate morphine intake and to model the
effect of processing. This resulted in signiﬁcantly lower estimated values at P97.5: for unprocessed poppy
seeds this ranged between 25.6 and 40.9 lg/kg bw per day for adults (6 different options calculated)
and between 59.1 and 63.3 lg/kg bw per day for children (2 different options calculated). When the
effects of processing were included, the exposure at P97.5 was calculated as 18.3–25.4 lg/kg bw per
day for adults (2 options calculated) and 32.9 lg/kg bw per day for children (1 option calculated).
No point estimates or probabilistic calculations were performed for the other opium alkaloids
present in the poppy seeds. Overall, the dietary exposure to morphine from poppy seed-containing
foods reported in the open literature is in-line with the acute dietary exposure estimated in this
Scientiﬁc Opinion (see Section 3.3.1).
3.3.3. Non-dietary sources of exposure
Besides the exposure from poppy seed consumption as a food, consumers can be exposed to
opium alkaloids from other sources.
As described in Section 3.1.3 (Observations in humans), some opium alkaloids and their derivatives
are used as licensed medicines and this can lead to additional exposure.
Morphine has been reported to occur in wastewater, surface water and ground water.
Concentrations ranging from 12.3 to 1,346 ng/L have been reported in inﬂuents from wastewater
treatment plants and concentrations ranging from < 3.95 (LOQ) to 929 ng/L in efﬂuents as reviewed
by Pal et al. (2013). In surface water, concentrations ranging from 1.74 to 148 ng/L have been
reported and in ground water a concentration of 1.4 ng/L has been reported (Pal et al., 2013;
Mendoza et al., 2014). Morphine was not detected in tap water (Mendoza et al., 2014) but it was
detected, as well as codeine, in both treated and untreated drinking water (Rodayan et al., 2016).
These data indicate a potential but low additional exposure to opium alkaloids via drinking water.
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As described by the CONTAM Panel in 2011, poppy seeds are used as an ingredient in warm
beverages such as milk to calm infants and to prepare tea which is used as an agent of abuse or to
treat opioid dependency. These uses are not considered as food use in this Scientiﬁc Opinion.
Also, traditional Chinese medicine herbal preparations, which are used as an antitussive in China,
have been reported to contain morphine, codeine, thebaine, noscapine and papaverine. These
preparations often contain Pericarpium papaveris (Yin Su Qiao) as one of the ingredients. Liu et al.
(2016b) analysed a total of 40 herbal products and the ranges found were: 5.0–1,311 mg/kg morphine,
0.6–14.4 mg/kg codeine, 1.8–113 mg/kg thebaine, 0.7–473 mg/kg noscapine and 1.6–317 mg/kg
papaverine.
Pericarpium papaveris is also illicitly used as an additive in hot pot, a popular dish served in Chinese
restaurants in China (Guo et al., 2013). A survey was conducted including 29 samples of hot pot broth
from local restaurants and supermarkets. Samples were analysed for morphine, codeine, thebaine,
noscapine and papaverine with LC–MS/MS (LOQs ranged from 0.01 to 0.1 lg/kg). The survey yielded
3 positive samples, two samples containing 22.5 and 28.9 lg/kg morphine, respectively, while a third
sample contained traces of noscapine and papaverine.
3.4. Risk characterisation
The mean and high (P95) acute dietary exposure to morphine alone and to morphine and codeine,
expressed as morphine equivalents, calculated from ‘low-morphine’ poppy seed samples (primarily
varieties for food use) and ‘high-morphine’ poppy seed samples (i.e. those grown primarily for
pharmaceutical use), were compared with the ARfD of 10 lg/kg bw (Annex B, Tables B.4 and B.6). It
should be noted that the exposure estimates presented in this Scientiﬁc Opinion refer to consumers of
poppy seeds.
The estimates of high (P95) acute dietary exposure to morphine alone from poppy seed considered
to have high levels of opium alkaloids (i.e. those from varieties grown primarily for pharmaceutical use
of which the seeds are used as a by-product for food purposes) demonstrated that the group ARfD of
10 lg morphine equivalents/kg bw was exceeded by all age groups for which data were available. At
the highest estimated exposure, which is seen in the toddler age group based on one survey only, the
group ARfD is exceeded by up to 33-fold. The estimates of mean dietary exposure for this type of
poppy seeds also exceed the group ARfD in most surveys in all age groups. Based on the mean
morphine occurrence in these poppy seed samples, consumers in 34 out of 44 population groups are
estimated to be exposed for at least 50% of the consumption days to a level of morphine higher than
the group ARfD of 10 lg/kg bw. For poppy seeds, considered to have relatively lower concentrations
of opium alkaloids (primarily varieties for food use), exceedance of the group ARfD is also seen at high
levels of dietary exposure in most surveys, but to a lesser extent (up to 4- to 5-fold). Based on the
mean occurrence of morphine in these poppy seed samples, the estimated exposure to morphine
exceeded the group ARfD on less than 50% of the consumption days in all but one population group.
Comparison of the dietary exposure to morphine alone with the combined exposure to morphine
and codeine, expressed as morphine equivalents, shows that codeine makes a minor contribution to
the sum. Exposures and exceedances of the ARfD are marginally increased by the inclusion of codeine
into the sum (Table B.6 of Annex B).
However, when considering individual poppy seed samples containing high concentrations of codeine,
their consumption may result in a codeine exposure, expressed in morphine equivalents, that exceeds the
group ARfD. Based on the highest P95 consumption of poppy seeds of 55 g/day (see Annex B, Table B.3)
and assuming a default body weight of 70 kg for an adult, the group ARfD might be exceeded when
consuming poppy seeds contaminated with codeine at a concentration higher than 65 mg/kg.
It should be noted that exposure estimates are based on reported concentrations of alkaloids in
poppy seed samples due to the lack of occurrence data on food products containing poppy seeds.
However, food processing steps (i.e. washing, soaking, heat treatment, grinding) may reduce the
alkaloid content in raw poppy seeds by 25–100% in the ﬁnal product. Therefore, the group ARfD is
most likely to be exceeded when large portions are consumed or if foods containing unprocessed
poppy seeds are consumed.
The CONTAM Panel reconﬁrms that, although there are few reports of adverse reactions arising
from traditional consumption of poppy seeds in foods, in the absence of formal reporting systems, it
cannot be assumed that such reactions do not occur from time to time. Pregnant women, infants,
people above 75 years of age and those suffering from health conditions with impaired respiratory
function are subgroups that are more sensitive to adverse effects of morphine.
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In principle, oripavine could contribute to morphine-like effects, but the available toxicological and
occurrence data were insufﬁcient for risk characterisation.
For thebaine, the estimated dietary exposures are slightly lower than those for morphine. LD50
values in rodents indicate that thebaine is more acutely toxic than morphine. In view of this evidence,
the dietary exposures could be a health risk. However, hazard characterisation is not possible due to
the lack of data from which to derive a HBGV and consequently no risk characterisation could be
carried out.
The estimated dietary exposures to noscapine and papaverine are lower than for morphine and
based on very limited data it appears that they are less toxic than the other alkaloids discussed in this
opinion. However, the available data are insufﬁcient to propose HBGVs. Instead, the CONTAM
Panel compared estimated dietary exposure to noscapine and papaverine with the limited information
regarding the recommended therapeutic doses in humans. Therefore, risk characterisation for these
alkaloids is incomplete. For noscapine, dietary exposure is at least 80-fold lower than the
recommended therapeutical dose, which does not suggest a health concern. For papaverine, the
dietary exposure is about 2,000-fold lower than the recommended therapeutical dose and it is highly
unlikely that this would be a health concern.
3.5. Uncertainty analysis
The evaluation of the inherent uncertainties in the assessment of exposure to opium alkaloids in
poppy seed samples has been performed following the guidance of the Opinion of the Scientiﬁc
Committee related to Uncertainties in Dietary Exposure Assessment (EFSA, 2006). In addition, the
report on ‘Characterizing and Communicating Uncertainty in Exposure Assessment’ has been
considered (WHO/IPCS, 2008). According to the guidance provided by the EFSA opinion (2006) the
following sources of uncertainties have been considered: assessment objectives, exposure scenario,
exposure model, and model input (parameters).
3.5.1. Assessment objectives
The objectives of the assessment were clearly speciﬁed in the terms of reference.
3.5.2. Exposure scenario/exposure model
The ﬁnal data set on opium alkaloids was composed of 7,669 data points (of which 6,369 on poppy
seeds). With respect to the occurrence data used in the 2011 EFSA opinion, the number of reporting
countries and most importantly the country of origin of the poppy seeds increased. However, a source
of uncertainty is the representativity of the data set with respect to the countries of sampling and/or
origin of the samples (the largest amount of data were reported by Germany, Hungary and the Czech
Republic).
The alkaloid proﬁle strongly differs between P. somniferum cultivars. The CONTAM Panel noted a
large variation in the alkaloid proﬁle of the available poppy seed samples and observed a clear trend of
association between the country of origin of the poppy seeds and high median morphine
concentrations. Therefore, the occurrence data set was divided in three groups based on the country
of origin: the poppy seed samples assumed to represent primarily varieties grown for the
pharmaceutical sector (‘high-morphine’ group; samples originating from Australia, China, France, Spain
and the UK), poppy seed samples assumed to represent primarily varieties grown for the food sector
(‘low-morphine’ group; samples originating from other countries) and poppy seed samples with
unknown origin. However, it should be noted that countries may produce varieties for both food and
pharmaceutical use. Consequently, high morphine concentrations were observed in the ‘low-morphine’
group as well. This may result in an overestimation of P95 dietary exposure for the ‘low-morphine’
scenario. In addition, the application of cleaning practices after harvest might reduce the level of
morphine in the poppy seeds. Furthermore, seeds of different poppy varieties (data providers did not
report information on poppy varieties) may be mixed before entering the food market. These factors
introduce some uncertainty in the applied division.
Poppy seed samples from unknown origin were not taken into account in the exposure assessment
for morphine, codeine, morphine equivalents and thebaine. However, the concentrations reported for
the unknown group were similar to the concentrations reported for the ‘low-’ and ‘high-morphine’
group and therefore the uncertainty for excluding these data from the exposure assessment is limited.
Opium alkaloids in poppy seeds
www.efsa.europa.eu/efsajournal 71 EFSA Journal 2018;16(5):5243
A further source of uncertainty is related to the assumptions regarding the percentage of poppy
seeds in different types of poppy seed-containing foods. It can be assumed that the presence of
poppy seeds in foods was not always captured in the dietary surveys, particularly when small amount
of poppy seeds are present in the food. This leads to an underestimation of the frequency of poppy
seed consumption and a bias in the consumption statistics for consumers of poppy seeds since
particularly low consumption events may be underreported. In addition, the number of consumers of
poppy seeds is likely underestimated due to the limited number of reporting days per subject (from 1
to 7 per subject).
Most of the available data in this opinion related to unprocessed poppy seeds and no effect of food
processing was taken into account in the assessment of acute dietary exposure reported in this
opinion. However, it is expected that the alkaloid content of the poppy seeds is reduced during the
pre-treatment and processing (i.e. washing, soaking, heat treatment, grinding) and reductions of 25–
100% have been reported (see Section 3.2.3). A comparison of calculated and reported morphine
concentrations in bread, indicate that the uncertainty due to the use of analytical results in poppy seed
samples instead of bread may be limited. However, this veriﬁcation was only done for one food and on
a limited data set and therefore there is uncertainty regarding the effect of food processing.
For the calculation of the morphine equivalents, the median percentage of codeine to morphine
was imputed for 454 samples for which the codeine concentration was not reported. With few
exceptions, the variability of the percentage of codeine to morphine was limited and, considering the
low contribution of codeine to the morphine equivalent, this source of uncertainty can be considered
as minor.
In relation to the dietary exposure assessment, uncertainties and limitations related to the use of
EFSA’s Comprehensive Food Consumption Database are described in EFSA’s guidance (EFSA, 2011a)
and are not further detailed in this opinion. Out of the 41 dietary surveys available for this assessment,
consumption of poppy seeds and related foods was reported in only 18 of them. Consumption data
were available for Austria, Bulgaria, the Czech Republic, Denmark, Germany, Hungary, Ireland, Poland,
Romania, Slovakia, Slovenia, Sweden and the United Kingdom. Moreover, not all age groups were
covered for each country. For instance for Slovakia and Slovenia, data on the consumption of poppy
seeds were available for adults only. Finally, poppy seed-containing foods are partially seasonal foods
eaten during Christmas or Easter time, and these periods are not always covered by the dietary
national surveys. This can represent a source of underestimation of the dietary exposure.
3.5.3. Model input (parameters)
Currently, no ofﬁcial standard methods are available for the analysis of opium alkaloids in foods.
Analytical results used for the exposure assessment were therefore obtained using different analytical
methods and varying LOQ/LODs. Although for papaverine and noscapine, a large proportion of left-
censored results was found, the difference between LB and UB exposure estimates was limited. For
morphine, codeine and thebaine, the proportion of left-censored results was small and consequently
the difference between LB and UB exposure estimates was negligible. This indicates that the
uncertainty due to left-censored data is limited.
3.5.4. Other uncertainties
The uncertainties described in the 2011 opinion remain valid: ‘The ARfD is derived from the lowest
known single oral therapeutic dose of morphine. A range of adverse reactions is reported to occur
during therapeutic use of morphine, but the extent to which these occur at the lowest known single
oral therapeutic dose or even below is not clear. Furthermore, the medical literature refers to
contraindications in which morphine treatment should be avoided. There is also uncertainty if the low
doses that are efﬁcient in the therapy of dyspnoea via the reduction of ventilatory drive may impose
additional risks on persons with different forms of sleep apnoea or sleep disordered breathing’.
Additive effects or interactions with accompanying alkaloids in poppy seeds and/or with
concomitant intake of alcohol, opioid drugs or central depressant drugs is not taken into account as is
the case for decreased elimination of morphine, codeine or their metabolites, e.g. in consequence of
hepatic or renal impairment.
The toxicological properties of noscapine and papaverine are less characterised than for morphine
and codeine. However, from the therapeutic uses, information for dose–adverse effect relationships in
humans are available for noscapine and papaverine. These adverse effects (e.g. dizziness, headache)
are considered less severe compared to those known from the pharmaceutical uses of morphine.
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The available data did not allow taking into account the toxicity of thebaine and oripavine, which
may be present in poppy seed samples. This could be especially relevant for poppy seeds derived from
poppy varieties bred for pharmaceutical uses with speciﬁc alkaloid proﬁles (e.g. high concentrations of
thebaine, oripavine).
3.5.5. Summary of uncertainties
In Table 19, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of
exposure to opium alkaloids in poppy seed samples is considerable. The exposure is more likely to be
overestimated than underestimated. The risk associated with dietary exposure to morphine and
codeine is considered to be overestimated. However, risks linked to exposure to thebaine and oripavine
could not be characterised.
4. Conclusions
Poppy seeds are obtained from the opium poppy (P. somniferum L.). The latex (milky sap) of the
opium poppy contains up to 80 different alkaloids, including morphine and codeine, which have been
used by man for the treatment of severe pain for generations but are also subject to misuse. The
seeds are used as food and to produce edible oil.
Alkaloid accumulation in the poppy plant depends on both genetic factors and environmental/
cultivation conditions. Breeding is focusing on the development of either cultivars with a high and
speciﬁc alkaloid content to fulﬁl the requirements of the pharmaceutical industry or cultivars with a low
alkaloid content for seed/oil production. However, poppy seeds from P. somniferum varieties with high
alkaloid content especially bred for pharmaceutical purposes are used as a by-product for food
purposes. Mature poppy seeds do not contain the latex, but can become contaminated with opium
alkaloids as a result of pest damage and during harvest.
Table 19: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of opium alkaloids in poppy seeds
Sources of uncertainty Direction(a)
Extrapolation of occurrence data to the whole of Europe +/
Effect of food processing not taken into account in the exposure assessment +
Overestimation of P95 dietary exposure for the ‘low-morphine’ scenario due to the presence of
poppy seed samples from varieties grown for pharmaceutical use
+
Underestimation of dietary exposure for the ‘high-morphine’ scenario due to the possible
presence of poppy seed samples from varieties grown for use as food

Imputation of codeine content in a number of samples for the calculation of morphine
equivalents
+/
Use of mean disaggregation factors to convert eating occasions of poppy seed-containing foods
into amounts of consumed poppy seeds
+/
Consumption of foods containing small amounts of poppy seeds not always captured in dietary
surveys (e.g. bread roll)
+/
Dietary surveys not capturing possible high consumption of poppy seeds during festivities (e.g.
Easter)

Uncertainty in the LOAEL for establishing the ARfD 
Possible interactions of morphine and codeine with other opium alkaloids contaminating poppy
seeds
+/
Additive adverse effects of morphine and codeine with concomitant intake of alcohol, or central
depressant drugs are not taken into account

Intrinsic toxicity of thebaine could not be taken into account in the risk assessment 
LOAEL: lowest-observed-adverse-effect level.
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
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Opium alkaloids detected in samples of poppy seeds and poppy seed-containing foods include the
phenanthrenes: principally morphine, codeine, thebaine and oripavine, and the benzylisoquinolines:
principally papaverine and noscapine. In this Scientiﬁc Opinion, the term ‘opium alkaloids’ refers to
these compounds.
4.1. Hazard identiﬁcation and characterisation
4.1.1. Toxicokinetics
Morphine
• Morphine is extensively absorbed from the GI tract and is distributed throughout the body. The
oral bioavailability of morphine is reduced by both Phase I and II presystemic metabolism in
the GI tract and liver.
• Morphine diffuses across the placenta, and transfers into milk.
• Morphine is metabolised via N-demethylation and O-glucuronidation in the gut and the liver.
Metabolites are normorphine, M3G and M6G.
• The rate and pathways of opioid metabolism and distribution of morphine may be inﬂuenced
by genetic factors (active transport proteins, including the P-glycoprotein) and medical
conditions (liver and kidney disease), which can account for part of the observed inter-
individual variation in morphine effects.
Codeine
• Codeine is readily and extensively absorbed from the GI tract following oral administration and
is distributed throughout the body.
• Codeine penetrates the placental barrier and enters fetal circulation. It is also excreted in
breast milk.
• Codeine is metabolised via O-demethylation, N-demethylation and O-glucuronidation in the
liver and gut. Main metabolites are morphine, norcodeine and C6G. The formed morphine is
further metabolised into normorphine, M3G and M6G.
• Codeine metabolism to morphine is dependent of the CYP2D6 activity. Individuals can be
classiﬁed into poor metaboliser, intermediate metaboliser, extensive metaboliser or ultra-rapid
metaboliser. The extensive metaboliser represents the majority of the Caucasian population.
The phenotypes generated by different CYP2D6 alleles affects the sensitivity of humans to
adverse effects of codeine.
• There is a sharp increase in both morphine AUC and Cmax following codeine exposure in
extensive/ultra-rapid metabolisers.
• No new data were identiﬁed that provide a basis to change the previous conclusion from 2011
that the maximal metabolic conversion of codeine into morphine does not exceed 20%.
Thebaine, oripavine, noscapine and papaverine
• Based on limited information, oral bioavailability of thebaine, oripavine, noscapine and
papaverine appears to be reduced due to pre-systemic metabolism in the GI tract and liver
primarily involving demethylation reactions but also glucuronidation.
• There are indications that thebaine is metabolised into several metabolites, including oripavine
and morphine.
4.1.2. Toxicity in experimental animals
Morphine
• In experimental animals, morphine acts on the nervous system and its development. Most of
the available data were generated by using routes of administration and doses that are not
relevant for the purpose of the present opinion.
• Chronic toxicity, including carcinogenicity, of morphine has not been systematically evaluated.
Based on the lack of carcinogenicity of codeine which is metabolised to morphine, it is unlikely
that morphine is carcinogenic.
• Morphine is genotoxic only in vivo but most likely by a non-DNA reactive mode of action.
• Depressed sexual activity, reduced testicular function and spermatogenesis, disruption of ovarian
cyclicity and decreased pregnancy rate have been observed in rats exposed to morphine.
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• Oral morphine exposure of pregnant rats or mice affects the normal development of the
placenta and the brain.
• Morphine causes immunosuppressive actions.
Codeine
• Long-term feeding studies in rats and mice showed no evidence of carcinogenic activity.
• Codeine is not genotoxic.
• Based on limited data it is concluded that oral administration of codeine did not result in
teratogenicity.
• There are no data to make conclusions on the neurotoxic effects of codeine.
Thebaine and oripavine
• Based on LD50 values, thebaine and oripavine are more toxic than morphine.
Noscapine
• Noscapine has a lower acute toxicity compared to the other opium alkaloids considered in this
Scientiﬁc Opinion.
• Repeated exposure of rats and dogs to noscapine did not result in adverse effects.
• Noscapine is an aneugen in vitro most likely by a non-DNA reactive mechanism. Taking into
account also its low systemic availability, a risk of genotoxic damage in vivo is very unlikely.
Papaverine
• The LD50 values, by oral and parenteral administration are similar to those for morphine.
However, evidence of toxicity was not seen following oral administration of papaverine to rats
at 50 and 100 mg/kg bw per day and to dogs at 10 mg/kg bw per day.
4.1.3. Observations in humans
• According to recent literature most conclusions in the 2011 opinion are still valid.
• Morphine has a high afﬁnity for the l-opioid receptor as an agonistic ligand. Activation of l-
opioid receptors leads to adverse effects such as nausea, vomiting, sedation, drowsiness,
euphoria, miosis, respiratory depression and obstipation. Therapeutic doses of morphine may
impair the ability to drive or to operate machinery due to changes in attentiveness and reactive
skills.
• The lowest known single oral therapeutic dose reported is 1.9 mg morphine, corresponding to
27 lg/kg bw for an adult weighing 70 kg.
• The pharmacology of codeine is strongly related to that of morphine, as it is a precursor of
morphine itself.
• Recent literature focused on cases of life-threatening toxicity in paediatric patients given
therapeutic doses of codeine. This has been associated with the genotype predisposing to
ultra-rapid metabolism of codeine into morphine by the isoenzyme CYP2D6.
• Morphine and codeine have dependency potential. Longer term use can result in tolerance.
• The adverse reactions to codeine are similar to those of morphine but seen to a lesser extent
at clinical doses. The most frequent side effects of codeine are constipation and nausea.
• For oripavine and thebaine, no data after oral or parenteral exposure of humans are available.
• Noscapine and papaverine do not show opiate-like pharmacology. Noscapine is used as an
antitussive agent. Papaverine acts as a smooth muscle relaxant. Compared to morphine,
adverse effects of noscapine and papaverine given orally in therapeutic doses are less severe
(e.g. dizziness, headache).
4.1.4. Mode of action
• Morphine, codeine, thebaine and oripavine interact with three different receptors namely the
l-, d- and j-opioid receptors. The l-opioid receptor plays a crucial role in both the desired
(analgesia) and undesired (respiratory depression) effects of morphine and codeine in
medicinal use.
• The rank order of potency of natural opium alkaloids at the l-opioid receptor is
morphine ≫ oripavine > codeine > thebaine.
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• No indication has been found that the effects of noscapine and papaverine are mediated via
opioid receptors.
• M6G is an active metabolite of morphine with similar or higher activity as morphine, whereas
M3G has weak afﬁnity for the l-opioid receptor.
• The codeine metabolites C6G, norcodeine and N6G have weak afﬁnity for the l-opioid receptor.
4.1.5. Considerations of critical effects, dose-response modelling and possibilities
for derivation of a health-based guidance value
• The CONTAM Panel conﬁrms its previous conclusion that the critical effects of morphine are on
the CNS mediated by its high afﬁnity to the l-opioid receptor as an agonistic ligand.
• From data on humans and experimental animals, it is clear that morphine can interfere with
brain development of the fetus resulting in behavioural effects at later life-stages; however,
data are too limited to derive a dose-response relationship.
• The critical effects of codeine are the same as those of morphine, because morphine is the
active metabolite of codeine.
• The data that have become available since the 2011 CONTAM opinion, do not provide a basis
for revising the ARfD for morphine of 10 lg/kg bw, which is derived from the lowest
therapeutic dose of morphine. In order to characterise the risks of combined exposure to
morphine and codeine, the ARfD is a group ARfD for morphine and codeine, expressed in
morphine equivalents using an equivalence factor of 0.2 for codeine.
• Oripavine also acts as an agonist to the l-opioid receptor, with a lower activity than morphine
and a higher activity than codeine. Non-oral LD50 values in rodents indicate that oripavine is
more acutely toxic than morphine. However, the available data are insufﬁcient to characterise
the hazard or to identify a factor for conversion to morphine equivalents.
• The toxicological properties of thebaine have not been well characterised. A contribution to
morphine-like toxicity due to its possible metabolism into morphine and oripavine may occur,
but is expected to be small. Oral LD50 values in rodents indicate that thebaine is more acutely
toxic than morphine. The available data are insufﬁcient to identify a factor for conversion to
morphine equivalents, to propose a HBGV, or to identify a reference point for calculating
margins of exposure.
• Noscapine and papaverine do not exhibit morphine-like properties and therefore they are not
included in the group ARfD. Their toxicological properties have not been well characterised and
it is not possible to establish HBGVs.
• Based on the limited data available, it appears that noscapine and papaverine are less toxic
than the other alkaloids discussed in this opinion.
4.2. Occurrence/exposure
• To estimate acute dietary exposure to opium alkaloids, two batches of analytical results on the
occurrence of opium alkaloids in food and poppy seeds were available. A ﬁrst batch of 2,678
analytical results were collected by EFSA until 2011 and presented in the previous CONTAM
opinion on opium alkaloids. This data set contained analytical results from 55 Australian poppy
seed samples that were not used for dietary exposure assessment since their opium alkaloid
proﬁle was considered different from poppy seed samples available on the EU market at that
time. A second batch of data contained 4,991 analytical results and was collected by EFSA
between 2012 and 2017.
• Considering the limited amount of data on food categories other than poppy seeds, the
CONTAM Panel decided to base the assessment on poppy seed samples only.
• The occurrence data on opium alkaloids show the presence of poppy seed samples with high
concentrations of morphine, codeine and/or thebaine. The opium alkaloid proﬁle seems to be
related to the country of origin of the poppy seed samples and ultimately to the poppy variety.
• Based on the available data per country of origin and batch, the CONTAM Panel concluded that
the proﬁles in the two batches are comparable. In addition, the proﬁle in the Australian poppy
seeds is compatible with the proﬁle in the European poppy seeds. Therefore, the Australian
data were included in the data set and the two batches of data submitted to EFSA were
merged.
• Based on evidence from the currently available data set and background information, the
CONTAM Panel divided the poppy seed samples with known country of origin into two groups.
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The ‘high-morphine’ group, which is assumed to represent primarily poppy seeds from varieties
grown for the pharmaceutical sector and the ‘low-morphine’ group, which is assumed to
represent primarily varieties grown for the food sector. It emerged that both types are
available, although in unknown proportion, on the European market, therefore the CONTAM
Panel has consequently elaborated two separate acute exposure scenarios.
• In poppy seed samples, the highest mean MB concentrations were reported for morphine
(147 mg/kg in the ‘high-morphine’ group and 16.4 mg/kg in the ‘low-morphine’ group) and
thebaine (92.5 and 3.92 mg/kg, respectively) compared to codeine (22.7 and 2.88 mg/kg,
respectively) and oripavine (20.0 and 2.14 mg/kg, respectively). For noscapine and
papaverine, the mean MB concentrations were smaller and not exceeding 2 mg/kg.
• In the ‘high-morphine’ group, thebaine was present at a concentration higher than morphine in
more than 25% of the samples and codeine was higher than morphine in about 5% of the
samples. In the ‘low-morphine’ group, morphine was the opium alkaloid present at the highest
concentration in almost all samples.
• Among consumers of poppy seeds, the average estimated poppy seed consumption from the
Comprehensive Food Consumption Database ranged from 0.5 (Other children, Sweden) to
25 g poppy seeds/day (Adults, Hungary) in 44 population groups. Only in 7 population groups
it was possible to calculate the P95 ranging from 1 (Other children, Sweden) to 55 g poppy
seeds/day (Adults, Germany).
• For morphine, under the MB scenario, the mean acute dietary exposure (based on the mean
consumption and mean occurrence) for consumers only, ranged from 2.1 to 100 lg/kg bw per
day across dietary surveys and age groups when considering the poppy seed samples from the
‘high-morphine’ group. The P95 acute dietary exposure (based on the P95 consumption and
P95 occurrence) ranged from 21 up to 330 lg/kg bw day. For the ‘low-morphine’ group, the
mean MB acute dietary exposure ranged from 0.2 to 11 lg/kg bw per day across dietary
surveys and age groups and the P95 from 2.8 to 46 lg/kg bw per day. The mean acute
dietary exposure was the highest for other children. Maximum exposure at the P95 was similar
for all age groups for which data were available.
• For codeine, acute dietary exposure was lower compared to morphine, with the P95 dietary
exposure similar to the mean dietary exposure to morphine.
• Acute dietary exposure estimates for morphine and codeine, expressed as morphine
equivalents are quite similar compared to morphine alone and codeine makes a minor
contribution to the morphine equivalents.
• For thebaine, the mean MB acute dietary exposure for consumers only, ranged from 1.3 to
63 lg/kg bw per day across dietary surveys and age groups when considering the poppy seed
samples from the ‘high-morphine’ group. For the ‘low-morphine’ group, the mean MB acute
dietary exposure ranged from 0.06 to 2.7 lg/kg bw per day across dietary surveys and age
groups. The P95 acute dietary exposure ranged from 18 to 288 lg/kg bw per day for the
‘high-morphine’ group and from 0.7 to 11 lg/kg bw per day for the ‘low-morphine’ group. The
mean acute dietary exposure was the highest for other children. Maximum exposure at the
P95 was similar for the age groups for which data were available.
• No exposure assessment was performed for oripavine due to the very limited amount of
occurrence data.
• For noscapine, the mean dietary exposure for consumers only, ranged from 0.02 to 1.5 lg/kg
bw per day (min LB–max UB) across dietary surveys and age groups and was the highest for
other children. The P95 acute dietary exposure ranged from 0.3 to 4.4 lg/kg bw per day (min
LB–max UB) across dietary surveys and age groups.
• Among the opium alkaloids considered in this Scientiﬁc Opinion, acute dietary exposure for
consumers only, was the lowest for papaverine, not exceeding 1 lg/kg bw per day.
4.3. Risk characterisation
• Exposure estimates are based on reported concentrations of alkaloids in poppy seed samples
due to the low amount of occurrence data on food products containing poppy seeds. However,
food processing steps (i.e. washing, soaking, heat treatment, grinding) may reduce the
alkaloid content in raw poppy seeds by 25–100% in the ﬁnal product. The group ARfD is most
likely to be exceeded when large portions are consumed or if foods containing unprocessed
poppy seeds are consumed.
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• Considering data related to poppy seeds containing relatively high levels of opium alkaloids,
such as those from varieties primarily grown for pharmaceutical use, mean and high levels of
dietary exposure to morphine from poppy seeds result in the group ARfD of 10 lg morphine
equivalents/kg bw being exceeded in most age groups by up to 33-fold.
• For poppy seeds considered to have relatively lower concentrations of opium alkaloids
(primarily varieties for food use), exceedance of the group ARfD is also seen at high levels of
dietary exposure in most surveys, but to a lesser extent at up to 4 to 5-fold.
• Based on the mean morphine occurrence, 34 out of 44 population groups are estimated to be
exposed for at least 50% of the consumption days to a level of morphine higher than the
group ARfD of 10 lg/kg bw for the ‘high-morphine’ scenario and only 1 population group for
the ‘low-morphine’ scenario.
• Codeine makes a minor contribution to exceedance of the group ARfD. However when
considering individual poppy seed samples containing high concentrations of codeine, their
consumption might result in a codeine exposure exceeding the group ARfD.
• There are few reports of adverse reactions arising from traditional consumption of poppy seeds
in foods, but in the absence of formal reporting systems it cannot be assumed that such
reactions do not occur from time to time, particularly in sensitive individuals.
• Pregnant women, infants, people above 75 years of age and those suffering from health
conditions with impaired respiratory function are subgroups that are more sensitive to adverse
effects of morphine.
• In principle, oripavine could contribute to morphine-like effects, but the available toxicological
and occurrence data were insufﬁcient for risk characterisation.
• For thebaine, no quantitative risk characterisation could be carried out. The estimated dietary
exposures are slightly lower than those for morphine. On the other hand, although the lack of
data did not allow the establishment of a HBGV, the CONTAM Panel noted that LD50 values for
thebaine are 3- to 10-fold lower than for morphine, suggesting that the estimated exposure
levels might pose a health risk.
• For noscapine, dietary exposure is at least 80-fold lower than the recommended therapeutical
dose, which does not suggest a health concern.
• For papaverine, the dietary exposure is about 2000-fold lower than the recommended
therapeutical dose and it is highly unlikely that this would be a health concern.
5. Recommendations
• There is a need for toxicological data on thebaine and oripavine, including toxicokinetic data
particularly on the formation of active metabolites.
• There is a need for more occurrence data of the opium alkaloids considered in this opinion in
foods containing poppy seeds.
• There is a need for clariﬁcation of the occurrence of oripavine in poppy seed samples available
on the EU market.
• Certiﬁed reference materials of food products that contain opium alkaloids at relevant
concentrations should become available, as well as international proﬁciency tests.
• More information on consumption of poppy seeds and poppy seed-based food in the EU is
needed.
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Abbreviations
AD analgesic dose
ADME absorption, distribution, metabolism and excretion
ARfD acute reference dose
AUC Area under the curve
BfR Bundesinstitut f€ur Risikobewertung/ the German Federal Institute for Risk Assessment
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BNF British National Formulary
BrdU Bromodeoxyuridine
BVL Bundesamt f€ur Verbraucherschutz und Lebensmittelsicherheit
bw body weight
C6G codeine-6-glucuronide
cAMP cyclic adenosine monophosphate
CAS Chemical Abstracts Service
CHO Chinese hamster ovary
CI conﬁdence interval
Cmax maximum plasma concentrations
CNS central nervous system
COMT catechol-amino transferase
CONTAM Panel EFSA Panel on Contaminants in the Food Chain
CYP cytochrome P450
DMSO dimethyl sulfoxide
EEG electroencephalogram
EMA European Medicines Agency
FAO Food and Agriculture Organization of the UN
GC–MS gas chromatography–mass spectrometry
GI gastrointestinal
HBGV health-based guidance value
HPLC-UV high-performance liquid chromatography-ultraviolet
IgE immunoglobulin E
i.p. intraperitoneal
i.v. intravenously
IPCS International Programme on Chemical Safety
IUPAC International Union of Pure and Applied Chemistry
LB lower bound
LC left-censored data (values below the limit of detection or limit of quantiﬁcation)
LC–HRMS liquid chromatography coupled to high-resolution mass spectrometry
LC–MS/MS Liquid chromatography coupled to tandem mass spectrometry
LD lethal dose
LLE liquid/liquid extraction
LOAEL lowest-observed-adverse-effect level
LOD limit of detection
LOEL lowest-observed-effect-level
logP log of octanol:water partition coefﬁcient
LOQ limit of quantiﬁcation
M3G morphine-3-glucuronide
M6G morphine-6-glucuronide
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MW molecular weight
N6G norcodeine-6-glucuronide
NAS neonatal abstinence syndrome
NIH US National Institute of Health
NOAEL no-observed-adverse-effect level
NOEL no-observed-effect level
OCT organic cation transporters
P5/P95 5th percentile/95th percentile
PD pharmacodynamics
PK pharmacokinetics
pKa log of acid dissociation constant
PND post-natal day
PRAC Pharmacovigilance Risk Assessment Committee
RASFF Rapid Alert System for Food and Feed
REM rapid eye movement
s.c. subcutaneous
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SCE sister chromatid exchanges
SOP standard operating procedure
SPE solid-phase extraction
STS soft tissue sarcomas
TUNEL terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-X nick end labelling
TyDC tyrosine decarboxylase enzyme
UB upper bound
UGT uridine diphosphate-glucuronysyltransferase
UM ultra-rapid metabolisers
UN United Nations
UV ultraviolet
WG Working Group
WHO World Health Organization
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Appendix A – Biosynthetic pathway opium alkaloids in poppy seeds
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Multiple arrowheads denote more than one enzymatic step. Arrows without labelling reﬂect conversions that have not
been enzymatically characterised. Enzymes that have been characterised are labelled, and those for which cognate
cDNAs have been isolated are circled. The basic benzylisoquinoline pathway is shaded in dark grey, whereas the
promorphinan and morphinan pathways are shaded in light grey. Abbreviations: 4-HPAA: p-hydroxyphenyl
acetaldehyde; 40OMT: (S)30-hydroxy-N-methylcoclaurine 40-O-methyltransferase; 6OMT: (S)-norcoclaurine 6-O-
methyltransferase; 7OMT: (R,S)-reticuline 7-O-methyltransferase; BBE: berberine bridge enzyme; BBS: berbamunine
synthase; CAS: (S)-canadine synthase; CFS: (S)-cheilanthifoline synthase; CNMT: (S)-coclaurine N-methyltransferase;
CoOMT: columbamine O-methyltransferase; CoR1: codeinone reductase 1; CTS: (S)-corytuberine synthase
(CYP80G2); DBOX: dihydrobenzophenanthridine oxidase; DRR: 1,2-dehydroreticuline reductase; DRS: 1,2-
dehydroreticuline synthase; MSH: methylstylopine 14-hydroxylase; N7OMT: (S)-norreticuline7-O-methyltransferase;
NCS: (S)-norcoclaurine synthase; NMCH: (S)-N-methylcoclaurine 30-hydroxylase (CYP80B subfamily); P6H: protopine
6-hydroxylase; SalAT: 7(S)-salutaridinol 7-O-acetyltransferase; SalR: salutaridine reductase; SalSyn: salutaridine
synthase (CYP719B1); SOMT: scoulerine 9-O-methyltransferase; STOX: (S)-tetrahydroprotoberberine oxidase; StyS:
(S)-stylopine synthase; THS: thebaine synthase; TNMT: tetrahydroprotoberberine N-methyltransferase; TYDC:
tyrosine decarboxylase.24
Figure A.1: Benzylisoquinoline alkaloid biosynthesis (Ziegler et al., 2009)
24 Reprinted from Phytochemistry, volume 70, Ziegler J, Facchini PJ, Geissler R, Schmidt J, Ammer C, Kramell R, Voigtl€ander S,
Gesell A, Pienkny S and Brandt W, Evolution of morphine biosynthesis in opium poppy, 1696–1707, 2009, with permission from
Elsevier.
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Appendix B – Rapid Alert System for Food and Feed (RASFF) reports on the presence of morphine in poppy seed
samples
Product
category
Date Reference
Product
type
Notiﬁcation
type
Notiﬁcation
basis
Notiﬁed
by
Countries
concerned
Subject
Action
taken
Distribution
status
Risk
decision
Nuts, nut
products
and seeds
22-6-
2015
2015.0798 Food Alert Company’s
own check
Czech
Republic
Czech Republic
(D/O), Slovakia
(D)
High content of
morphine (59.13 mg/kg
– ppm) in ground poppy
seeds from the Czech
Republic
Withdrawal
from the
market
Distribution
restricted to
notifying
country
Serious
Nuts, nut
products
and seeds
17-6-
2015
2015.0776 Food Alert Ofﬁcial
control on
the market
Czech
Republic
Czech Republic
(D), France
(O), Poland,
Ukraine (D)
High content of
morphine (69.61 mg/kg
– ppm) in grey poppy
seeds from France, via
Poland
No distribution
from notifying
country
Serious
Nuts, nut
products
and seeds
3-6-
2015
2015.0675 Food Alert Ofﬁcial
control on
the market
Czech
Republic
Australia (O),
Czech Republic
(D),
Netherlands
High content of
morphine (137 mg/kg –
ppm) in blue poppy
seeds from Australia, via
the Netherlands
Detained by
operator
No distribution
from notifying
country
Serious
Nuts, nut
products
and seeds
21-5-
2015
2015.0619 Food Alert Ofﬁcial
control on
the market
Czech
Republic
Czech Republic
(D), France
(O), Poland
(D), Ukraine
(D)
High content of
morphine (96.93 mg/kg
– ppm) in poppy seed
from France, via Poland
Informing
recipients
Distribution to
other member
countries
Serious
Nuts, nut
products
and seeds
16-5-
2014
2014.0670 Food Alert Ofﬁcial
control on
the market
Czech
Republic
Commission
Services, Czech
Republic (D),
France (O),
Slovakia (O)
High content of
morphine (56.2 mg/kg –
ppm) in blue poppy
seeds from France,
packaged in Slovakia
Withdrawal
from the
market
Distribution to
other member
countries
Serious
Nuts, nut
products
and seeds
14-1-
2014
2014.0053 Food Alert Ofﬁcial
control on
the market
Czech
Republic
Czech Republic
(D), Hungary
(O), Poland
(D), Slovakia
(D)
High content of
morphine (88.1 mg/kg –
ppm) in poppy seeds
from Hungary
Withdrawal
from the
market
Distribution to
other member
countries
Serious
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Product
category
Date Reference
Product
type
Notiﬁcation
type
Notiﬁcation
basis
Notiﬁed
by
Countries
concerned
Subject
Action
taken
Distribution
status
Risk
decision
Nuts, nut
products
and seeds
24-6-
2010
2010.0837 Food Alert Ofﬁcial
control on
the market
Germany Germany (D),
Hungary (D),
Netherlands
(O), unknown
origin (O)
High content of
morphine (72 mg/kg –
ppm) in poppy seeds
from unknown origin, via
the Netherlands
Destruction Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
26-10-
2007
2007.0774 Food Alert Company’s
own check
Hungary Hungary (D/O),
Slovakia (D)
High content of
morphine (80 mg/kg –
ppm) in poppy seeds in
bulk from Hungary
Prohibition
to trade –
sales ban
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
26-10-
2007
2007.0773 Food Alert Company’s
own check
Hungary Hungary (D/O),
Netherlands
(D), Russia (D),
Ukraine (D)
High content of
morphine (40 mg/kg –
ppm) in poppy seeds in
bulk from Hungary
Prohibition
to trade –
sales ban
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
7-9-
2007
2007.CCX Food Information Company’s
own check
Hungary Hungary (D/O),
Russia (D)
High content of
morphine (60 mg/kg –
ppm) in poppy seed
from Hungary
Physical/
chemical
treatment
Distribution
restricted to
notifying
country
Undecided
Nuts, nut
products
and seeds
22-1-
2007
2007.0050 Food Alert Ofﬁcial
control on
the market
Hungary Austria (D),
Czech Republic
(O), Germany
(D), Hungary
(D), Poland
(D), Romania
(D), Slovakia
(D)
High content of
morphine (60.0;
80.0 mg/kg – ppm) in
poppy seed from the
Czech Republic via the
Slovak Republic
Withdrawal
from the
market
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
22-12-
2006
2006.0927 Food Alert Ofﬁcial
control on
the market
Germany Czech Republic
(O), Germany
(D),
Liechtenstein
(O),
Netherlands
High content of
morphine (93 mg/kg –
ppm) in poppy seed
from the Czech Republic
via the Netherlands and
via Liechtenstein
Withdrawal
from the
market
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
19-12-
2006
2006.0903 Food Alert Company’s
own check
Hungary Hungary (D),
Slovakia (O)
High content of
morphine (40 mg/kg –
ppm) in poppy seed
from the Slovak Republic
Ofﬁcial
detention
Distribution on
the market
(possible)
Undecided
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Product
category
Date Reference
Product
type
Notiﬁcation
type
Notiﬁcation
basis
Notiﬁed
by
Countries
concerned
Subject
Action
taken
Distribution
status
Risk
decision
Nuts, nut
products
and seeds
19-12-
2006
2006.0902 Food Alert Company’s
own check
Hungary Czech Republic
(O), Hungary
(D), Slovakia
High content of
morphine (53 mg/kg –
ppm) in poppy seed
from the Czech Republic
via the Slovak Republic
Ofﬁcial
detention
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
13-1-
2006
2006.0039 Food Alert Ofﬁcial
control on
the market
Hungary Hungary (D),
Poland,
Slovakia (O)
High content of
morphine (44 mg/kg –
ppm) in poppy seed
from the Slovak Republic
Destination
of the
product
changed
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
10-1-
2006
2006.0024 Food Alert Ofﬁcial
control on
the market
Germany Austria (D),
Germany (D),
Netherlands
(O)
High content of
morphine (200 mg/kg –
ppm) in poppy seed
from the Netherlands
Product
recall or
withdrawal
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
28-12-
2005
2005.DHV Food Information Ofﬁcial
control on
the market
Hungary Croatia (D),
Hungary (D/O),
Slovakia (D)
High content of
morphine (44.4 mg/kg –
ppm) in poppy seed
from Hungary
Product
recall or
withdrawal
Product past
use-by date
Undecided
Nuts, nut
products
and seeds
21-12-
2005
2005.DFK Food Information Ofﬁcial
control on
the market
Germany Germany (D),
unknown origin
(O)
High content of
morphine (200 mg/kg –
ppm) in poppy seed
from unknown origin
Product
recall or
withdrawal
Distribution
restricted to
notifying
country
Undecided
Nuts, nut
products
and seeds
7-12-
2005
2005.892 Food Alert Ofﬁcial
control on
the market
Hungary Austria (O),
Hungary (D)
High content of
morphine (48 mg/kg –
ppm) in ground poppy
seeds from Austria
Product
recall or
withdrawal
Distribution on
the market
(possible)
Undecided
Nuts, nut
products
and seeds
27-10-
2005
2005.CTA Food Information Ofﬁcial
control on
the market
Germany Australia (O),
Germany (D)
High content of
morphine (228 mg/kg –
ppm) in poppy seed
from Australia
Product
recall or
withdrawal
Distribution
restricted to
notifying
country
Undecided
D: country of distribution; O: country of origin.
Opium alkaloids in poppy seeds
www.efsa.europa.eu/efsajournal 101 EFSA Journal 2018;16(5):5243
Appendix C – Identiﬁcation and selection of evidence relevant for the risk
assessment of opium alkaloids in poppy seeds
C.1. Literature search for supporting information for the assessment,
and previously reported occurrence data and exposure
Searches in Google Scholar, Science Direct and Web of Science were conducted to identify scientiﬁc
papers on up-to-date regarding:
• the inﬂuence of environmental factors and agrotechnical measures on the alkaloid content of
poppy capsules;
• recent breeding efforts concerning alkaloid spectrum of poppy varieties;
• the analysis of opium alkaloids and on the occurrence of and exposure to opium alkaloids in
poppy seeds and poppy seed containing products.
Used search terms (without time span): selection and poppy; breeding and poppy; variety and
poppy; cultivar and poppy; (inheritance and alkaloid) and Papaver; genetic* and Papaver;
(development or ontogenesis) and poppy; poppy and growing; poppy and cultivation; temperature and
morphine; temperature and alkaloids; water and alkaloids; (precipitation or irrigation) and poppy;
contamination and seed and poppy; Papaver bracteatum; opium alkaloid* and analysis; Papaver
somniferum and analysis; poppy seed* and analysis; poppy seed food*; poppy seed product*; survey
and poppy seed*; exposure and opium alkaloid*; consumption and poppy seeds*.
The ofﬁcially registered varieties of Papaver somniferum L. were assessed both from the OECD
Variety List25 and the EU Plant Variety Catalogue.11
The Rapid Alert System for Food and Feed (RASFF) of the European Commission was assessed for
notiﬁcations on the presence of morphine or opium alkaloids in poppy seeds and poppy seed food
products.26
C.2. Literature search for hazard identiﬁcation and characterisation
C.2.1. Search for papers regarding morphine
C.2.1.1. Toxicity
Since the previous assessment was based on a reference point identiﬁed in humans, only a limited
search in PubMed was conducted to identify papers on toxicity in experimental animals. The following
search string was used.
A. PubMed
(“Morphine”[Mesh] OR “morphine”[tiab] OR “morﬁn”[tiab] OR “morﬁne”[tiab] OR “morphia”[tiab]
OR “morphin”[tiab] OR “morphine”[tiab] OR “morphinium”[tiab] OR “morphium”[tiab] OR 57-27-2[rn])
AND (“Reproduction”[Mesh] OR “Prenatal Injuries”[Mesh] OR “Congenital Abnormalities”[Mesh] OR
“Maternal Exposure”[Mesh] OR “Embryonic and Fetal Development”[Mesh] OR embryo* development
[tiab] OR pregnan*[tiab] OR developmental tox*[tiab] OR “reprotox*”[tiab] OR “embryotox*”[tiab] OR
reproductive tox*[tiab] OR “Teratogens”[Mesh] OR “teratogen*”[tiab] OR “Mutagenicity Tests”[Mesh]
OR “genotox*”[tiab] OR mutagen*[tiab] OR “Carcinogenicity Tests”[Mesh] OR carcinogen*[tiab] OR
“Immune System/drug effects”[Mesh] OR immunotox*[tiab] OR immune effect*[tiab] OR
immunosuppress*[tiab] OR “Neurotoxicity Syndromes”[Mesh] OR neurotox*[tiab] OR neurological
effect*[tiab] OR “repeated dose”[tiab]) AND (animal*[tiab] OR mouse[tiab] OR mice[tiab] OR rat[tiab]
OR rats[tiab] OR rodent*[tiab] OR primate*[tiab] OR monkey*[tiab])
Time span: 2011–2017.
25 OECD List of Varieties eligible for seed certiﬁcation, http://www.oecd.org/tad/code/oecd-list-of-varieties-eligible-for-certifica
tion.htm, Accessed 1.1.2018.
26 https://webgate.ec.europa.eu/rasff-window/portal/?event=searchForm&cleanSearch=1
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C.2.1.2. Metabolism and kinetics
Since little new information has become available in recent years regarding the metabolism and
kinetics of morphine, no comprehensive literature search was conducted but experts in the ﬁeld
identiﬁed relevant papers in areas for which new information had become available.
C.2.1.3. Human data
A comprehensive search was carried out in Embase, PubMed and Web of Science to retrieve human
data on morphine using the following search strings:
A. Embase
‘morphine’/mj/dd_ae,dd_ct,dd_to OR ((‘morﬁn’:ti,ab OR ‘morﬁne’:ti,ab OR ‘morphia’:ti,ab OR
‘morphin’:ti,ab OR ‘morphine’:ti,ab OR ‘morphinium’:ti,ab OR ‘morphium’:ti,ab) AND (‘adverse drug
reaction’/exp/mj OR ‘adverse effect*’:ti,ab OR ‘clinical study’/exp/mj OR ‘clinical stud*’:ti,ab OR ‘clinical
trial*’:ti,ab OR ‘case report*’:ti,ab OR ‘case stud*’:ti,ab OR ‘human experiment’/exp OR ‘human stud*’:
ti,ab OR ‘volunteer’/exp OR ‘human volunteer*’:ti,ab OR ‘drug surveillance program’/exp OR
‘pharmacovigilance’:ti,ab))
Time span: 2011–2017
Database: Embase, Embase classic (w/o Medline)
Quick limit: humans
B. PubMed
((“Morphine/adverse effects”[Mesh] OR “Morphine/contraindications”[Mesh] OR “Morphine/
poisoning”[Mesh] OR “Morphine/toxicity” [Mesh]) OR ((“Morphine”[Mesh] OR “morphine”[tiab] OR
“morﬁn”[tiab] OR “morﬁne”[tiab] OR “morphia”[tiab] OR “morphin”[tiab] OR “morphine”[tiab] OR
“morphinium”[tiab] OR “morphium”[tiab] OR 57-27-2[rn]) AND (“Drug-Related Side Effects and Adverse
Reactions”[Mesh] OR adverse effect*[tiab] OR “Clinical Study” [Publication Type] OR “Clinical Studies as
Topic”[Mesh] OR clinical trial*[tiab] OR clinical stud*[tiab] OR “Case Reports” [Publication Type] OR case
report*[tiab] OR “Human Experimentation”[Mesh] OR human stud*[tiab] OR “Volunteers”[Mesh] OR
“human volunteer*”[tiab] OR “Pharmacovigilance”[Mesh] OR “pharmacovigilance”[tiab]))) NOT
(“Animals”[Mesh] NOT “Humans”[Mesh])
Time span: 2011–2017
C. Web of Science
TOPIC: (morphine OR morﬁn OR morﬁne OR morphia OR morphin OR morphine OR morphinium
OR morphium) AND TOPIC:(((clinical OR human) NEAR/2 (trial* OR stud*)) OR (case NEAR/2 report*)
OR “human volunteer*” OR ((adverse OR toxic*) NEAR/2 effect*) OR pharmacovigilance)
Reﬁned by: Databases: (FSTA OR WOS OR CSCD OR DRCI OR CCC OR SCIELO OR RSCI OR BCI
OR KJD OR ZOOREC)
(w/o CABI, Zoological, Medline)
[excluding] RESEARCH AREAS: (VETERINARY SCIENCES OR ZOOLOGY)
Time span: 2011–2017
All the retrieved references were uploaded in Endnote and screened for relevance.
C.2.2. Search for papers regarding codeine
C.2.2.1. Toxicity
Searches in Embase, PubMed and Web of Science were conducted to identify papers on toxicity
(in vitro and in vivo) by using the following search strings.
A. Embase
‘codeine’/mj/dd_to OR ((‘codeine’:ti,ab OR ‘codein’:ti,ab OR ‘methyl morphine’:ti,ab OR ‘methyl
morﬁn’:ti,ab OR ‘morphine methyl ether’:ti,ab OR ‘morphine monomethyl ether’:ti,ab) AND (‘toxicity’/
exp/mj OR ‘toxicity testing’/exp/mj OR ‘toxicity assay’/exp/mj OR ‘toxic substance’/exp/mj OR
carcinogen*:ti,ab OR cardiotox*:ti,ab OR cytotox*:ti,ab OR ‘endocrine toxic*’:ti,ab OR ‘endocrine
disruptor*’:ti,ab OR genotox*:ti,ab OR hemotoxic*:ti,ab OR hematotoxic*:ti,ab OR hepatotox*:ti,ab OR
immunotox*:ti,ab OR ‘liver toxic*’:ti,ab OR mutagen*:ti,ab OR nephrotox*:ti,ab OR neurotox*:ti,ab OR
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reprotox*:ti,ab OR terato*:ti,ab OR toxic*:ti,ab OR ‘toxic effect*’:ti,ab OR tumorigen*:ti,ab OR ‘in vivo’:
ti,ab OR ‘in vitro’:ti,ab))
Time span: 2011–2017
Database: all
B. PubMed
“Codeine/toxicity”[Mesh] OR ((Codeine[tiab] OR Codein[tiab] OR “N-Methylmorphine”[tiab] OR
“Methyl morphine”[tiab] OR “methyl morﬁne”[tiab] OR “morphine methyl ether”[tiab] OR “morphine
monomethyl ether”[tiab] OR “76-57-3”[rn]) AND (“Toxic Actions”[Mesh] OR “Toxicity Tests”[Mesh] OR
carcinogen*[tiab] OR cardiotox*[tiab] OR cytotox*[tiab] OR endocrine toxic*[tiab] OR endocrine
disruptor*[tiab] OR genotox*[tiab] OR hemotoxic*[tiab] OR hematotoxic*[tiab]OR hepatotox*[tiab]OR
immunotox*[tiab] OR liver toxic*[tiab] OR mutagen*[tiab] OR nephrotox*[tiab] OR neurotox*[tiab] OR
reprotox*[tiab] OR terato*[tiab] OR toxic*[tiab] OR toxic effect*[tiab] OR tumorigen*[tiab] OR
“in vivo”[tiab] OR “in vitro”[tiab]))
Time span: 2011–2017
C. Web of Science
TOPIC: (Codeine OR Codein OR “Methyl morphine” OR “methyl morﬁne” OR “morphine methyl ether”
OR “morphine monomethyl ether”) AND TOPIC: (carcinogen* OR cardiotox* OR cytotox* OR endocrine
toxic* OR endocrine disruptor* OR genotox* OR hemotoxic* OR hematotoxic*OR hepatotox*OR
immunotox* OR liver toxic* OR mutagen* OR nephrotox* OR neurotox* OR reprotox* OR terato* OR
toxic* OR toxic effect* OR tumorigen* OR “in vivo” OR “in vitro”)
Time span: 2011–2017
Database: all
C.2.2.2. Metabolism and kinetics
Searches in Embase, PubMed and Web of Science were conducted to identify papers on metabolism
and kinetics by using the following search strings.
A. Embase
‘codeine’/mj/dd_pk,dd_pd OR ((‘codeine’:ti,ab OR ‘codein’:ti,ab OR ‘methyl morphine’:ti,ab OR
‘methyl morﬁn’:ti,ab OR ‘morphine methyl ether’:ti,ab OR ‘morphine monomethyl ether’:ti,ab) AND
(‘biological marker’/exp/mj OR ‘drug receptor’/exp/mj OR ‘metabolism’/exp/mj OR metabolism:ti,ab OR
kinetic*:ti,ab OR toxicokinetic*:ti,ab OR pharmacokinetic*:ti,ab OR absorption:ti,ab OR distribution:ti,
ab OR excretion:ti,ab OR mechanism*:ti,ab OR mode:ti,ab OR action:ti,ab OR biomarker*:ti,ab OR
biotransformation:ti,ab OR pharmacology:ti,ab OR receptor*:ti,ab OR “mu receptor”:ti,ab OR “opioid
receptor”:ti,ab))
Time span: 2011–2017
Database: all
B. PubMed
“Codeine/metabolism”[Mesh] OR “Codeine/pharmacokinetics”[Mesh] OR “Codeine/pharmacology”
[Mesh] OR ((Codeine[tiab] OR Codein[tiab] OR “N-Methylmorphine”[tiab] OR “76-57-3”[rn]) AND
(“Biomarkers”[Mesh] OR “Metabolism”[Mesh] OR “Receptors, Drug”[Mesh] OR “Receptors, Opioid,
mu”[Mesh] OR “Pharmacology”[Mesh] OR metabolism[tiab] OR kinetic*[tiab] OR toxicokinetic*[tiab] OR
pharmacokinetic*[tiab] OR absorption[tiab] OR distribution[tiab] OR excretion[tiab] OR mechanism*
[tiab] OR mode[tiab] OR action[tiab] OR biomarker*[tiab] OR biotransformation[tiab] OR pharmacology
[tiab] OR receptor*[tiab] OR “mu receptor”[tiab] OR “opioid receptor”[tiab]))
Time span: 2011–2017
C. Web of Science
(Codeine OR Codein OR “Methyl morphine” OR “methyl morﬁne” OR “morphine methyl ether” OR
“morphine monomethyl ether”) AND TOPIC: (metabolism OR kinetic* OR toxicokinetic* OR
pharmacokinetic* OR absorption OR distribution OR excretion OR mechanism* OR mode OR action OR
biomarker* OR biotransformation OR pharmacology OR receptor* OR “mu receptor” OR “opioid receptor”)
Time span: 2011–2017
Database: all
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C.2.2.3. Human data
Searches in Embase, PubMed and Web of Science were conducted to identify papers on human
data by using the following search strings.
A. Embase
‘codeine’/mj/dd_ae OR ((‘codeine’:ti,ab OR ‘codein’:ti,ab OR ‘methyl morphine’:ti,ab OR ‘methyl
morﬁn’:ti,ab OR ‘morphine methyl ether’:ti,ab OR ‘morphine monomethyl ether’:ti,ab) AND
(‘epidemiology’/exp/mj OR ‘adverse drug reaction’/exp/mj OR ‘volunteer’/exp OR ‘human experiment’/
exp OR ‘epidemiolog*’:ti,ab OR ‘case control’:ti,ab OR ‘case stud*’:ti,ab OR ‘cohort’:ti,ab OR ‘cross
sectional’:ti,ab OR ‘adverse effect*’:ti,ab OR ‘biomarker*’:ti,ab OR ‘human volunteers’:ti,ab OR ‘human
stud*’:ti,ab))
Time span: 2011–2017
Database: all
‘codeine’/mj/dd_ct OR ((‘codeine’:ti,ab OR ‘codein’:ti,ab OR ‘methyl morphine’:ti,ab OR ‘methyl
morﬁn’:ti,ab OR ‘morphine methyl ether’:ti,ab OR ‘morphine monomethyl ether’:ti,ab) AND (‘clinical
study’/exp/mj OR ‘clinical stud*’:ti,ab OR ‘clinical trial*’:ti,ab OR ‘case report*’:ti,ab)) AND [2011-
2017]/py
Time span: 2011–2017
Database: all
B. PubMed
“Codeine/adverse effects”[Mesh] OR ((Codeine[tiab] OR Codein[tiab] OR “N-Methylmorphine”[tiab]
OR “76-57-3”[rn]) AND (“Epidemiologic Studies”[Mesh] OR “Drug-Related Side Effects and Adverse
Reactions”[Mesh] OR “Volunteers”[Mesh] OR “Human Experimentation”[Mesh] OR epidemiolog*[tiab]
OR “case control”[tiab] OR case stud*[tiab] OR cohort[tiab] OR “cross sectional”[tiab] OR adverse
effect*[tiab] OR “human volunteers”[tiab] or human stud*[tiab]))
Time span: 2011–2017
(Codeine[tiab] OR Codein[tiab] OR “N-Methylmorphine”[tiab] OR “76-57-3”[rn]) AND (“Clinical
Study” [Publication Type] OR “Clinical Studies as Topic”[Mesh] OR “Case Reports” [Publication Type]
OR clinical stud*[tiab] OR clinical trial*[tiab] OR case report*[tiab])
Time span: 2011–2017
C. Web of Science
TOPIC: Codeine OR Codein OR “Methyl morphine” OR “methyl morﬁne” OR “morphine methyl
ether” OR “morphine monomethyl ether”) AND TOPIC: (epidemiolog* OR “case control” OR case stud*
OR cohort OR “cross sectional” OR adverse effect* OR “human volunteers” or human stud*)
Time span: 2011–2017
Database: all
TOPIC: (Codeine OR Codein OR “Methyl morphine” OR “methyl morﬁne” OR “morphine methyl
ether”) AND TOPIC: (clinical stud* OR clinical trial* OR case report*)
Time span: 2011–2017
Database: all
All the retrieved references for codeine were uploaded in Endnote and screened for relevance.
C.2.3. Search for papers regarding thebaine
C.2.3.1. Toxicity
Searches in Embase, PubMed and Web of Science were conducted to identify papers on toxicity
(in vitro and in vivo) by using the following search strings.
A. Embase
‘thebaine’/mj/dd_to OR ((‘thebaine’:ti,ab OR ‘thebain’:ti,ab OR ‘paramorphine’:ti,ab) AND (‘toxicity’/
exp/mj OR ‘toxicity testing’/exp/mj OR ‘toxicity assay’/exp/mj OR ‘toxic substance’/exp/mj OR
carcinogen*:ti,ab OR cardiotox*:ti,ab OR cytotox*:ti,ab OR ‘endocrine toxic*’:ti,ab OR ‘endocrine
disruptor*’:ti,ab OR genotox*:ti,ab OR hemotoxic*:ti,ab OR hematotoxic*:ti,ab OR hepatotox*:ti,ab OR
immunotox*:ti,ab OR ‘liver toxic*’:ti,ab OR mutagen*:ti,ab OR nephrotox*:ti,ab OR neurotox*:ti,ab OR
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reprotox*:ti,ab OR terato*:ti,ab OR toxic*:ti,ab OR ‘toxic effect*’:ti,ab OR tumorigen*:ti,ab OR ‘in vivo’:
ti,ab OR ‘in vitro’:ti,ab))
Time span: all years
Database: all
B. PubMed
“Thebaine/toxicity”[Mesh] OR ((thebaine[tiab] OR thebain[tiab] OR paramorphine[tiab] OR 115-37-
7[rn]) AND (“Toxic Actions”[Mesh] OR “Toxicity Tests”[Mesh] OR carcinogen*[tiab] OR cardiotox*[tiab]
OR cytotox*[tiab] OR endocrine toxic*[tiab] OR endocrine disruptor*[tiab] OR genotox*[tiab] OR
hemotoxic*[tiab] OR hematotoxic*[tiab]OR hepatotox*[tiab]OR immunotox*[tiab] OR liver toxic*[tiab]
OR mutagen*[tiab] OR nephrotox*[tiab] OR neurotox*[tiab] OR reprotox*[tiab] OR terato*[tiab] OR
toxic*[tiab] OR toxic effect*[tiab] OR tumorigen*[tiab] OR “in vivo”[tiab] OR “in vitro”[tiab]))
Time span: all years
C. Web of Science
TOPIC: (thebaine OR thebain OR paramorphine) AND TOPIC: (carcinogen* OR cardiotox* OR
cytotox* OR endocrine toxic* OR endocrine disruptor* OR genotox* OR hemotoxic* OR hematotoxic*
OR hepatotox*OR immunotox* OR liver toxic* OR mutagen* OR nephrotox* OR neurotox* OR
reprotox* OR terato* OR toxic* OR toxic effect* OR tumorigen* OR “in vivo” OR “in vitro”)
Time span: all years
Database: all
C.2.3.2. Metabolism and kinetics
Searches in Embase, PubMed and Web of Science were conducted to identify papers on metabolism
and kinetics by using the following search strings.
A. Embase
‘thebaine’/mj/dd_pk,dd_pd OR ((‘thebaine’:ti,ab OR ‘thebain’:ti,ab OR ‘paramorphine’:ti,ab) AND
(‘biological marker’/exp/mj OR ‘drug receptor’/exp/mj OR ‘metabolism’/exp/mj OR metabolism:ti,ab OR
kinetic*:ti,ab OR toxicokinetic*:ti,ab OR pharmacokinetic*:ti,ab OR absorption:ti,ab OR distribution:ti,
ab OR excretion:ti,ab OR mechanism*:ti,ab OR mode:ti,ab OR action:ti,ab OR biomarker*:ti,ab OR
biotransformation:ti,ab OR pharmacology:ti,ab OR receptor*:ti,ab OR “mu receptor”:ti,ab OR “opioid
receptor”:ti,ab))
Time span: all years
Database: all
B. PubMed
(“Thebaine/metabolism”[Mesh] OR “Thebaine/pharmacokinetics”[Mesh] OR “Thebaine/
pharmacology”[Mesh]) OR ((thebaine[tiab] OR thebain[tiab] OR paramorphine[tiab] OR 115-37-7[rn])
AND (“Biomarkers”[Mesh] OR “Metabolism”[Mesh] OR “Receptors, Drug”[Mesh] OR “Receptors, Opioid,
mu”[Mesh] OR “Pharmacology”[Mesh] OR metabolism[tiab] OR kinetic*[tiab] OR toxicokinetic*[tiab]
OR pharmacokinetic*[tiab] OR absorption[tiab] OR distribution[tiab] OR excretion[tiab] OR
mechanism*[tiab] OR mode[tiab] OR action[tiab] OR biomarker*[tiab] OR biotransformation[tiab] OR
pharmacology[tiab] OR receptor*[tiab] OR “mu receptor”[tiab] OR “opioid receptor”[tiab]))
Time span: all years
C. Web of Science
TOPIC: (thebaine OR thebain OR paramorphine) AND TOPIC: (metabolism OR kinetic* OR
toxicokinetic* OR pharmacokinetic* OR absorption OR distribution OR excretion OR mechanism* OR
mode OR action OR biomarker* OR biotransformation OR pharmacology OR receptor* OR “mu
receptor” OR “opioid receptor”)
Time span: all years
Database: all
C.2.3.3. Human data
Searches in Embase, PubMed and Web of Science were conducted to identify papers on human
data by using the following search strings.
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A. Embase
‘thebaine’/mj/dd_ae OR ((‘thebaine’:ti,ab OR ‘thebain’:ti,ab OR ‘paramorphine’:ti,ab) AND
(‘epidemiology’/exp/mj OR ‘adverse drug reaction’/exp/mj OR ‘volunteer’/exp OR ‘human experiment’/exp
OR ‘epidemiolog*’:ti,ab OR ‘case control’:ti,ab OR ‘case stud*’:ti,ab OR ‘cohort’:ti,ab OR ‘cross sectional’:ti,
ab OR ‘adverse effect*’:ti,ab OR ‘biomarker*’:ti,ab OR ‘human volunteers’:ti,ab OR ‘human stud*’:ti,ab))
Time span: all years
Database: all
‘thebaine’/mj/dd_ct OR ((‘thebaine’:ti,ab OR ‘thebain’:ti,ab OR ‘paramorphine’:ti,ab) AND (‘clinical
study’/exp/mj OR ‘clinical stud*’:ti,ab OR ‘clinical trial*’:ti,ab OR ‘case report*’:ti,ab)) AND [2011-
2017]/py
Time span: all years
Database: all
B. PubMed
“Thebaine/adverse effects”[Mesh] OR “Thebaine/pharmacokinetics”[Mesh] OR “Thebaine/
pharmacology”[Mesh] OR ((thebaine[tiab] OR thebain[tiab] OR paramorphine[tiab] OR 115-37-7[rn])
AND (“Epidemiologic Studies”[Mesh] OR “Drug-Related Side Effects and Adverse Reactions”[Mesh] OR
“Volunteers”[Mesh] OR “Human Experimentation”[Mesh] OR epidemiolog*[tiab] OR “case control”[tiab]
OR case stud*[tiab] OR cohort[tiab] OR “cross sectional”[tiab] OR adverse effect*[tiab] OR “human
volunteers”[tiab] or human stud*[tiab]))
Time span: all years
(thebaine[tiab] OR thebain[tiab] OR paramorphine[tiab] OR 115-37-7[rn]) AND (“Clinical Study”
[Publication Type] OR “Clinical Studies as Topic”[Mesh] OR “Case Reports” [Publication Type] OR
clinical stud*[tiab] OR clinical trial*[tiab] OR case report*[tiab])
Time span: all years
C. Web of Science
TOPIC: (thebaine OR thebain OR paramorphine) AND TOPIC: (epidemiolog* OR “case control” OR
case stud* OR cohort OR “cross sectional” OR adverse effect* OR “human volunteers” or human stud*)
Time span: all years
Database: all
TOPIC: (thebaine OR thebain OR paramorphine) AND TOPIC: (clinical stud* OR clinical trial* OR
case report*)
Time span: all years
Database: all
All the retrieved references were uploaded in Endnote and screened for relevance.
C.2.3.4. Receptor binding
Searches in PubMed and Web of Science were conducted to identify papers on receptor binding by
using the following search strings.
A. PubMed
thebaine and receptor
Time span: all years
B. Web of Science
TOPIC: (thebaine and receptor)
Time span: all years
Database: all
All the retrieved references in PubMed (50) and Web of Science (73) were uploaded in Endnote
and, after removal of the duplicates, 103 references were screened for relevance.
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C.2.4. Search for papers regarding oripavine
C.2.4.1. Toxicity
Searches in Embase, PubMed and Web of Science were conducted to identify papers on toxicity
(in vitro and in vivo) by using the following search strings.
A. Embase
‘oripavine’/mj/dd_to OR ((‘oripavine’:ti,ab) AND (‘toxicity’/exp/mj OR ‘toxicity testing’/exp/mj OR
‘toxicity assay’/exp/mj OR ‘toxic substance’/exp/mj OR carcinogen*:ti,ab OR cardiotox*:ti,ab OR
cytotox*:ti,ab OR ‘endocrine toxic*’:ti,ab OR ‘endocrine disruptor*’:ti,ab OR genotox*:ti,ab OR
hemotoxic*:ti,ab OR hematotoxic*:ti,ab OR hepatotox*:ti,ab OR immunotox*:ti,ab OR ‘liver toxic*’:ti,
ab OR mutagen*:ti,ab OR nephrotox*:ti,ab OR neurotox*:ti,ab OR reprotox*:ti,ab OR terato*:ti,ab OR
toxic*:ti,ab OR ‘toxic effect*’:ti,ab OR tumorigen*:ti,ab OR ‘in vivo’:ti,ab OR ‘in vitro’:ti,ab))
Time span: all years
Database: all
B. PubMed
(“oripavine”[Supplementary Concept] OR “oripavine”[tiab] OR 467-04-9[rn]) AND (“Toxic
Actions”[Mesh] OR “Toxicity Tests”[Mesh] OR carcinogen*[tiab] OR cardiotox*[tiab] OR cytotox*[tiab]
OR endocrine toxic*[tiab] OR endocrine disruptor*[tiab] OR genotox*[tiab] OR hemotoxic*[tiab] OR
hematotoxic*[tiab]OR hepatotox*[tiab]OR immunotox*[tiab] OR liver toxic*[tiab] OR mutagen*[tiab]
OR nephrotox*[tiab] OR neurotox*[tiab] OR reprotox*[tiab] OR terato*[tiab] OR toxic*[tiab] OR toxic
effect*[tiab] OR tumorigen*[tiab] OR “in vivo”[tiab] OR “in vitro”[tiab])
Time span: all years
C. Web of Science
TOPIC: (oripavine) AND TOPIC: (carcinogen* OR cardiotox* OR cytotox* OR endocrine toxic* OR
endocrine disruptor* OR genotox* OR hemotoxic* OR hematotoxic*OR hepatotox*OR immunotox* OR
liver toxic* OR mutagen* OR nephrotox* OR neurotox* OR reprotox* OR terato* OR toxic* OR toxic
effect* OR tumorigen* OR “in vivo” OR “in vitro”)
Time span: all years
Database: all
C.2.4.2. Metabolism and kinetics
Searches in Embase, PubMed and Web of Science were conducted to identify papers on metabolism
and kinetics by using the following search strings.
A. Embase
‘oripavine’/mj/dd_ae,dd_to OR ((‘oripavine’:ti,ab) AND (‘biological marker’/exp/mj OR ‘drug receptor’/
exp/mj OR ‘metabolism’/exp/mj OR metabolism:ti,ab OR kinetic*:ti,ab OR toxicokinetic*:ti,ab OR
pharmacokinetic*:ti,ab OR absorption:ti,ab OR distribution:ti,ab OR excretion:ti,ab OR mechanism*:ti,ab
OR mode:ti,ab OR action:ti,ab OR biomarker*:ti,ab OR biotransformation:ti,ab OR pharmacology:ti,ab
OR receptor*:ti,ab OR “mu receptor”:ti,ab OR “opioid receptor”:ti,ab))
Time span: all years
Database: all
B. PubMed
(“oripavine”[Supplementary Concept] OR “oripavine”[tiab] OR 467-04-9[rn]) AND
(“Biomarkers”[Mesh] OR “Metabolism”[Mesh] OR “Receptors, Drug”[Mesh] OR “Receptors, Opioid,
mu”[Mesh] OR “Pharmacology”[Mesh] OR metabolism[tiab] OR kinetic*[tiab] OR toxicokinetic*[tiab] OR
pharmacokinetic*[tiab] OR absorption[tiab] OR distribution[tiab] OR excretion[tiab] OR mechanism*
[tiab] OR mode[tiab] OR action[tiab] OR biomarker*[tiab] OR biotransformation[tiab] OR pharmacology
[tiab] OR receptor*[tiab] OR “mu receptor”[tiab] OR “opioid receptor”[tiab])
Time span: all years
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C. Web of Science
TOPIC: (oripavine) AND TOPIC: (metabolism OR kinetic* OR toxicokinetic* OR pharmacokinetic* OR
absorption OR distribution OR excretion OR mechanism* OR mode OR action OR biomarker* OR
biotransformation OR pharmacology OR receptor* OR “mu receptor” OR “opioid receptor”)
Time span: all years
Database: all
C.2.4.3. Human data
Searches in Embase, PubMed and Web of Science were conducted to identify papers on human
data by using the following search strings.
A. Embase
‘oripavine’/mj/dd_ae OR ((‘oripavine’:ti,ab) AND (‘epidemiology’/exp/mj OR ‘adverse drug reaction’/
exp/mj OR ‘volunteer’/exp OR ‘human experiment’/exp OR ‘epidemiolog*’:ti,ab OR ‘case control’:ti,ab
OR ‘case stud*’:ti,ab OR ‘cohort’:ti,ab OR ‘cross sectional’:ti,ab OR ‘adverse effect*’:ti,ab OR
‘biomarker*’:ti,ab OR ‘human volunteers’:ti,ab OR ‘human stud*’:ti,ab))
Time span: all years
Database: all
‘oripavine’/mj/dd_ct OR (‘oripavine:ti,ab AND (‘clinical study’/exp/mj OR ‘clinical stud*’:ti,ab OR
‘clinical trial*’:ti,ab OR ‘case report*’:ti,ab))
Time span: all years
Database: all
B. PubMed
(“oripavine”[Supplementary Concept] OR “oripavine”[tiab] OR 467-04-9[rn]) AND (“Epidemiologic
Studies”[Mesh] OR “Drug-Related Side Effects and Adverse Reactions”[Mesh] OR “Volunteers”[Mesh]
OR “Human Experimentation”[Mesh] OR epidemiolog*[tiab] OR “case control”[tiab] OR case stud*
[tiab] OR cohort[tiab] OR “cross sectional”[tiab] OR adverse effect*[tiab] OR “human volunteers”[tiab]
or human stud*[tiab])
Time span: all years
(“oripavine”[Supplementary Concept] OR “oripavine”[tiab] OR 467-04-9[rn]) AND (“Clinical Study”
[Publication Type] OR “Clinical Studies as Topic”[Mesh] OR “Case Reports” [Publication Type] OR
clinical stud*[tiab] OR clinical trial*[tiab] OR case report*[tiab])
Time span: all years
C. Web of Science
TOPIC: (oripavine) AND TOPIC: (epidemiolog* OR “case control” OR case stud* OR cohort OR
“cross sectional” OR adverse effect* OR “human volunteers” or human stud*)
Time span: all years
Database: all
TOPIC: (oripavine) AND TOPIC: (clinical stud* OR clinical trial* OR case report*)
Time span: all years
Database: all
All the retrieved references were uploaded in Endnote and were screened for relevance.
C.2.5. Search for papers regarding noscapine
C.2.5.1. Toxicity
Searches in Embase, PubMed and Web of Science were conducted to identify papers on toxicity
(in vitro and in vivo) by using the following search strings.
A. Embase
‘noscapine’/mj/dd_to OR ((‘noscapine’:ti,ab OR ‘noscapin’:ti,ab OR ‘narcotine’:ti,ab) AND (‘toxicity’/
exp/mj OR ‘toxicity testing’/exp/mj OR ‘toxicity assay’/exp/mj OR ‘toxic substance’/exp/mj OR
carcinogen*:ti,ab OR cardiotox*:ti,ab OR cytotox*:ti,ab OR ‘endocrine toxic*’:ti,ab OR ‘endocrine
disruptor*’:ti,ab OR genotox*:ti,ab OR hemotoxic*:ti,ab OR hematotoxic*:ti,ab OR hepatotox*:ti,ab OR
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immunotox*:ti,ab OR ‘liver toxic*’:ti,ab OR mutagen*:ti,ab OR nephrotox*:ti,ab OR neurotox*:ti,ab OR
reprotox*:ti,ab OR terato*:ti,ab OR toxic*:ti,ab OR ‘toxic effect*’:ti,ab OR tumorigen*:ti,ab OR ‘in vivo’:
ti,ab OR ‘in vitro’:ti,ab))
Time span: 2011–2017
Database: all
B. PubMed
“Noscapine/toxicity”[Mesh] OR ((“noscapine”[tiab] OR “narcotine”[tiab] OR “noscapin”[tiab] OR 128-
62-1[rn]) AND (“Toxic Actions”[Mesh] OR “Toxicity Tests”[Mesh] OR carcinogen*[tiab] OR cardiotox*
[tiab] OR cytotox*[tiab] OR endocrine toxic*[tiab] OR endocrine disruptor*[tiab] OR genotox*[tiab] OR
hemotoxic*[tiab] OR hematotoxic*[tiab]OR hepatotox*[tiab]OR immunotox*[tiab] OR liver toxic*[tiab]
OR mutagen*[tiab] OR nephrotox*[tiab] OR neurotox*[tiab] OR reprotox*[tiab] OR terato*[tiab] OR
toxic*[tiab] OR toxic effect*[tiab] OR tumorigen*[tiab] OR “in vivo”[tiab] OR “in vitro”[tiab]))
Time span: 2011–2017
C. Web of Science
TOPIC: (Noscapine OR Noscapin OR Narcotine) AND TOPIC: (carcinogen* OR cardiotox* OR cytotox*
OR endocrine toxic* OR endocrine disruptor* OR genotox* OR hemotoxic* OR hematotoxic* OR
hepatotox*OR immunotox* OR liver toxic* OR mutagen* OR nephrotox* OR neurotox* OR reprotox* OR
terato* OR toxic* OR toxic effect* OR tumorigen* OR “in vivo” OR “in vitro”)
Time span: 2011–2017
Database: all
C.2.5.2. Metabolism and kinetics
Searches in Embase, PubMed and Web of Science were conducted to identify papers on metabolism
and kinetics by using the following search strings.
A. Embase
‘noscapine’/mj/dd_pk,dd_pd OR ((‘noscapine’:ti,ab OR ‘noscapin’:ti,ab OR ‘narcotine’:ti,ab) AND
(‘biological marker’/exp/mj OR ‘drug receptor’/exp/mj OR ‘metabolism’/exp/mj OR metabolism:ti,ab OR
kinetic*:ti,ab OR toxicokinetic*:ti,ab OR pharmacokinetic*:ti,ab OR absorption:ti,ab OR distribution:ti,
ab OR excretion:ti,ab OR mechanism*:ti,ab OR mode:ti,ab OR action:ti,ab OR biomarker*:ti,ab OR
biotransformation:ti,ab OR pharmacology:ti,ab OR receptor*:ti,ab OR “mu receptor”:ti,ab OR “opioid
receptor”:ti,ab))
Time span: 2011–2017
Database: all
B. PubMed
“Noscapine/metabolism”[Mesh] OR “Noscapine/pharmacokinetics”[Mesh] OR “Noscapine/
pharmacology”[Mesh] OR ((“noscapine”[tiab] OR “narcotine”[tiab] OR “noscapin”[tiab] OR 128-62-1
[rn]) AND (“Biomarkers”[Mesh] OR “Metabolism”[Mesh] OR “Receptors, Drug”[Mesh] OR “Receptors,
Opioid, mu”[Mesh] OR “Pharmacology”[Mesh] OR metabolism[tiab] OR kinetic*[tiab] OR toxicokinetic*
[tiab] OR pharmacokinetic*[tiab] OR absorption[tiab] OR distribution[tiab] OR excretion[tiab] OR
mechanism*[tiab] OR mode[tiab] OR action[tiab] OR biomarker*[tiab] OR biotransformation[tiab] OR
pharmacology[tiab] OR receptor*[tiab] OR “mu receptor”[tiab] OR “opioid receptor”[tiab]))
Time span: 2011–2017
C. Web of Science
TOPIC: (Noscapine OR Noscapin OR Narcotine) AND TOPIC: (metabolism OR kinetic* OR
toxicokinetic* OR pharmacokinetic* OR absorption OR distribution OR excretion OR mechanism* OR
mode OR action OR biomarker* OR biotransformation OR pharmacology OR receptor* OR “mu
receptor” OR “opioid receptor”)
Time span: 2011–2017
Database: all
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C.2.5.3. Human data
Searches in Embase, PubMed and Web of Science were conducted to identify papers on human
data by using the following search strings.
A. Embase
‘noscapine’/mj/dd_ae OR ((‘noscapine’:ti,ab OR ‘noscapin’:ti,ab OR ‘narcotine’:ti,ab) AND
(‘epidemiology’/exp/mj OR ‘adverse drug reaction’/exp/mj OR ‘volunteer’/exp OR ‘human experiment’/
exp OR ‘epidemiolog*’:ti,ab OR ‘case control’:ti,ab OR ‘case stud*’:ti,ab OR ‘cohort’:ti,ab OR ‘cross
sectional’:ti,ab OR ‘adverse effect*’:ti,ab OR ‘biomarker*’:ti,ab OR ‘human volunteers’:ti,ab OR ‘human
stud*’:ti,ab))
Time span: 2011–2017
Database: all
‘noscapine’/mj/dd_ct OR ‘noscapine’:ti,ab OR ‘noscapin’:ti,ab OR ‘narcotine’:ti,ab AND (‘clinical study’/
exp/mj OR ‘clinical stud*’:ti,ab OR ‘clinical trial*’:ti,ab OR ‘case report*’:ti,ab) AND [2011-2017]/py
Time span: 2011–2017
Database: all
B. PubMed
“Noscapine/adverse effects”[Mesh] OR ((“noscapine”[tiab] OR “narcotine”[tiab] OR “noscapin”[tiab]
OR 128-62-1[rn]) AND (“Epidemiologic Studies”[Mesh] OR “Drug-Related Side Effects and Adverse
Reactions”[Mesh] OR “Volunteers”[Mesh] OR “Human Experimentation”[Mesh] OR epidemiolog*[tiab]
OR “case control”[tiab] OR case stud*[tiab] OR cohort[tiab] OR “cross sectional”[tiab] OR adverse
effect*[tiab] OR “human volunteers”[tiab] or human stud*[tiab]))
Time span: 2011–2017
(“noscapine”[tiab] OR “narcotine”[tiab] OR “noscapin”[tiab] OR 128-62-1[rn]) AND (“Clinical Study”
[Publication Type] OR “Clinical Studies as Topic”[Mesh] OR “Case Reports” [Publication Type] OR
clinical stud*[tiab] OR clinical trial*[tiab] OR case report*[tiab])
Time span: 2011–2017
C. Web of Science
TOPIC: (Noscapine OR Noscapin OR Narcotine) AND TOPIC: (epidemiolog* OR “case control” OR case
stud* OR cohort OR “cross sectional” OR adverse effect* OR “human volunteers” or human stud*)
Time span: 2011–2017
Database: all
TOPIC: (Noscapine OR Noscapin OR Narcotine) AND TOPIC: (clinical stud* OR clinical trial* OR case
report*)
Time span: 2011–2017
Database: all
All the retrieved references were uploaded in Endnote and screened for relevance.
C.2.6. Search for papers regarding papaverine
C.2.6.1. Toxicity
Searches in Embase, PubMed and Web of Science were conducted to identify papers on toxicity
(in vitro and in vivo) by using the following search strings.
A. Embase
‘papaverine’/mj/dd_to OR ((‘papaverine’:ti,ab OR ‘papaverin’:ti,ab) AND (‘toxicity’/exp/mj OR
‘toxicity testing’/exp/mj OR ‘toxicity assay’/exp/mj OR ‘toxic substance’/exp/mj OR carcinogen*:ti,ab
OR cardiotox*:ti,ab OR cytotox*:ti,ab OR ‘endocrine toxic*’:ti,ab OR ‘endocrine disruptor*’:ti,ab OR
genotox*:ti,ab OR hemotoxic*:ti,ab OR hematotoxic*:ti,ab OR hepatotox*:ti,ab OR immunotox*:ti,ab
OR ‘liver toxic*’:ti,ab OR mutagen*:ti,ab OR nephrotox*:ti,ab OR neurotox*:ti,ab OR reprotox*:ti,ab
OR terato*:ti,ab OR toxic*:ti,ab OR ‘toxic effect*’:ti,ab OR tumorigen*:ti,ab OR ‘in vivo’:ti,ab OR
‘in vitro’:ti,ab))
Time span: 2011–2017
Database: all
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B. PubMed
“Papaverine/toxicity”[Mesh] OR ((papaverine[tiab] OR papaverin[tiab] OR 58-74-2[rn]) AND (“Toxic
Actions”[Mesh] OR “Toxicity Tests”[Mesh] OR carcinogen*[tiab] OR cardiotox*[tiab] OR cytotox*[tiab]
OR endocrine toxic*[tiab] OR endocrine disruptor*[tiab] OR genotox*[tiab] OR hemotoxic*[tiab] OR
hematotoxic*[tiab]OR hepatotox*[tiab]OR immunotox*[tiab] OR liver toxic*[tiab] OR mutagen*[tiab]
OR nephrotox*[tiab] OR neurotox*[tiab] OR reprotox*[tiab] OR terato*[tiab] OR toxic*[tiab] OR toxic
effect*[tiab] OR tumorigen*[tiab] OR “in vivo”[tiab] OR “in vitro”[tiab]))
Time span: 2011–2017
C. Web of Science
TOPIC: (Papaverine OR Papaverin) AND TOPIC: (carcinogen* OR cardiotox* OR cytotox* OR
endocrine toxic* OR endocrine disruptor* OR genotox* OR hemotoxic* OR hematotoxic* OR
hepatotox*OR immunotox* OR liver toxic* OR mutagen* OR nephrotox* OR neurotox* OR reprotox*
OR terato* OR toxic* OR toxic effect* OR tumorigen* OR “in vivo” OR “in vitro”)
Time span: 2011–2017
Database: all
C.2.6.2. Metabolism and kinetics
Searches in Embase, PubMed and Web of Science were conducted to identify papers on metabolism
and kinetics by using the following search strings.
A. Embase
‘papaverine’/mj/dd_pk,dd_pd OR ((‘papaverine’:ti,ab OR ‘papaverin’:ti,ab) AND (‘biological marker’/
exp/mj OR ‘drug receptor’/exp/mj OR ‘metabolism’/exp/mj OR metabolism:ti,ab OR kinetic*:ti,ab OR
toxicokinetic*:ti,ab OR pharmacokinetic*:ti,ab OR absorption:ti,ab OR distribution:ti,ab OR excretion:ti,
ab OR mechanism*:ti,ab OR mode:ti,ab OR action:ti,ab OR biomarker*:ti,ab OR biotransformation:ti,ab
OR pharmacology:ti,ab OR receptor*:ti,ab OR “mu receptor”:ti,ab OR “opioid receptor”:ti,ab))
Time span: 2011–2017
Database: all
B. PubMed
“Papaverine/metabolism”[Mesh] OR “Papaverine/pharmacokinetics”[Mesh] OR “Papaverine/pharma-
cology”[Mesh] OR ((papaverine[tiab] OR papaverin[tiab] OR 58-74-2[rn]) AND (“Biomarkers”[Mesh] OR
“Metabolism”[Mesh] OR “Receptors, Drug”[Mesh] OR “Receptors, Opioid, mu”[Mesh] OR “Pharma-
cology”[Mesh] OR metabolism[tiab] OR kinetic*[tiab] OR toxicokinetic*[tiab] OR pharmacokinetic*[tiab]
OR absorption[tiab] OR distribution[tiab] OR excretion[tiab] OR mechanism*[tiab] OR mode[tiab] OR
action[tiab] OR biomarker*[tiab] OR biotransformation[tiab] OR pharmacology[tiab] OR receptor*[tiab]
OR “mu receptor”[tiab] OR “opioid receptor”[tiab]))
Time span: 2011–2017
C. Web of Science
TOPIC: (Papaverine OR Papaverin) AND TOPIC: (metabolism OR kinetic* OR toxicokinetic* OR
pharmacokinetic* OR absorption OR distribution OR excretion OR mechanism* OR mode OR action OR
biomarker* OR biotransformation OR pharmacology OR receptor* OR “mu receptor” OR “opioid receptor”)
Time span: 2011–2017
Database: all
C.2.6.3. Human data
Searches in Embase, PubMed and Web of Science were conducted to identify papers on human
data by using the following search strings.
A. Embase
‘papaverine’/mj/dd_ae OR ((‘papaverine’:ti,ab OR ‘papaverin’:ti,ab) AND (‘epidemiology’/exp/mj OR
‘adverse drug reaction’/exp/mj OR ‘volunteer’/exp OR ‘human experiment’/exp OR ‘epidemiolog*’:ti,ab
OR ‘case control’:ti,ab OR ‘case stud*’:ti,ab OR ‘cohort’:ti,ab OR ‘cross sectional’:ti,ab OR ‘adverse
effect*’:ti,ab OR ‘biomarker*’:ti,ab OR ‘human volunteers’:ti,ab OR ‘human stud*’:ti,ab))
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Time span: 2011–2017
Database: all
‘papaverine’/mj/dd_ct OR ((‘papaverine’:ti,ab OR ‘papaverin’:ti,ab) AND (‘clinical study’/exp/mj OR
‘clinical stud*’:ti,ab OR ‘clinical trial*’:ti,ab OR ‘case report*’:ti,ab)) AND [2011-2017]/py
Time span: 2011–2017
B. PubMed
“Papaverine/adverse effects”[Mesh] OR ((papaverine[tiab] OR papaverin[tiab] OR 58-74-2[rn]) AND
(“Epidemiologic Studies”[Mesh] OR “Drug-Related Side Effects and Adverse Reactions”[Mesh] OR
“Volunteers”[Mesh] OR “Human Experimentation”[Mesh] OR epidemiolog*[tiab] OR “case control”[tiab]
OR case stud*[tiab] OR cohort[tiab] OR “cross sectional”[tiab] OR adverse effect*[tiab] OR “human
volunteers”[tiab] or human stud*[tiab]))
Time span: 2011–2017
(papaverine[tiab] OR papaverin[tiab] OR 58-74-2[rn]) AND (“Clinical Study” Publication Type] OR
“Clinical Studies as Topic”[Mesh] OR “Case Reports” [Publication Type] OR clinical stud*[tiab] OR
clinical trial*[tiab] OR case report*[tiab])
Time span: 2011–2017
C. Web of Science
TOPIC: (Papaverine OR Papaverin) AND TOPIC: (epidemiolog* OR “case control” OR case stud* OR
cohort OR “cross sectional” OR adverse effect* OR “human volunteers” or human stud*)
Time span: 2011–2017
Database: all
TOPIC: (Papaverine OR Papaverin) AND TOPIC: (clinical stud* OR clinical trial* OR case report*)
Time span: 2011–2017
Database: all
All the retrieved references were uploaded in Endnote and screened for relevance.
C.2.7. Search for papers regarding poppy seeds
C.2.7.1. Human data
Searches in Embase, PubMed and Web of Science were conducted to identify papers on adverse
effects in humans related to the ingestion of poppy seed using the following search strings:
A. Embase
‘poppy seed’/exp OR ‘poppy seed*’:ti,ab AND (‘clinical study’/exp/mj OR ‘clinical stud*’:ti,ab OR
‘clinical trial*’:ti,ab OR ‘case report*’:ti,ab OR ‘case stud*’:ti,ab OR ‘intoxication’/exp/mj OR
‘intoxication*:ti,ab’ OR ‘adverse effect*’:ti,ab OR ‘human experiment’/exp OR ‘human stud*’:ti,ab OR
‘volunteer’/exp OR ‘human volunteer*’:ti,ab) AND [2011-2017]/py
Time span: 2011–2017
Database: all
B. PubMed
poppy seed*[tiab] AND (“Clinical Study” [Publication Type] OR “Clinical Studies as Topic”[Mesh] OR
“Case Reports” [Publication Type] OR clinical stud*[tiab] OR clinical trial*[tiab] OR case report*[tiab]
OR case stud*[tiab] OR “Poisoning”[Mesh] OR intoxication*[tiab] OR adverse effect*[tiab] OR “Human
Experimentation”[Mesh] OR human stud*[tiab] OR “Volunteers”[Mesh] OR “human volunteer*”[tiab])
Time span: 2011–2017
C. Web of Science
TOPIC: (poppy seed*) AND TOPIC: (clinical stud* OR clinical trial* OR case report* OR case stud*
OR adverse effect* OR intoxication* OR poisoning* OR human stud* OR human volunteer*)
Time span: 2011–2017
Database: all
All the retrieved references were uploaded in Endnote and screened for relevance.
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C.3. Exclusion criteria for abstracts
The titles and abstracts of the references retrieved from the literature search described in Section C.2
were screened to identify the relevant papers. Papers on the following subjects were excluded:
• Papers related to the use of analgesic opioids in the clinical practice and/or in speciﬁc category
of patients (e.g. cancer patients) not reporting adverse effects (except reviews);
• Papers related to opioids sparing effects and rotation in clinical practice (i.e. the strategy
applied during opioid therapy for pain treatment that refers to a switch from one opioid to
another in an effort to improve clinical outcomes);
• Papers related to the pattern of prescription and use of opioids in clinical practice and/or self-
medication;
• Papers related to the risk of fall injuries after consumption of analgesic opioids;
• Papers related to the development of vaccines against drugs of abuse (including opioids);
• Papers related to the detection and/or distribution of opioids in post-mortem tissue/organs;
• Papers describing the analgesic activity and/or adverse effects of opium alkaloids derivatives;
• Studies reporting adverse effects in opium smokers (no clear information about the composition
of the substances smoked and therefore not useful for identiﬁcation reference point);
• Papers related to repeated use and/or exposure to high doses of opium alkaloids, i.e. misuse,
abuse, hyperalgesia and withdrawal syndrome;
• Human studies in which morphine was administered post-operatively for pain control (with the
exception of those explicitly reporting opioid-related adverse effects);
• Studies evaluating the effects of morphine on cancer growth/recurrence (except reviews);
• Human studies in which opium alkaloids were not administered via oral route;
• Toxicity studies in experimental animals in which the route of exposure was not oral (except
for acute toxicity, immunotoxicity and genotoxicity studies);
• Studies in experimental animals evaluating the molecular mechanism of opioid analgesic
effects, tolerance and/or withdrawal syndrome (except studies related to the pharmacology of
the opioid receptor).
C.4. EFSA guidance documents applied for the risk assessment
The following EFSA guidance documents pertaining to risk assessment were followed for the
development of the risk assessment:
• EFSA (European Food Safety Authority), 2005. Opinion of the Scientiﬁc Committee on a
request from EFSA related to a harmonised approach for risk assessment of substances which
are both genotoxic and carcinogenic. EFSA Journal 2005;3(10):282, 31 pp. https://doi.org/10.
2903/j.efsa.2005.282
• EFSA (European Food Safety Authority), 2006. Guidance of the Scientiﬁc Committee on a
request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal, 4
(12):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.438
• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
transparency in the scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: general
principles. The EFSA Journal 2009;6(9):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051
• EFSA (European Food Safety Authority), 2010. Standard sample description for food and feed.
EFSA Journal 2010;8(1):1457, 54 pp. https://doi.org/10.2903/j.efsa.2010.1457
• EFSA (European Food Safety Authority), 2010. Management of left-censored data in dietary
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.
org/10.2903/j.efsa.2010.1557
• EFSA (European Food Safety Authority), 2011. Overview of the procedures currently used at
EFSA for the assessment of dietary exposure to different chemical substances. EFSA Journal
2011;9(12):2490, 33 pp. https://doi.org/10.2903/j.efsa.2011.2490
• EFSA (European Food Safety Authority), 2011. Use of the EFSA Comprehensive European Food
Consumption Database in Intakes Assessment. EFSA Journal 2011;9(3):2097, 34 pp. https://
doi.org/10.2903/j.efsa.2011.2097
• EFSA Scientiﬁc Committee, 2011. Scientiﬁc Opinion on genotoxicity testing strategies applicable
to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. https://doi.org/10.
2903/j.efsa.2011.2379
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• EFSA Scientiﬁc Committee, 2012. Guidance on selected default values to be used by the EFSA
Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA
Journal 2012;10(3):2579, 32 pp. https://doi.org/10.2903/j.efsa.2012.2579
• EFSA Scientiﬁc Committee, 2012. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA
Journal 2012;10(5):2664, 43 pp. https://doi.org/10.2903/j.efsa.2012.2664
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S,
Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D,
Benfenati E, Chaudhry QM, Craig P, Frampton G, Greiner M, Hart A, Hogstrand C, Lambre C, Luttik
R, Makowski D, Siani A, Wahlstroem H, Aguilera J, Dorne J-L, Fernandez Dumont A, Hempen M,
Valtue~na Martınez S, Martino L, Smeraldi C, Terron A, Georgiadis N and Younes M, 2017. Scientiﬁc
Opinion on the guidance on the use of the weight of evidence approach in scientiﬁc assessments.
EFSA Journal 2017;15(8):4971, 69 pp. https://doi.org/10.2903/j.efsa.2017.4971
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S,
Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck
D, Younes M, Bresson J-L, Grifﬁn J, Hougaard Benekou S, van Loveren H, Luttik R, Messean A,
Penninks A, Ru G, Stegeman JA, van der Werf W, Westendorf J, Woutersen RA, Barizzone F,
Bottex B, Lanzoni A, Georgiadis N and Alexander J, 2017. Guidance on the assessment of the
biological relevance of data in scientiﬁc assessments. EFSA Journal 2017;15(8):4970, 73 pp.
https://doi.org/10.2903/j.efsa.2017.4970
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Appendix D – Detailed description of studies on mode of action
D.1. Apoptosis
A number of in vivo studies have reported the occurrence of apoptotic cell death in the nervous
system upon administration of morphine via different routes.
Intrathecal infusion of 20 lg twice daily for 7 days induces apoptosis in rat spinal cord with increased
caspase 3, Bax, decreased Bcl-2. NMDA receptors were also involved suggesting that glutamate may
have a role (Mao et al., 2002). Apoptosis was also induced in rat spinal cord via a caspase-mediated
mechanism following intrathecal administration of 10 lg twice daily for 7 days (Lim et al., 2005).
Morphine administered to rats i.p. (4 mg/kg per day for the ﬁrst 10 days, 8 mg/kg per day
between 11 and 20 days, and 12 mg/kg per day between 21 and 30 days) has been shown to induce
apoptosis in the parietal, frontal, temporal, occipital, pyriform, entorhinal cortex as well as in the
hippocampal CA1, CA2 and CA3 regions, and in the spinal cord (Atici et al., 2004).
Nasiraei-Moghadam et al. (2010) have shown that exposure to morphine from the ﬁrst day of
gestation to the time of sampling (embryonic day 9.5 and 13.5) increases neuroblast apoptosis as
revealed by changes in the expression of Bax, Bcl-2 and cleaved caspase 3.
The same group evaluated whether morphine-induced memory deﬁcit in adolescent and adult rats
from dams exposed during pregnancy or 1 week postconception is associated to an increased rate of
neuronal apoptosis. Immunostainings with antibodies recognising apoptotic proteins such as Bax, Bcl-2
and cleaved caspase 3 were performed on sections from hippocampi. The Bax/Bcl-2 ratio, as well as
the level of activated caspase 3 were found signiﬁcantly increased in the hippocampus of both d1–13
and d1–21 adolescent and adult females, but only in d1–21 adolescent male rats (Nasiraei-Moghadam
et al., 2013).
In vitro studies performed on cultures of neurons and microglia exposed to 10-6 M morphine also
showed the occurrence of apoptosis. In contrast, apoptotic cell death was not observed in astrocytes
exposed to morphine at a similar concentration (Hu et al., 2002).
D.2. Other effects
Studies aimed at clarifying the molecular mechanisms behind opiate tolerance and dependence
have contributed data that may be relevant for understanding morphine mode of action. As reviewed
by Ammon-Treiber and H€ollt (2005), several studies focused on gene expression analysis in the brain
after administration of morphine s.c. or i.p.
Acute and chronic morphine was reported to induce a rapid and transient increase in the
expression of c-fos and c-jun in various areas of the brain such as striatum, cerebral cortex and
nucleus accumbens. Chang et al. (1988) showed that in rats acute administration of 10 mg/kg bw s.c
increases c-fos mRNA and protein in the caudate/putamen, suggesting that Fos may be involved in the
morphine post-receptor signal transduction.
Morphine hydrochloride (10 mg/kg s.c. for up to 9 days) differentially affects the expression of beta
arrestins 1 and 2 in locus coeruleus, cerebral cortex or hippocampus of rats. Arrestins are involved in
the regulation of opioid receptor signaling (Fan et al., 2003).
mRNA of fos related antigen family members and AP-1 DNA binding activity increase in the nucleus
accumbens and striatum in response to chronic morphine (1 pellet s.c. containing 75 mg of morphine
base for 5 days). These changes may be part of the adaptive response to chronic morphine and also
involved in the modiﬁcation in dendritic spines observed in the nucleus accumbens after morphine
(Nye and Nestler, 1996).
CyclicAMP response element binding protein (CREB) increases in the locus coeruleus in response to
chronic morphine (pellets with 75 mg morphine base given s.c. for 5 days) and has been suggested to
play a role in development of dependence to opiate (Lane-Ladd et al., 1997).
Morphine hydrochloride (10–40 mg/kg s.c. up to 5 days) increases dynamin mRNA in the caudate
putamen via the l receptors. The increase may be linked to intracellular adaptation following repeated
exposure (Noble et al., 2000).
Several receptors are affected by morphine: after 10 mg/kg i.p for 8 days the mRNAs of dopamine
receptors D1, D2 and D3 are differentially regulated in the caudate putamen. While D1R mRNA does
not change, D2R mRNA decreases about 25% and D3R mRNA increases 85%. These changes
probably occur in the attempt to normalise the abnormal DA transmission thus reducing the effect of
morphine (Spangler et al., 2003).
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Le Greves et al. (1998) have shown that acute administration of 10 mg/kg s.c. morphine chloride
modiﬁes the expression of NMDA NR1, 2A and 2B in the hippocampus and hypothalamus already after
4 h. Since this glutamate receptor subtype is involved in the development of dependency to morphine,
the results suggest that this effect starts after the ﬁrst administration of the drug.
Numan et al. (1998) showed that morphine base 75 mg in s.c. pellet for 5 days, differentially
affects nerve growth factors, BDNF and NT3 as well as their receptors. In locus coeruleus, which is
implicated in opioid physical dependency and withdrawal, BDNF and NT3 expression increases while
tjeir receptors trkB and C are not changed. These modiﬁcations may play a critical role in the
morphine-induced changes in plasticity in locus coeruleus.
Other gene expression studies have shown that morphine hydrochloride 10 mg/kg up to 14 days
modiﬁes the expression of 159 genes in the nucleus accumbens. Molecules involved in
neurotransmission, such as DA, neuropeptides (encephalin, dynorphin, CART, substance P are affected
by morphine (Spijker et al., 2004). Acute exposure to 10 mg/kg morphine i.p. alter the expression of
genes related to mitochondrial function, cytoskeletal functions, secretory vesicle and cell adhesion, and
regulatory proteins (Loguinov et al., 2001).
Several in vitro studies have addressed the effects of very low concentrations of morphine. 10-14 M
morphine has neurotrophic effects and increases the length of the longest process of rat spinal and
cortical neurons (24% and 18% respectively) (Brailoiu et al., 2004). At higher concentration (10-6 M),
no signiﬁcant effects were observed.
Electrophysiological studies on dorsal root ganglion neurons showed that extremely low
concentrations of morphine (fM-nM) induced direct excitatory effects, whereas higher concentrations
(micromolar) evoked inhibitory effects (Crain and Shen, 2001).
Bandaru et al. (2011) have shown that transgenic mice expressing gp120 (the HIV virus envelope
protein) are highly reactive to morphine. After administration via pellets that delivered 5 mg/day morphine
for 5 days s.c., there was a decrease in sphingomyelin and accumulation of ceramide in the brain.
Campbell et al. (2015) have shown that morphine (10 mg/kg bw escalating to 30 mg/kg bw s.c. for
5 days) has protective effects against neurotoxicity induced by intracerebral injection of gp120Bal likely
by increasing the level of the chemokine CCL5.
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Annex A – Occurrence of opium alkaloids
Tables A.1–A.10 of Annex A can be found in the online version of this output (‘Supporting
information’ section): https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2018.5243
Description: Supporting tables on the occurrence of opium alkaloids in poppy seeds and poppy
seed-containing food.
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Annex B – Consumption data and dietary exposure for humans
Tables B.1–B.9 of Annex B can be found in the online version of this output (‘Supporting
information’ section): https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2018.5243
Description: Supporting tables on poppy seed consumption and human dietary exposure.
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